Conditions: Cystic Fibrosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 423
Healthy volunteers: no

Brief summary:
This trial aims to provide prospective evidence of the safety and efficacy of mannitol 400 mg b.i.d. in subjects aged 18 years and above.

We hypothesize that inhaled mannitol 400 mg b.i.d. will increase the mean change from baseline FEV1 (mL) compared to control over the 26-week treatment period in adult subjects with cystic fibrosis. Any improvement in FEV1 is considered clinically meaningful, however, this trial has set a threshold of 80 mL for the purposes of determining an appropriate sample size for statistical power while retaining trial feasibility in an orphan disease population

Detailed description:
This is a double-blind, randomized, parallel arm, controlled, multicenter, and interventional clinical trial. Potential subjects will sign the informed consent form (ICF) and be assessed for eligibility. After satisfying all inclusion \& exclusion criteria, subjects will be given a mannitol tolerance test (MTT). Those subjects that pass the MTT will be randomized to receive inhaled mannitol (400 mg b.i.d.) or control b.i.d. for a period of 26-weeks.

Arms:
arm 1: Active treatment. Inhaled Mannitol arm 2: Arm B

Interventions: intervention 1: Inhaled mannitol intervention 2: Placebo Comparator: Arm B - Control
Intervention descriptions: intervention 1: Inhaled mannitol 400 mg BD for 26 weeks intervention 2: Placebo Comparator: Arm B - Control BD for 26 weeks

Protocol document:
Prot_000.pdf: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DPM-CF-303 Long Term Administration of Inhaled Mannitol in Cystic Fibrosis -  A Safety 
and Efficacy in Adult Cystic Fibrosis Subjects 
 
Protocol: v2.0 13 October 2014 
 
NCT02134353 
 




 
DPM-CF-303 Protocol v2.0 13th October  2014 
Page 2 of 72 
 
Confidential 
 
 
SYNOPSIS 
Protocol Version & 
Date: 
V2.0 
13th October 2014 
Drug Name: 
Dry powder mannitol 
Trial Number: 
DPM-CF-303 
Phase: 
III 
Indication: 
Cystic fibrosis 
Trial Centers: 
Multicenter 
Title: 
Long Term Administration of Inhaled Mannitol in Cystic Fibrosis – 
A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects 
Sponsor: 
Pharmaxis Limited, 20 Rodborough Road, Frenchs Forest, NSW 
2086 Australia. Tel: +61 2 9454 7200 
Trial Duration 
28 weeks 
Number of Subjects 
350 to 440 
Trial Design 
Randomized, multicenter, double-blind, controlled, parallel group 
Primary 
Objective(s): 
To determine whether inhaled mannitol (400 mg b.i.d.) is superior to 
control (50 mg b.i.d.) for improving lung function as measured by 
mean change from baseline FEV1 (mL) over the 26-week treatment 
period in adult subjects with cystic fibrosis (CF). 
Secondary 
Objectives: 
There are hierarchical and non-hierarchical secondary objectives.  
Analysis of hierarchical secondary objectives will continue until a 
non-significant p-value (i.e. p > 0.05) is returned. 
Hierarchical secondary objectives 
1. 
To determine whether inhaled mannitol (400 mg b.i.d.) is 
superior to control for improving lung function as measured 
by mean change from baseline FVC (mL) over the 26-week 
treatment period in adult subjects with CF; 
2. 
To determine whether inhaled mannitol (400 mg b.i.d.) is 
superior to control in increasing the time to first pulmonary 
exacerbation over the 26-week treatment period in adult 
subjects with CF; 
3. 
To determine whether in adult subjects with CF, inhaled 
mannitol (400 mg b.i.d.) is superior to control for reducing 
the number of days on antibiotics due to pulmonary 
exacerbation (oral, inhaled or IV); 
4. 
To determine whether in adult subjects with CF, inhaled 
mannitol (400 mg b.i.d.) is superior to control for decreasing 
the number of days in hospital due to pulmonary 
exacerbation; and 
5. 
To determine whether inhaled mannitol (400 mg b.i.d.) 
decreases the rate of pulmonary exacerbations over the 26-
week treatment period compared to control in adult subjects 
with CF. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October  2014 
Page 3 of 72 
 
Confidential 
 
 
Non-hierarchical secondary objectives 
To determine whether in adult subjects with CF, inhaled mannitol 
(400 mg b.i.d.) is superior to control  
• for decreasing the incidence of exacerbations (i.e. the proportion 
of subjects with one or more exacerbation); 
• for improving ease of expectoration; and 
• for improving subject reported respiratory symptoms as measured 
by CFQ-R respiratory domain. 
Primary 
Endpoint(s): 
The primary endpoint is the mean change in FEV1 (mL) from 
baseline (Visit 1) over the 26-week treatment period (to Visit 4). 
Secondary 
Endpoints: 
• Mean change from baseline FVC (mL) over the 26-week 
treatment period; 
• Time to first pulmonary exacerbation over the 26-week treatment 
period; 
• Rate of pulmonary exacerbations over the 26-week treatment 
period; 
• Number of days in hospital due to pulmonary exacerbation; 
• The incidence of pulmonary exacerbations; 
• Number of days on antibiotics (oral, inhaled or IV) due to 
pulmonary exacerbation; 
• Ease of expectoration measured using a visual analogue scale; 
and 
• CFQ-R respiratory domain score. 
Hypothesis: 
We hypothesize that inhaled mannitol 400 mg b.i.d. will increase the 
mean change from baseline FEV1 (mL) compared to control over the 
26-week treatment period in adult subjects with cystic fibrosis.  For 
the purposes of determining an appropriate sample size for statistical 
power while retaining trial feasibility in an orphan disease population 
the trial is powered to detect a difference of 80 mL, however any 
improvement in FEV1 could be considered clinically meaningful. 


 
DPM-CF-303 Protocol v2.0 13th October  2014 
Page 4 of 72 
 
Confidential 
 
 
Trial 
Population: 
(Diagnosis for main criteria 
for inclusion) 
Subject Inclusion Criteria 
The subject must meet all of the following criteria: 
1. 
Have given written informed consent to participate in this trial in 
accordance with local regulations; 
2. 
Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride 
value ≥ 60 mEq/L) and/or genotype with two identifiable mutations 
consistent with CF, accompanied by one or more clinical features 
consistent with the CF phenotype); 
3. 
Be aged at least 18 years old; 
4. 
Have FEV1 > 40 % and < 90% predicted (using NHanes III [1]); 
5. 
Be able to perform all the techniques necessary to measure lung function;  
6. 
Be adherent with maintenance therapies (antibiotics and/or rhDNase), if 
used, for at least 80% of the time in the two weeks prior to visit 1; and 
7. 
If rhDNase and/or maintenance antibiotic are being used treatment must 
have been established at least 1 month prior to screening (Visit 0).  The 
subject should remain on the rhDNase and / or maintenance antibiotics for 
the duration of the trial.  The subject should not commence treatment with 
rhDNase or maintenance antibiotics during the trial. 
Subject Exclusion Criteria 
The subject must NOT meet any of the following criteria: 
1. 
Be investigators, site personnel directly affiliated with this trial, or their 
immediate families. Immediate family is defined as a spouse, parent, child 
or sibling, whether biologically or legally adopted; 
2. 
Be considered “terminally ill” or eligible for lung transplantation; 
3. 
Have had a lung transplant; 
4. 
Be using maintenance nebulized hypertonic saline in the 2 weeks prior to 
visit 1; 
5. 
Have had a significant episode of hemoptysis (> 60 mL) in the three 
months prior to Visit 0; 
6. 
Have had a myocardial infarction in the three months prior to Visit 0; 
7. 
Have had a cerebral vascular accident in the three months prior to Visit 0; 
8. 
Have had major ocular surgery in the three months prior to Visit 0; 
9. 
Have had major abdominal, chest or brain surgery in the three months 
prior to Visit 0; 
10. 
Have a known cerebral, aortic or abdominal aneurysm; 
11. 
Be breast feeding or pregnant, or plan to become pregnant while in the 
trial; 
12. 
Be using an unreliable form of contraception (female subjects at risk of 
pregnancy only); 
13. 
Be participating in another investigative drug trial, parallel to, or within 4 
weeks of screening (Visit 0); 
14. 
Have a known allergy to mannitol; 
15. 
Be using non-selective oral beta blockers; 
16. 
Have uncontrolled hypertension –i.e. systolic BP > 190 and / or diastolic 
BP > 100; 
17. 
Have a condition or be in a situation which in the Investigator’s opinion 
may put the subject at significant risk, may confound results or may 
interfere significantly with the subject’s participation in the trial; or 
18. 
Have a failed or incomplete mannitol tolerance test (MTT) (as evaluated 
in Section 8.1.1.1). 


 
DPM-CF-303 Protocol v2.0 13th October  2014 
Page 5 of 72 
 
Confidential 
 
 
Dosage and 
Administration: 
Mannitol (400 mg b.i.d.) or control (50 mg b.i.d.) 
Blinding: 
Double-blind 
Data Collection: 
Refer to the time and events schedule for a schedule of activities 
Efficacy 
Evaluations: 
Refer to the time and events schedule for a schedule of activities 
Safety Evaluations: 
Refer to the time and events schedule for a schedule of activities 
Statistical Methods: 
Sample size:  The minimum sample size is based on the assumption 
that the change from baseline in FEV1 on control is 0 mL and the 
change from baseline in FEV1 on mannitol is 80 mL.  A sample size 
of 350 (175 Mannitol : 175 Control) subjects will yield 90 % power 
at the 0.05 significance level to detect this difference between the 
treatment groups assuming a pooled standard deviation of 230 mL. 
Primary Endpoint: The mean absolute change from baseline FEV1 
(mL) over weeks 6, 14 and 26 will be compared between the two 
treatment groups with a restricted maximum likelihood (REML) 
based repeated measures approach.  
Secondary Endpoints: The mean absolute change in FVC, the 
changes from baseline in ease of expectoration and the CFQ-R 
respiratory domain score will be modeled as per the primary 
endpoint.  The time to first pulmonary exacerbation will be explored 
using Cox Proportional Hazards. Changes in rates of pulmonary 
exacerbations, antibiotic use and days in hospital will be explored 
using negative binomial models.  Analysis of incidence of pulmonary 
exacerbation will be completed using logistic regression. 
 






 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 8 of 72 
 
Confidential 
 
 
 
TABLE OF CONTENTS 
SYNOPSIS ............................................................................................................................... 2 
TIME AND EVENTS SCHEDULE ........................................................................................ 6 
TABLE OF CONTENTS ......................................................................................................... 8 
CONTACT LIST .................................................................................................................... 11 
ABBREVIATIONS ................................................................................................................ 12 
1 INTRODUCTION ............................................................................................................ 14 
1.1 Background ............................................................................................................... 14 
1.1.1 Findings from non-clinical trials ........................................................................ 15 
1.1.2 Findings from clinical trials ............................................................................... 15 
1.1.3 Pharmacokinetics................................................................................................ 16 
1.1.4 Efficacy .............................................................................................................. 16 
1.1.5 Safety .................................................................................................................. 17 
1.2 Rationale for trial....................................................................................................... 18 
2 TRIAL OBJECTIVES AND PURPOSE ......................................................................... 19 
2.1 Primary objective ...................................................................................................... 19 
2.2 Secondary objectives ................................................................................................. 19 
2.2.1 Hierarchical secondary objectives ...................................................................... 19 
2.2.2 Non-hierarchical secondary objectives .............................................................. 19 
2.3 Hypothesis ................................................................................................................. 19 
3 COMPLIANCE STATEMENT ....................................................................................... 20 
3.1 Variations to the protocol .......................................................................................... 20 
4 OVERVIEW OF TRIAL DESIGN .................................................................................. 20 
4.1 Trial design ................................................................................................................ 20 
4.2 Trial design rationale ................................................................................................. 21 
4.2.1 Primary endpoint ................................................................................................ 21 
4.2.2 Secondary endpoints........................................................................................... 21 
5 TRIAL POPULATION .................................................................................................... 22 
5.1 General considerations .............................................................................................. 22 
5.2 Subject inclusion criteria ........................................................................................... 22 
5.3 Subject exclusion criteria .......................................................................................... 22 
6 INVESTIGATIONAL MEDICINAL PRODUCT (IMP) ................................................ 23 
6.1 Dosage and administration ........................................................................................ 23 
6.1.1 Treatment adherence .......................................................................................... 24 
6.1.2 Investigational medicinal product – formulation and manufacture.................... 24 
6.1.3 Labeling, packaging and storage ........................................................................ 24 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 9 of 72 
 
Confidential 
 
 
6.1.4 Investigational medicinal product supply and accountability ............................ 26 
6.2 Pre-trial and concomitant medications ...................................................................... 26 
6.2.1 Pre-trial medication ............................................................................................ 27 
6.2.2 Concomitant medication..................................................................................... 27 
6.2.3 Concomitant medications that must be withheld prior to the trial visits ............ 27 
6.2.4 Prohibited medications and non-pharmacological treatments............................ 28 
7 INVESTIGATIONAL MEDICATION TREATMENT ALLOCATION ....................... 28 
8 TREATMENT EVALUATIONS..................................................................................... 28 
8.1 Visit procedures ......................................................................................................... 28 
8.1.1 Screening (Visit 0).............................................................................................. 29 
8.1.2 Double-blind treatment visits ............................................................................. 36 
8.2 Efficacy ..................................................................................................................... 41 
8.2.1 Efficacy evaluations ........................................................................................... 41 
8.3 Safety ......................................................................................................................... 45 
8.3.1 Safety evaluations............................................................................................... 45 
8.3.2 Criteria ................................................................................................................ 47 
8.3.3 Adverse event reporting ..................................................................................... 47 
8.3.4 Reporting procedures ......................................................................................... 50 
9 SUBJECT COMPLETION / DISCONTINUATION ...................................................... 52 
9.1 Completion ................................................................................................................ 52 
9.2 Trial treatment discontinuation ................................................................................. 52 
9.3 Trial withdrawal ........................................................................................................ 52 
10 STATISTICAL METHODS .......................................................................................... 53 
10.1 General considerations ............................................................................................ 53 
10.1.1 Sample size justification ................................................................................... 53 
10.1.2 Analysis sets ..................................................................................................... 54 
10.1.3 Missing data ..................................................................................................... 54 
10.1.4 Multiple comparisons ....................................................................................... 55 
10.1.5 Sample size re-estimation ................................................................................. 55 
10.1.6 Interim analysis ................................................................................................ 55 
10.1.7 Subject disposition ........................................................................................... 55 
10.1.8 Baseline demographic and clinical characteristics ........................................... 56 
10.2 Efficacy analysis...................................................................................................... 56 
10.2.1 Primary objective ............................................................................................. 56 
10.2.2 Primary endpoint .............................................................................................. 56 
10.2.3 Primary analysis ............................................................................................... 56 
10.2.4 Primary analysis – missing data ....................................................................... 56 
10.2.5 Primary sensitivity analyses ............................................................................. 57 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 10 of 72 
 
Confidential 
 
 
10.2.6 Primary per protocol analysis ........................................................................... 58 
10.2.7 Secondary analyses........................................................................................... 58 
10.2.8 Hierarchical testing of key secondary objectives ............................................. 60 
10.2.9 Secondary analyses – missing data .................................................................. 60 
10.2.10 Key secondary sensitivity analyses ................................................................ 61 
10.2.11 Subgroup analyses .......................................................................................... 61 
11 ETHICAL ASPECTS ..................................................................................................... 61 
11.1 Informed consent ..................................................................................................... 61 
11.2 Heath authorities, independent ethics committees / institutional review boards .... 62 
11.3 Confidentiality regarding trial subjects ................................................................... 62 
11.4 Data safety monitoring board (DSMB) ................................................................... 62 
12 TRIAL MANAGEMENT & ADMINISTRATIVE REQUIREMENTS ....................... 62 
12.1 Protocol amendments .............................................................................................. 62 
12.2 Direct access to source data / documents ................................................................ 62 
12.3 Monitoring and quality assurance ........................................................................... 63 
12.3.1 Information to trial personnel ........................................................................... 63 
12.3.2 Trial monitoring ............................................................................................... 63 
12.3.3 Audit and inspection ......................................................................................... 63 
12.4 Protocol deviations .................................................................................................. 64 
13 DATA HANDLING AND RECORD KEEPING .......................................................... 64 
13.1 Source data .............................................................................................................. 64 
13.2 Case report form (CRF) ........................................................................................... 64 
13.3 Archiving of trial documentation ............................................................................ 65 
14 FINANCING AND INSURANCE ................................................................................ 65 
15 REPORTING AND PUBLICATION OF RESULTS .................................................... 65 
15.1 Authorship ............................................................................................................... 66 
16 REFERENCES ............................................................................................................... 67 
17 SIGNATURE PAGE ...................................................................................................... 68 
 
 
 
 
 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 11 of 72 
 
Confidential 
 
 
 
CONTACT LIST 
A full trial contact list will be provided as a separate document. 
Changes in the names, addresses or telephone numbers of these contacts will in general not 
require a protocol amendment. A protocol amendment maybe required for contact 
information being referenced, for the addition or removal of the primary Principal 
Investigator, regulatory authorities documented notifications or updates. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 12 of 72 
 
Confidential 
 
 
ABBREVIATIONS 
ADR 
 
adverse drug reaction 
AE 
 
adverse event 
ATS/ERS 
American Thoracic Society / European Respiratory Society 
b.i.d. 
 
twice daily 
BOCF  
baseline observation carried forward 
BTPS 
 
body temperature and pressure, saturated 
CF 
 
cystic fibrosis 
CFTR 
 
cystic fibrosis transmembrane conductance regulator 
cGMP  
current Good Manufacturing Practice 
CRF 
 
case report form 
eCRF 
 
electronic case report form 
DSMB  
data safety monitoring board 
FAO 
 
Food and Agriculture Organization of the United Nations 
FDA 
 
US Food and Drug Administration 
FEF25-75  
forced expiratory fraction from 25% to 75% of vital capacity 
FEV1 
 
forced expiratory volume in one second 
FVC 
 
forced vital capacity 
GCP 
 
Good Clinical Practice 
HR 
 
hazard ratio 
HRCT  
high resolution computed tomography 
ICF 
 
informed consent form 
ICH 
 
International Conference on Harmonization 
ICMJE  
international committee of medical journal editors 
IEC 
 
Independent Ethics Committee 
IRB 
 
Institutional Review Board 
IMP 
 
investigational medicinal product 
IWRS 
 
interactive web response system 
ITT 
 
intent to treat 
IUDR 
 
imputation using dropout reason 
IV 
 
intravenous 
JECFA  
The joint FAO / WHO expert committee on food additives 
MDI 
 
metered dose inhaler 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
 
multiple imputation 
MMRM  
mixed-effect model repeated measures 
MTT 
 
mannitol tolerance test 
PEF 
 
peak expiratory flow 
PP 
 
per protocol 
REML  
restricted maximum likelihood 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 13 of 72 
 
Confidential 
 
 
rhDNase 
Recombinant human deoxyribonuclease 
 
SABA  
Short-acting beta2 agonist 
SAE 
 
serious adverse event 
SAP 
 
statistical analysis plan 
SOP 
 
standard operating procedure 
SpO2 
 
blood oxygen saturation 
VAS 
 
visual analogue scale 
WHO 
 
World Health Organization 
WOCF  
worst observation carried forward 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 14 of 72 
 
Confidential 
 
 
 
1 INTRODUCTION 
1.1 Background 
Cystic fibrosis (CF) is an autosomal recessive inherited disorder caused by mutations in the 
gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR) [1].  It is 
characterized by fat and protein malabsorption, failure to thrive and pulmonary disease [2].  
Cystic fibrosis is a life-threatening and chronically debilitating disease that markedly impairs 
quality of life [1].  To date, there are more than 1,600 specific mutations in the CF gene that 
are known [3].  The incidence of CF varies by ethnic group, with the greatest incidence 
occurring in Caucasians (1:3,200).  Far less people of African or Asian descent have this 
disease (incidence between 1:15,000 and 1:31,000) [2].  Despite genetic counseling, the 
prevalence of CF is likely to increase as the median survival time for subjects with CF 
increases [2]. 
Chronic progressive lung disease is the main negative prognostic factor in CF subjects [3].  
Subjects have progressive cycles of infection and inflammation, ultimately leading to 
respiratory failure [2].  The lungs become colonized with bacteria, probably due to the 
presence of thick, inspissated mucus in the airways, which traps inhaled microbes [2]. 
Cystic fibrosis has no cure.  Current life expectancy is between 30 and 40 years [1], although 
life expectancy is related to phenotype, with those with severe phenotypes having reduced 
life expectancy.  The goal of therapy is to delay disease progression [1].  The goal of therapy 
with respect to pulmonary disease is to maintain or improve respiratory function, as assessed 
by forced expiratory volume in one second (FEV1) [1].  Slowing the decline of lung function 
occurs by clearing airways of mucus, by controlling respiratory infections and by improving 
and maintaining respiratory function [1].  Clearing mucus occurs using physical techniques, 
such as active cycle of breathing, positive pressure autogenic drainage and physical therapy.  
Currently available pharmacological treatments include therapy with mucolytic drugs to 
improve mucociliary clearance of lower-airway secretions and treat chronic obstructive 
pulmonary disease [1].  Mucus clearance can be increased using hypertonic saline solutions 
[1], while rhDNase is used as a mucolytic agent.  Inhaled mannitol is being developed as a 
therapeutic agent for the treatment of cystic fibrosis and other diseases characterized by 
difficult to clear, thickened respiratory mucus.  Inhaled mannitol has been shown to increase 
mucociliary clearance and cough clearance [4, 5]. The exact mechanisms responsible remain 
unclear, however, due to its osmotic activity a combination of factors including changes in 
the rheology of mucus favoring ciliary and cough clearance may be responsible [6-8].  
Osmotic agents may change the viscoelastic properties of mucus by reducing the number of 
entanglements that mucin polymers form.  While ionic agents may achieve this by shielding 
the fixed charges along the mucin macromolecules, non-ionic agents such as mannitol may 
achieve this by disrupting the hydrogen bonds between mucins [6, 9]. Osmotic agents also 
increase the amount of water in the airway lumen potentially normalizing the airway surface 
liquid layer. This increased hydration may contribute to an increase in the activity of cilia 
and transportability of mucus. Additionally, osmotic agents may increase clearance of mucus 
by stimulating mucus secretion. The effect of osmolarity on mucus secretion could be direct 
or indirect via release of mediators from epithelial and mast cells and neuropeptides from 
sensory nerves which are known to be secretagogues. Although an increase in mucus 
secretion is not seen to be a desirable effect, this stimulation of mucus secretion may help 
increase clearance of viscous and stagnated mucus.  


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 15 of 72 
 
Confidential 
 
 
Mannitol may benefit subjects by reducing the mucus load acutely, or it may have a 
prolonged beneficial effect on mucociliary clearance. As excessive mucus in the airways 
may result in some limitation of airflow, a reduction in the mucus load should improve 
airway function irrespective of age. 
While adult subjects (aged at least 18 years) have been studied in previous phase III clinical 
trials of inhaled mannitol that assessed improvements in lung function [10, 11], there are 
remaining uncertainties around the effect size of inhaled mannitol 400 mg b.i.d. in this 
population. 
Therefore the primary purpose of this trial is to assess the efficacy of inhaled mannitol 
compared with control in subjects with cystic fibrosis aged 18 years and above. 
1.1.1 Findings from non-clinical trials 
Information regarding the findings from Non-Clinical Studies is presented in the 
Investigator’s Brochure Section NONCLINICAL STUDIES.   
Mannitol is present naturally in plants, algae, fungi and some bacteria.  It is used extensively 
as a food additive.  It does not appear to be mutagenic, cytotoxic, carcinogenic or 
teratogenic.  One trial has shown increased incidence of adrenal medullary hyperplasia plus 
pheochromocytoma in rats.  However, these were not dose related and were considered 
unrelated to the administration of mannitol. 
When ingested, mannitol has a laxative effect when given in doses greater than 10 to 20 g.  
The accepted daily intake of mannitol set by the joint FAO / WHO expert committee on food 
additives (JECFA) is 50 mg/kg. It is unlikely however, that the inhalation of less than 1g of 
mannitol per day via inhalation would reach this level. 
In animals, mannitol is rapidly absorbed following inhalation (peaking within 1 hour of 
completion of the dose), with negligible serum levels detected after 24 hours. 
1.1.2 Findings from clinical trials 
Findings from clinical studies are discussed in detail in the Investigator’s Brochure, section 
EFFECTS IN HUMANS. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 16 of 72 
 
Confidential 
 
 
 
1.1.3 Pharmacokinetics 
Refer to the Investigator’s Brochure (see Sections 5.2, 5.3 and 6.1.2). 
1.1.4 Efficacy 
The DPM-CF-301 trial [10] assessed the safety and efficacy of inhaled mannitol 400 mg 
b.i.d. compared to control in subjects aged six years or more with a diagnosis of cystic 
fibrosis.  This was a multicenter, randomized, controlled, parallel arm, double-blind phase III 
trial over 26 weeks.  It was followed by an optional 26-week open-label extension of the trial 
during which all subjects received inhaled mannitol 400 mg b.i.d..  The treatment effect of 
mannitol was superior to that of control (p < 0.001, Table 1).  Changes in other measures of 
lung function (FVC and FEF25-75) were consistent with the improvements in FEV1. 
DPM-CF-302 [11] was essentially the same as DPM-CF-301 in design, with only minor 
differences in the inclusion / exclusion criteria.  In this trial, inhaled dry powder mannitol 
improved absolute change in FEV1 compared with control over six-month treatment period, 
although this failed to reach statistical significance (p = 0.059, Table 1).  However, there 
were significant improvements in the relative change in FEV1 when subjects were treated 
with mannitol were compared to control groups – a difference of 3.75% (p = 0.029). 
A pooled analysis of DPM-CF-301 and DPM-CF-302 studies found a mean absolute change 
from baseline in FEV1 for dry powder mannitol versus control over 6 months was 73.4 mL 
(p<0.001).  Overall the studies show that dry powder mannitol improves lung function by six 
weeks, and the improvement was sustained over 26 weeks. The increase in FEV1 at six 
weeks was highly correlated with the improvement over the 26-week treatment period. 
Table 1: Treatment effect from the CF-301 and CF-302 studies 
Lung function 
measure 
CF-301 
Mannitol 400 mg 
b.i.d. vs. control 
across 26-weeks 
CF-302 
Mannitol 400 mg 
b.i.d. vs. control 
across 26-weeks 
Absolute change in 
FEV1 (mL) 
94.5 
p<0.001 
54.1 
p=0.059 
Absolute change in 
FVC (mL) 
126 
p<0.001 
71.4 
p=0.022 
 
Significant improvements in FEV1 were observed in subjects aged 18 and above in post-hoc 
analyses of studies DPM-CF-301 and DPM-CF-302 (Table 2). 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 17 of 72 
 
Confidential 
 
 
 
Table 2: Treatment effect in adults from the CF-301 and CF-302 studies 
Lung function measure 
CF-301 
Mannitol 400 mg 
b.i.d. vs. control 
across 26-weeks 
CF-302 
Mannitol 400 mg 
b.i.d. vs. control 
across 26-weeks 
Absolute change in FEV1 (mL) 
108.46 
p<0.001 
85.94 
 
p=0.038 
Absolute change in FVC (mL) 
138.71 
 
p<0.001 
113.77 
 
p=0.011 
1.1.5 Safety 
Detailed description on the safety of inhaled dry powder mannitol in subjects with cystic 
fibrosis can be found in the Investigator’s Brochure, section SAFETY IN BRONCHITOL 
CLINICAL TRIALS. 
A total of 672 subjects have received mannitol in all the completed mannitol CF studies.  
The most frequently reported adverse drug reactions (ADRs) were cough (9.23 %), condition 
aggravated (cystic fibrosis pulmonary exacerbation) (6.10 %) and hemoptysis (5.36 %).  
Cough was very common (> 1/10), condition aggravated and hemoptysis were common 
(frequency ≥ 1/100, < 1/10). 
Other common ADRs (frequency ≥ 1/100, < 1/10) were: pharyngolaryngeal pain, headache, 
wheezing, bronchospasm, productive cough, throat irritation, post-tussive vomiting and 
vomiting, chest discomfort, upper and lower respiratory tract infections, and bacteria 
identified in the sputum. 
Adverse events with a difference of at least 2 % between mannitol 400 mg b.i.d. and control 
in the combined Phase 3 data (DPM-CF-301 and DPM-CF-302) are listed in Table 3. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 18 of 72 
 
Confidential 
 
 
 
Table 3: Adverse events with a difference of at least 2 % between mannitol 400 mg b.i.d. and control in 
the combined Phase 3 data (DPM-CF-301 and DPM-CF-302) 
MedDRA System Organ Class/ Preferred Term 
Mannitol 400 
mg b.i.d. 
N=361  
n (%) 
Control  
N=239  
n (%) 
Gastrointestinal Disorders 
 
 
Diarrhea 
17 (4.7) 
6 (2.5) 
Vomiting 
22 (6.1) 
6 (2.5) 
General Disorders and Administration Site Conditions 
 
 
Condition aggravated 
133 (36.8) 
96 (40.2) 
Infections and Infestations 
 
 
Lower respiratory tract infection 
22 (6.1) 
24 (10.0) 
Nervous System Disorders 
 
 
Headache 
64 (17.7) 
50 (20.9) 
Reproductive System and Breast Disorders 
 
 
Dysmenorrhea 
8 (2.2) 
0 (0.0) 
Respiratory, Thoracic and Mediastinal Disorders 
 
 
Cough 
76 (21.1) 
40 (16.7) 
Hemoptysis 
34 (9.4) 
13 (5.4) 
Pharyngolaryngeal pain 
44 (12.2) 
18 (7.5) 
 
Post-hoc analysis of CF-301 and CF-302 studies found that the incidence of hemoptysis was 
similar in the mannitol 400 mg and control arms of these studies in adults, although this has 
not been tested prospectively.   
1.2 Rationale for trial 
Given the improvements in FEV1 observed in adult subjects the post-hoc analysis of DPM-
CF-301 and DPM-CF-302, this trial (DPM-CF-303) aims to provide prospective evidence of 
the safety and efficacy of mannitol 400 mg b.i.d. in subjects aged 18 years and above. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 19 of 72 
 
Confidential 
 
 
 
2 TRIAL OBJECTIVES AND PURPOSE 
2.1 Primary objective 
To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control (50 mg b.i.d.) 
for improving lung function as measured by mean change from baseline FEV1 (mL) over the 
26-week treatment period in adult subjects with CF. 
2.2 Secondary objectives 
There are hierarchical and non-hierarchical secondary objectives.  Analysis of hierarchical 
secondary objectives will continue until a non-significant p-value (i.e. p > 0.05) is returned. 
2.2.1 Hierarchical secondary objectives 
1. To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control for 
improving lung function as measured by mean change from baseline FVC (mL) over 
the 26-week treatment period in adult subjects with CF. 
2. To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control in 
increasing the time to first pulmonary exacerbation over the 26-week treatment 
period in adult subjects with CF. 
3. To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is 
superior to control for reducing the number of days on antibiotics (oral, inhaled or 
IV) due to pulmonary exacerbation;  
4. To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is 
superior to control for decreasing the number of days in hospital due to pulmonary 
exacerbation; and 
5. To determine whether inhaled mannitol (400 mg b.i.d.) decreases the rate of 
pulmonary exacerbations over the 26-week treatment period compared to control in 
adult subjects with CF. 
2.2.2 Non-hierarchical secondary objectives 
To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is superior 
to control  
• for decreasing the incidence of exacerbations (i.e. the proportion of subjects with one 
or more exacerbation); 
• for improving ease of expectoration; and 
• for improving subject reported respiratory symptoms as measured by CFQ-R 
respiratory domain. 
2.3 Hypothesis 
We hypothesize that inhaled mannitol 400 mg b.i.d. will increase the mean change from 
baseline FEV1 (mL) compared to control over the 26-week treatment period in adult subjects 
with cystic fibrosis. Any improvement in FEV1 is considered clinically meaningful, 
however, this trial has set a threshold of 80 mL for the purposes of determining an 
appropriate sample size for statistical power while retaining trial feasibility in an orphan 
disease population. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 20 of 72 
 
Confidential 
 
 
3 COMPLIANCE STATEMENT 
The trial will be conducted in accordance with the protocol and the International Conference 
on Harmonization (ICH) and Good Clinical Practice (GCP) guidelines.  In addition, the trial 
will be conducted in compliance with all applicable laws and regulatory requirements 
relevant to the use of new therapeutic agents in each participating country.  Agreement of the 
Investigator(s) to conduct and administer this trial in accordance with the protocol and 
associated regulations will be documented in trial agreements with the Sponsor, and other 
forms as required by national authorities in the country where the trial center is located. 
The Investigator(s) is/are responsible for ensuring the privacy, safety and welfare of the 
subjects during and after the trial, and must ensure that fully functional resuscitation 
equipment and personnel trained in its proper use are immediately available in case of a 
medical emergency. The Investigator(s) must be familiar with the background and 
requirements of the trial and with the properties of the investigational medication as 
described in the Investigator's Brochure. 
The Principal Investigator at each center has the overall responsibility for the conduct and 
administration of the trial at their center, and for contact with trial center management, the 
Independent Ethics Committee (IEC) / Institutional Review Board (IRB), and local 
authorities. 
3.1 Variations to the protocol 
No changes from the final approved (signed) protocol will be initiated by the Investigator 
without agreement by the Sponsor, and if required, the ethics committee’s prior written 
approval of favorable opinion of a written amendment, except when necessary to eliminate 
immediate hazards to the subjects. Changes that are considered only logistical or 
administrative, do not require prior ethics committee prior approval.  The Principal 
Investigator(s) and the Sponsor must sign any protocol amendment. 
4 OVERVIEW OF TRIAL DESIGN 
4.1 Trial design 
This is a double-blind, randomized, parallel arm, controlled, multicenter, and interventional 
clinical trial.  Potential subjects will sign the informed consent form (ICF) and be assessed 
for eligibility.  After satisfying all inclusion & exclusion criteria, subjects will be given a 
mannitol tolerance test (MTT). Those subjects that pass the MTT will be randomized to 
receive inhaled mannitol (400 mg b.i.d.) or control b.i.d. for a period of 26-weeks, in a 1:1 
fashion (See trial flowchart in Figure 1). Note: No tests should be performed before consent 
is obtained (also refer to the TIME AND EVENTS schedule). 
  




 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 22 of 72 
 
Confidential 
 
 
5 TRIAL POPULATION 
5.1 General considerations 
Potential subjects must meet all the inclusion, but none of the exclusion criteria, as listed 
below. 
5.2 Subject inclusion criteria 
The subject must meet all of the following criteria: 
1. 
Have given written informed consent to participate in this trial in accordance with 
local regulations; 
2. 
Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 
mEq/L) and/or genotype with two identifiable mutations consistent with CF, 
accompanied by one or more clinical features consistent with the CF phenotype); 
3. 
Be aged at least 18 years old; 
4. 
Have FEV1 > 40 % and < 90% predicted (using NHanes III [1]);  
5. 
Be able to perform all the techniques necessary to measure lung function;  
6. 
Be adherent with maintenance therapies (antibiotics and/or rhDNase), if used, for at 
least 80% of the time in the two weeks prior to visit 1; and 
7. 
If rhDNase and/or maintenance antibiotic are being used treatment must have been 
established at least 1 month prior to screening (Visit 0).  The subject should remain 
on the rhDNase and / or maintenance antibiotics for the duration of the trial.  The 
subject should not commence treatment with rhDNase or maintenance antibiotics 
during the trial. 
5.3 Subject exclusion criteria 
The subject must NOT meet any of the following criteria: 
1. 
Be investigators, site personnel directly affiliated with this trial, or their immediate 
families. Immediate family is defined as a spouse, parent, child or sibling, whether 
biologically or legally adopted; 
2. 
Be considered “terminally ill” or eligible for lung transplantation; 
3. 
Have had a lung transplant; 
4. 
Be using maintenance nebulized hypertonic saline including in the 2 weeks prior to 
visit 1; 
5. 
Have had a significant episode of hemoptysis (>60 mL) in the three months prior to 
Visit 0; 
6. 
Have had a myocardial infarction in the three months prior to Visit 0; 
7. 
Have had a cerebral vascular accident in the three months prior to Visit 0; 
8. 
Have had major ocular surgery in the three months prior to Visit 0; 
9. 
Have had major abdominal, chest or brain surgery in the three months prior to Visit 
0; 
10. 
Have a known cerebral, aortic or abdominal aneurysm; 
11. 
Be breast feeding or pregnant, or plan to become pregnant while in the trial; 
12. 
Be using an unreliable form of contraception (female subjects at risk of pregnancy 
only); 
13. 
Be participating in another investigative drug trial, parallel to, or within 4 weeks of 
visit 0; 
14. 
Have a known allergy to mannitol; 
15. 
Be using non-selective oral beta blockers; 
16. 
Have uncontrolled hypertension i.e. systolic BP > 190 and / or diastolic BP > 100; 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 23 of 72 
 
Confidential 
 
 
17. 
Have a condition or be in a situation which in the Investigator’s opinion may put the 
subject at significant risk, may confound results or may interfere significantly with 
the subject’s participation in the trial; 
18. 
Have a failed or incomplete MTT (as evaluated in Section 8.1.1.1);  
6 INVESTIGATIONAL MEDICINAL PRODUCT (IMP) 
6.1  Dosage and administration 
This is a parallel trial, including 26 weeks of treatment with either inhaled mannitol (400 mg 
b.i.d.) or control (mannitol 50 mg b.i.d.).  The inhalation technique for control and mannitol 
is identical. 
WHEN TO START TREATMENT FOR SUBJECTS WITH A 
CURRENT PULMONARY EXACERBATION 
Subjects should be stable and clear of pulmonary exacerbations for at 
least two weeks prior to visit 1. If a subject has an exacerbation after Visit 
0 (screening), Visit 1 should occur 2 to 5 weeks from the end of the 
treatment for the exacerbation or the end of the adverse event, whichever is later.   
There is no requirement to stop the IMP if a subject has a pulmonary exacerbation during a 
treatment phase. Subject can receive additional treatment as required. 
The IMP is to be administered in a standardized manner (see Figure 2).  The Investigator is 
responsible for instructing the subject on the correct IMP inhalation technique, and on use of 
the bronchodilator (albuterol/salbutamol metered dose inhaler (MDI) or similar) 5 to 15 
minutes prior to the IMP administration.  To ensure a good IMP delivery technique, training 
kits containing empty capsules are available. 
The Investigator will prescribe the subject with a bronchodilator (albuterol /salbutamol 
metered dose inhaler [MDI] or similar) to be used as premedication prior to inhalation of the 
IMP.  This bronchodilator may also be used in the event of post-treatment chest tightness.  
Premedication (albuterol/salbutamol MDI or preferred alternative) should be recorded in the 
Subject Diary.  Use of any bronchodilator following IMP for post-treatment chest tightness 
should also be recorded in the Subject Diary. 
Subjects will take IMP twice a day, once in the morning and once in the evening.  The 
evening dose should be administered approximately 2 hours before sleep.   
The recommended order of treatment procedures is: 
1. bronchodilator; 
2. mannitol/control; 
3. physiotherapy / exercise*; 
4. rhDNase; 
5. inhaled antibiotics; then 
6. inhaled corticosteroids. 
The procedures 4, 5 and 6 may not be applicable to all subjects and the order of procedures 
3, 4, 5 and 6 listed above is a suggestion only but the order in which they are used should 
remain consistent throughout the study.  Bronchodilator must always precede 
mannitol/control.  


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 24 of 72 
 
Confidential 
 
 
*When possible, individual physiotherapy and exercise (if used as a substitute to 
physiotherapy) techniques and routines should be kept consistent throughout the study. 
Subjects should record in the Subject Diary the date of any missed doses of IMP. 
Each kit dispensed contains additional supply to account for the allowed visit windows. 
6.1.1 Treatment adherence 
Treatment adherence will be determined by returned medication count. If the subject has 
missed doses of their medication, then they should be counseled about the importance of 
compliance, and re-educated on investigational medication intake.  Any possible treatment 
discontinuation due to non-adherence should be discussed with the Sponsor’s Project 
Manager and Sponsor’s Medical Director. 
6.1.2 Investigational medicinal product – formulation and manufacture 
Bronchitol has a centralized European marketing authorization for use in Adult patients with 
cystic fibrosis. However it does not have a marketing authorization or is not available in 
every participating country therefore it is being treated as Investigational medicinal 
product.  Details on the investigational product can be found in the Investigator’s Brochure.  
Trial treatment (mannitol and control) will be provided as indistinguishable red capsules. 
6.1.3 Labeling, packaging and storage 
IMP is labeled according to local regulatory requirements. The mannitol dry powder is 
encapsulated in opaque capsules prior to blister packing in aluminum foil. Blisters are 
contained within cartons with a dry powder inhaler device(s). IMP blinding is maintained by 
the use of kit numbers enabling traceable labeling. 
IMP is to be stored at room temperature (59°F to 77°F or 15°C to 25°C), in a secure area 
with restricted access.  The site Investigator/Pharmacist is responsible for storage, 
temperature monitoring and maintaining accurate accountability records. 
Once the IMP has been dispensed to subjects, it must not be refrigerated, nor kept in humid 
conditions, such as in the bathroom.  IMP must be stored at room temperature, in a clean, 
dry, environment.  Capsules should only be removed from the foil packaging immediately 
prior to use. 
 
Important: Instruct your subjects the IMP can only be used with the 
inhaler provided. 
 
 




 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 26 of 72 
 
Confidential 
 
 
6.1.4 Investigational medicinal product supply and accountability 
Pharmaxis will provide the participating sites with sufficient amount of IMP.   
The site Investigator must ensure that deliveries of investigational product from the Sponsor 
are correctly received by a responsible person (e.g., Pharmacist), that all receipts are 
recorded in writing, that the product is stored in a secure area under recommended and 
proper storage conditions, and that they are used in accordance with the protocol.  It is the 
responsibility of the Investigator to ensure that the integrity of the investigational medication 
is not jeopardized prior to dispensing.  The investigational medication must be dispensed as 
provided by the Sponsor with no further repackaging done at site.  
The site Pharmacist / Investigator(s) / legally qualified designee, as documented on the Site 
Signature / Delegation of Authority Log, will dispense/administer the investigational 
medication only to subjects enrolled in this trial following the procedures set out in Section 
6. The site Pharmacist / Investigator(s) is responsible for assuring the retrieval of all trial 
supplies from the subjects.  Unused investigational medication(s) (opened, unopened, or 
empty capsules) must be returned to the Sponsor or destroyed on site (if appropriate) after 
the investigational medication accountability has been completed and destruction has been 
authorized by the Sponsor. 
Trial drug accountability should be performed by counting the used (empty blisters) and 
unused trial drug remaining in blisters. 
The Investigator(s) must maintain accurate and adequate records including dates of receipt 
and return of IMP shipments, and batch numbers and quantities received/returned from/to 
Pharmaxis, as well as dates and amounts dispensed to/returned by trial subjects. Destruction 
of trial supplies should not be done without prior approval from the Sponsor.  Full 
accountability documentation (with witnessing) is required for all destroyed IMP at an 
investigator site. 
The Investigator / site Pharmacist will be required to provide the Monitor with access to the 
investigational medication and records for periodic review.  
Copies of the accountability records will be provided to the pharmacy monitor for inclusion 
in the trial master file. 
It is forbidden to use investigational medication for purposes other than defined in this 
protocol. 
6.2 Pre-trial and concomitant medications 
Any treatment that is considered necessary for the subject’s welfare may be given at the 
discretion of the Investigator.  Administration of all concomitant medications must be 
reported in the appropriate section of the CRF as noted below.  Generic names are to be 
recorded, along with the start and stop dates, dose, frequency, route and indication.  Trade 
names are acceptable for combination medications. 
 
 




 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 28 of 72 
 
Confidential 
 
 
6.2.3.1 Rescue medications 
If a subject develops chest tightness or shortness of breath as a consequence of withholding 
bronchodilators or other respiratory medications on the morning of the due visit, they should 
take their usual bronchodilator and phone or attend the clinic for advice.  Where the health of 
the subject is in question, the subject should attend the clinic for assessment.  Note should be 
made of the event precipitating the use of rescue medication and the subsequent 
management.  If necessary the due visit should be rescheduled. 
6.2.4 Prohibited medications and non-pharmacological treatments 
The following medications are prohibited from Screening (Visit 0) and throughout the trial 
protocol period: 
• Maintenance treatment with nebulized hypertonic saline 
• Non-selective oral beta-blockers 
7 INVESTIGATIONAL MEDICATION TREATMENT ALLOCATION 
Subjects will be randomized following informed consent and satisfying all the inclusion and 
none of the exclusion criteria.  Subjects are randomized in a 1:1 ratio to receive either 
inhaled mannitol 400 mg b.i.d. or control (inhaled mannitol 50 mg b.i.d.) for a period of 26-
weeks. Randomization will be stratified by rhDNase use and country. 
The Pharmacist, Investigator or legally responsible designee will dispense the treatment 
allocated to the subject and record the randomized kit numbers in the dispensing log. 
The subject, the investigative staff and Sponsor will be blinded to the treatment allocation. 
Appropriate site staff will be provided with access to unblinding information. In the event of 
a medical emergency, and when management of a subject’s condition requires knowledge of 
the IMP, his/her randomization information may be obtained. Such emergencies should be 
discussed with the Sponsor in advance whenever possible prior to disclosure of the subject’s 
treatment allocation. An automatic email is sent to the designated trial team member as soon 
as the subject is unblinded. 
Any subject giving consent, but not fulfilling the criteria to participate in the trial will not be 
entered into the Case Report Form (CRF) with the exception of mannitol tolerance test 
(MTT) status.  Subjects giving consent but not entered into the CRF will be documented as 
screen failures.  Subjects who are administered the MTT should be entered onto the CRF 
irrespective of the MTT result; however, the subject’s trial identifier and date of birth will be 
detailed in the IWRS. 
 
8 TREATMENT EVALUATIONS 
8.1 Visit procedures 
This trial consists five trial visits and 9 telephone calls over a period of 28-weeks (see TIME 
AND EVENTS SCHEDULE). 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 29 of 72 
 
Confidential 
 
 
8.1.1 Screening (Visit 0)  
Subjects will be screened for eligibility during the Screening phase.  Refer to the TIME 
AND EVENTS SCHEDULE for a complete list of procedures to be performed during the 
Screening visit. 
• Obtain written informed consent - this must be obtained before any trial related 
procedures, including medication-withholding requests, are undertaken. This may be 
done prior to V0; 
• Review inclusion / exclusion criteria; 
• Obtain demographic information:  
o date of birth; 
o height and weight (no shoes using a stadiometer); 
o race and gender; 
o age at diagnosis; 
o CFTR mutation  (if known)*; and 
o previous diagnosis of CF related bronchiectasis (yes, no, unknown)*. 
• Review medical history; 
• Review and record concomitant medications for the previous 3 months; 
• Perform physical examination, including but not limited to: 
o pulmonary function tests (FEV1, FVC, FEV1 % predicted  PEF, FEF25-75 ); 
o urine pregnancy test (for females of child-bearing potential); and 
o physical examination / vital signs (including chest sounds, weight, BP, HR, 
O2 saturation, temperature, respiratory rate). 
• 
Premedicate with four puffs of albuterol/salbutamol from a metered dose inhaler 
(MDI) (360-400µg)**; 
• Conduct mannitol tolerance test (MTT) (see section 8.1.1.1); 
• Collect 1 x sputum sample for qualitative microbiology (sent to local lab); 
alternatively, an oropharyngeal or cough swab is permitted. 
• Collect blood sample for hematology, electrolytes, urea, creatinine and liver function 
testing (collected following local laboratory procedures and sent to local lab); and 
• Issue subject diary and instruct the subject on how to complete it. 
* Enter this data only if known and confirmed evidence is available. 
** Bronchodilator is to be used approximately 5 -15 minutes prior to MTT. The default bronchodilator for this 
trial is 4 x puffs albuterol/salbutamol (360-400µg). However, the subject’s preferred alternative 
bronchodilator may be used as an alternative premedication. Please record premedication details. 
 
Re-screening of subjects may be considered upon approval by the Sponsor or delegate.  Re-
screening will not be considered for subjects who have had a ‘failed’ or ‘incomplete’ 
mannitol tolerance test. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 30 of 72 
 
Confidential 
 
 
 
8.1.1.1 Mannitol tolerance test (MTT) 
The MTT identifies subjects who have airway hyperresponsiveness in response to inhaled 
mannitol. Airway hyperresponsiveness is determined by measuring the degree of 
bronchoconstriction that occurs following sequential administrations of mannitol. 
As is standard in administering agents that have the potential to cause 
bronchoconstriction, a physician, appropriately trained, to treat acute 
bronchospasm, including the use of resuscitation equipment, must be available 
to respond to an emergency. 
As a minimum, the person conducting the MTT procedure must: 
• Be competent/trained, qualified and experienced in performing bronchial provocation 
tests; 
• Be familiar with safety and emergency procedures; 
• Know when to stop further testing; 
• Be proficient in the administration of inhaled bronchodilators and other rescue 
medications and equipment; and 
• Not be the same person who administers IMP in the clinic  
The following equipment must be available during the MTT procedure: 
• MTT kit with a dry powder inhaler; 
• Bronchodilator metered dose inhalers and spacers; 
• A spirometry system that meets ATS/ERS requirements; 
• Calculator and 60 second timer; 
• Pulse oximeter; 
• Adrenaline, atropine and oxygen; and 
• Resuscitation equipment. 






 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 33 of 72 
 
Confidential 
 
 
 
 
MTT Assessment 
Failed MTT (i.e. “positive” MTT) when the 
subject’s: 
1. oxygen saturation falls to < 89 %.  
Record this as an adverse event; 
2. FEV1 falls ≥ 20% from baseline 
following cumulative doses of 120 mg or 
240 mg of mannitol; 
3. FEV1 falls ≥ 20% from baseline 
following a cumulative dose of 400 mg 
of mannitol, and does not return to within 
20% of baseline FEV1 within 15 minutes; 
or 
4. FEV1 falls ≥ 50% from baseline 
following a cumulative dose of 400 mg 
of mannitol. 
Passed MTT (i.e. “negative” MTT) occurs 
when: 
1. a cumulative dose of 400 mg mannitol 
has been administered and no positive 
criteria have been met (see above); or 
2. a cumulative dose of 400 mg mannitol 
has been administered and FEV1 falls ≥ 
20% but <50% from baseline but returns 
to within 20% of baseline FEV1 within 
15 minutes. 
An Incomplete (failed) test occurs when: 
1. Cough is highly distressing or vomiting 
occurs during the procedure.  Record this 
as an adverse event; or 
2. Any other medical event not listed above 
that leads to the test not being completed.  
Record this as an adverse event. 
 
 
Record times of all spirometry during MTT procedure. 
 
 
Bronchoconstriction may occur during the MTT.  If the subject shows clinical 
signs and symptoms of bronchoconstriction measure FEV1 and treat 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 34 of 72 
 
Confidential 
 
 
accordingly.  If bronchoconstriction is severe or distressing, record as an adverse event. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 35 of 72 
 
Confidential 
 
 
Figure 3: The MTT procedure 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 36 of 72 
 
Confidential 
 
 
8.1.1.2  Phone call 1 week after visit 0 (Week -1 ± 1 day) 
One week after the screening (Visit 0) visit of the trial, the Investigator or designate, will call 
the subject to: 
• collect information on any adverse events experienced (including pulmonary 
exacerbations or hemoptysis); 
• collect information on current concomitant medications; 
• confirm attendance to next clinic visit; 
• remind the subject to adhere to withholding periods; and 
• remind the subject to complete their subject diary. 
 
8.1.2 Double-blind treatment visits 
Refer to the TIME AND EVENTS SCHEDULE for a complete list of procedures to be 
performed during the double-blind treatment visits.  
8.1.2.1 Baseline (Visit 1) 
Visit 1 will occur 2 to 5 weeks post screening visit  
Prior to the visit, confirm medication-withholding periods have been adhered to 
(including 2-weeks wash out from hypertonic saline).  If not, the subject’s visit 
should be postponed. 
Confirm that the subject is not currently having a pulmonary exacerbation.  In 
the event of a pulmonary exacerbation, visit 1 should occur 2 to 5 weeks from the 
end of the treatment for the exacerbation or of the adverse event, whichever is later. 
The following procedures will be performed: 
• Review subject diary. 
• Randomize eligible subjects if compliance with maintenance therapies (antibiotic & 
rhDNase) is at least 80% in the two weeks prior to visit 1 using the Subject Diary.; 
• Review concomitant medications, and adverse events; (including pulmonary 
exacerbations or hemoptysis); 
• Complete ease of expectoration VAS and respiratory domain of the CFQ-R  
questionnaire; 
• Conduct physical examination (chest sounds, weight, BP, HR, O2 saturation, temperature, 
respiratory rate); 
• Perform pre-mannitol pulmonary function testing (FEV1, FVC, PEF, FEF25-75); 
• Assign IMP using IWRS; 
• Dispense IMP and bronchodilator according to randomization schedule; 
• Premedicate with four puffs of albuterol/salbutamol from a metered dose inhaler (MDI) 
(360-400µg), 5 to 15 minutes prior to each dose of IMP.  The subject’s preferred 
bronchodilator may be used as an alternative premedication. Care must be taken to ensure 
that a bronchodilator is used prior to ALL doses of IMP; 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 37 of 72 
 
Confidential 
 
 
• Train the subjects on correct administration and inhalation of IMP, then administer initial 
dose of IMP (mannitol/control) according to ‘IMP Administration Procedure’ (see 
Section 6.1 figure 2) and randomization number; IMP administration should not be 
performed by the same person who administers the MTT. 
• Perform pulmonary function test 30 minutes post dose. If the subject has a measured fall 
in FEV1 >20% at 30 minutes post dose completion, no further study medication should 
be administered. The subject should be continued in the study on an intention to treat 
basis. Symptomatic bronchoconstriction should be managed as medically appropriate. 
The respiratory technician performing spirometry could be the same person who 
administers the IMP as long as they have not performed the MTT. 
• Access IWRS to complete the required visit information. 
 
8.1.2.2  Phone call 2 weeks after visit 1 (Week 2 ± 3 days) 
Two weeks after visit 1, the Investigator or designate, will telephone the subject to: 
• Collect information on any adverse events experienced (including pulmonary 
exacerbations or hemoptysis); 
• Collect information on current concomitant medications; 
• Remind the subject to adhere to withholding periods; 
• Discuss adherence to trial treatment; Is this subject continuing with the IMP treatment? If 
the answer is NO but the subject is continuing their participation in the trial, please 
schedule an IMP discontinuation visit (within 2 weeks after IMP discontinuation); 
• Remind the subject to return all trial drug (whether used or unused) at the next clinic 
visit; and 
• Remind the subject to complete all relevant sections of the subject diary and to bring the 
diary to each visit. 
 
8.1.2.3  Phone call 2 weeks before visit 2 (Week 4 ± 3 days) 
Two weeks before visit 2, the Investigator or designate, will call the subject to: 
• Collect information on any adverse events experienced (including pulmonary 
exacerbations or hemoptysis); 
• Collect information on current concomitant medications; 
• Confirm attendance to next clinic visit; 
• Remind the subject to adhere to withholding periods; 
• Discuss adherence to trial treatment; Is this subject continuing with the IMP treatment? If 
the answer is NO but the subject is continuing their participation in the trial, please 
schedule an IMP discontinuation visit (within 2 weeks after IMP discontinuation); 
• Remind the subject to return all trial drug (whether used or unused) at the next clinic visit; 
and 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 38 of 72 
 
Confidential 
 
 
• Remind the subject to complete all sections of the subject diary and to bring the diary to 
each visit. 
8.1.2.4 Visit 2 
Visit 2 should occur on completion of 6 weeks trial treatment (± 7 days) 
 
 
Prior to the visit, confirm medication-withholding periods have been adhered to.  
If not, the subject’s visit should be postponed. 
 
 
The following procedures will be performed: 
• Review subject diary. 
• Review concomitant medications and adverse events (including pulmonary exacerbations 
or  hemoptysis); 
• Complete ease of expectoration VAS and respiratory domain of the CFQ-R  
questionnaire; 
• Conduct physical examination (chest sounds, weight, BP, HR, O2 saturation, temperature, 
respiratory rate); 
• Perform pre-mannitol pulmonary function testing (FEV1, FVC,  PEF, FEF25-75); 
• Dispense IMP and bronchodilator according to randomization schedule; 
• Premedicate with four puffs of albuterol/salbutamol from a metered dose inhaler (MDI) 
(360-400µg), 5 to 15 minutes prior to each dose of IMP.  The subject’s preferred 
bronchodilator may be used as an alternative premedication. Care must be taken to ensure 
that a bronchodilator is used prior to ALL doses of IMP; 
• Administer dose of IMP (mannitol/control) according to ‘IMP Administration Procedure’ 
(see Section 6.1 figure 2) and randomization number.  Check the subject’s inhalation 
technique and re-train if required; 
• Perform pulmonary function test 30 minutes post dose. If the subject has a measured fall 
in FEV1 >20% at 30 minutes post dose completion, no further study medication should 
be administered. The subject should be continued in the study on an intention to treat 
basis. Symptomatic bronchoconstriction should be managed as medically appropriate); 
• Conduct drug accountability; and 
• Access IWRS to complete the required visit information. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 39 of 72 
 
Confidential 
 
 
 
8.1.2.5  Phone call 2 weeks after visit 2 (Week 8 ± 3 days) 
Two weeks after visit 2, the Investigator or designate, will telephone the subject, and 
complete the procedures as per Section 8.1.2.2.  
8.1.2.6  Phone call 2 weeks before visit 3 (Week 12 ± 3 days) 
Two weeks before visit 3, the Investigator or designate will telephone the subject.  
Information collected will be as per Section 8.1.2.3. 
 
8.1.2.7 Visit 3 
Visit 3 should occur at the end of 14 weeks trial treatment (± 7 days) 
 
 
Prior to the visit, confirm medication-withholding periods have been adhered to.  
If not, the subject’s visit should be postponed. 
 
 
The following procedures will be performed: 
• Review subject diary. 
• Review concomitant medications and adverse events (including pulmonary exacerbations 
or hemoptysis); 
• Complete ease of expectoration VAS and respiratory domain of the CFQ-R questionnaire;  
• Conduct physical examination (chest sounds, weight, BP, HR, O2 saturation, temperature, 
respiratory rate); 
• Perform pre-mannitol pulmonary function testing (FEV1, FVC, PEF, FEF25-75); 
• Dispense IMP and bronchodilator according to randomization schedule; 
• Premedicate with four puffs of albuterol/salbutamol from a metered dose inhaler (MDI) 
(360-400µg), 5 to 15 minutes prior to each dose of IMP.  The subject’s preferred 
bronchodilator may be used as an alternative premedication. Care must be taken to ensure 
that a bronchodilator is used prior to ALL doses of IMP; 
• Administer dose of IMP (mannitol/control) according to ‘IMP Administration Procedure’ 
(see Section 6.1 figure 2) and randomization number.  Check the subject’s inhalation 
technique and re-train if required; 
• Perform pulmonary function test 30 minutes post dose. If the subject has a measured fall 
in FEV1 >20% at 30 minutes post dose completion, no further study medication should 
be administered. The subject should be continued in the study on an intention to treat 
basis. Symptomatic bronchoconstriction should be managed as medically appropriate. 
• Conduct drug accountability; and 
• Access IWRS to complete the required visit information. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 40 of 72 
 
Confidential 
 
 
8.1.2.8  Phone call 2 weeks after visit 3 (Week 16 ± 3 days) 
Two weeks after visit 3, the Investigator or designate will telephone the subject.  Information 
collected will be as per Section 8.1.2.2. 
8.1.2.9  Phone call 6 weeks before visit 4 (Week 20 ± 3 days) 
Six weeks before visit 4, the Investigator or designate will telephone the subject.  Information 
collected will be as per Section 8.1.2.3. 
8.1.2.10  Phone call 2 weeks before visit 4 (Week 24 ± 3 days) 
Two weeks before visit 4, the Investigator or designate will telephone the subject.  
Information collected will be as per Section 8.1.2.3. 
8.1.2.11 Visit 4 
Visit 4 should occur at the end of 26 weeks of trial treatment (-7 to +28 days) 
 
Prior to the visit, confirm medication-withholding periods have been adhered to.  
If not, the subject’s visit should be postponed. 
 
The following procedures will be performed: 
• Review and collect subject diary. 
• Review concomitant medications and adverse events  (including pulmonary exacerbations 
or hemoptysis); 
• Complete ease of expectoration VAS and respiratory domain of the CFQ-R questionnaire;  
• Conduct physical examination (chest sounds, weight, BP, HR, O2 saturation, temperature, 
respiratory rate); 
• Perform pre-mannitol pulmonary function testing (FEV1, FVC, , PEF, FEF25-75); 
• Premedicate with four puffs of albuterol/salbutamol from a metered dose inhaler (MDI) 
(360-400µg), 5 to 15 minutes prior to each dose of IMP.  The subject’s preferred 
bronchodilator may be used as an alternative premedication. Care must be taken to ensure 
that a bronchodilator is used prior to ALL doses of IMP; 
• Administer dose of IMP (mannitol/control) according to ‘IMP Administration Procedure’ 
(see Section 6.1 figure 2) and randomization group;  
• Perform pulmonary function test 30 minutes post dose. Symptomatic bronchoconstriction 
should be managed as medically appropriate;  
• Conduct drug accountability; and 
• Access IWRS to complete the required visit information. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 41 of 72 
 
Confidential 
 
 
 
8.1.2.12  Final phone call 1 week after visit 4 (Week 27 ± 1 day) 
One week after the final visit of the trial, the Investigator or designate, will call the subject to: 
• Collect information on any adverse events experienced (including pulmonary 
exacerbations or hemoptysis); and 
• Collect information on current concomitant medications; and 
• Discharge subject from trial. 
8.1.2.13 IMP discontinuation visit (within 2 weeks after IMP discontinuation) 
Within two weeks of discontinuation of IMP, subjects should undergo an IMP 
discontinuation visit.  At this visit, the following procedures will be performed: 
• Review subject diary; 
• Review concomitant medications and adverse events (including pulmonary exacerbations 
or hemoptysis); 
• Complete ease of expectoration VAS and respiratory domain of the CFQ-R questionnaire;  
• Conduct physical examination (chest sounds, weight, BP, HR, O2 saturation, temperature, 
respiratory rate); 
• Perform pulmonary function testing (FEV1, FVC,  PEF, FEF25-75); 
• Access IWRS to complete the required visit information. 
8.2 Efficacy 
8.2.1 Efficacy evaluations 
Efficacy evaluations are highlighted in the TIME AND EVENTS SCHEDULE. Briefly, these 
include: 
8.2.1.1 Pulmonary function tests (Spirometry) 
Perform all trial spirometry according to the American Thoracic Society / European 
Respiratory Society (ATS/ERS) criteria [12], using a standardized spirometer that meets 
ATS/ERS requirements and using a trained, experienced, qualified technician.  Pharmaxis or 
designee must approve all trial staff responsible for performing spirometry prior to the 
staff being delegated this task. 
Perform all lung function measures using the same spirometer throughout the trial.  Perform 
spirometry at the same time of day for each visit (± 1 to 2 hours where possible).  All visits 
should coincide with the trough treatment effect – that is, approximately 6 to 24 hours 
following the previous inhaled mannitol dose.  Subjects must refrain from smoking within 1 
hour of testing, consuming alcohol within 4 hours of testing, and performing vigorous 
exercise within 30 minutes of testing.  Concomitant medications must be withheld prior to 
spirometry according to Table 4. 
Complete spirometry after the physical exam, but prior to administration of any 
bronchodilator. 
Seat the subject for the procedure unless they are obese, in which case testing in the standing 
position is preferred. 




 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 43 of 72 
 
Confidential 
 
 
Table 6: ATS/ERS Criteria for acceptable spirometry [12] 
ATS/ERS criterion 
Number of trials 
> 3 acceptable FVC maneuvers 
If more than eight attempts are made with the subject unable to perform a single 
acceptable maneuver, then discontinue testing. 
In some cases, testing can be continued after additional instruction and demonstration, 
where the subject’s clinical condition and tolerance allow. 
Acceptability 
1. Satisfactory “start of test” 
• 
No excessive hesitation or false start extrapolated volume; 
• 
Extrapolated volume < 5% of FVC or 0.150 L (whichever is greater); 
2. No coughing during the first second of the maneuver, or any other cough that the 
Trial Staff believe interferes with the measurement of accurate results; 
3. No early termination of expiration; 
4. No Valsalva maneuver (glottis closure) or hesitation during the maneuver that causes 
a cessation of airflow; 
5. No leak at the mouth; 
6. No obstructed mouthpiece; and 
7. No evidence of an extra breath being taken during the maneuver. 
A minimum exhalation time of ≥ 6 seconds or ≥ 3 seconds for children 
Repeatability 
After three acceptable spirograms have been obtained, apply the following tests: 
1. The two largest FVC must be within *0.150 L of each other; and  
2. The two largest FEV1 must be within *0.150 L of each other. 
If both are met, testing can be concluded, otherwise continue testing until both criteria 
are met or a total of eight tests have been performed or the subject cannot or should not 
continue. 
*For those with FVC of ≤1.0L, both these values are 0.100L. 
 
 
 




 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 45 of 72 
 
Confidential 
 
 
“Hospital in the home” or an equivalent program; or attendance / observation in the 
emergency department is not considered to be a hospital admission. Medications 
administered as part of any elective procedure or hospital in the home process, are to be 
recorded as concomitant medications.  
8.2.1.5  Hospital admission  
At the time of hospital admission, the following information will be recorded in the CRF and 
on the SAE Form, if available: 
• physical examination and medical history; 
• signs and symptoms checklist; 
• sputum microbiology results; 
• spirometry; 
• number of days since last hospital admission; 
• results of laboratory tests; and 
• chest X ray reports. 
8.2.1.6 Hospital discharge 
In addition to information recorded as per hospital admission, at the time of hospital 
discharge for an SAE the following information must be obtained as close as possible to the 
discharge date, and recorded in the CRF and on a follow-up SAE Form: 
• medications during admission; and 
• Start and end dates of hospitalization. 
8.2.1.7 Ease of expectoration 
A visual analogue scale will be used to assess the subjects’ perceptions on ease of 
expectoration [14] while using IMP.  Subjects will be asked to record the ease of 
expectoration over the previous week using a 10-cm visual analogue scale (0 = very difficult; 
10 = very easy). 
8.3 Safety 
Safety assessments are highlighted in the TIME AND EVENTS SCHEDULE. 
8.3.1 Safety evaluations 
Any clinically significant change in safety evaluation will be recorded as an adverse event 
(AE) as detailed in Section 8.3.1.1. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 46 of 72 
 
Confidential 
 
 
 
8.3.1.1 Adverse events (AEs) 
All observed or volunteered AEs regardless of treatment group or suspected causal 
relationship to the investigational medicinal product(s) will be recorded on the Adverse Event 
page of the CRF.  Subjects will be questioned for the occurrence of any new or worsening 
signs or symptoms at each visit by the following methods: 
• Information volunteered by the subject; 
• Open ended and non-leading questions such as: Have you had any health problems 
since your last visit?; 
• Observation by the investigational team, other care providers or relatives; or 
• Medical Record and Subject Diary review. 
The appropriate clinical individual at the trial site provides assessment and treatment of any 
trial related medical emergencies involving trial subjects.  
Please refer to Section 8.3.3 for further details on AE reporting procedures.  
8.3.1.2 Clinical laboratory tests 
Sputum microbiology, and screening bloods (hematology, electrolytes, urea, creatinine and 
liver function tests) are the only laboratory tests required for this trial protocol.  Laboratory 
tests are performed and analyzed following the local laboratory’s standard procedures.  If any 
other routine clinical laboratory testing is performed and a clinically significant result is 
obtained, then this must be recorded as an AE (see Section 8.3.3).  
8.3.1.3 Vital signs 
Temperature, pulse, respiratory rate and blood pressure will be assessed according to the 
TIME AND EVENTS SCHEDULE. 
Temperature should be taken at the same site each visit (e.g. oral, tympanic, or axillary). 
Blood pressure will be assessed seated.  
8.3.1.4 Physical examination 
Physical examinations will be as per the TIME AND EVENTS SCHEDULE.  A physician 
should preferably conduct the physical examination, but where timing prohibits this, a 
suitably trained nurse may undertake this task.  The physician should be consulted if any 
abnormality in the examination is detected. 
8.3.1.5 Pregnancy testing 
Perform urine pregnancy tests at screening on all females of child-bearing potential. Subjects 
who are pregnant are excluded from the trial. Female subjects who are at risk of becoming 
pregnant are expected to prevent pregnancy occurring while on treatment by using effective 
birth control methods e.g. oral contraceptive, condom, IUD, injectable contraceptive, or 
diaphragm. Male subjects have no contraceptive restrictions. 
The Investigator will inform the Sponsor immediately of any case of pregnancy and collect 
information on any subject who becomes pregnant during the trial using the Pregnancy 
Report Form. Discontinue pregnant subjects from treatment but continue to follow-up for 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 47 of 72 
 
Confidential 
 
 
scheduled safety assessments for the duration of the trial. Subjects will also be followed to 
determine the outcome of pregnancy.  See also section 8.3.4.3. 
8.3.2 Criteria 
An assessment of safety will be made on the basis of reviewing changes in physical 
examination, spirometry and using adverse event data. 
8.3.3 Adverse event reporting 
8.3.3.1 Definitions 
Adverse event  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a medicinal product and which does not necessarily have to have a causal 
relationship with this product.  
An AE can therefore be any unfavorable or unintended sign (for example an abnormal 
laboratory finding), a symptom or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not considered related to that product. 
Any worsening (e.g. clinically significant adverse change in frequency and/or intensity) of a 
pre-existing condition, which is temporally associated with the use of a medicinal product, is 
also considered an AE. Recurring symptoms associated with pre-existing conditions will not 
be considered AEs during the trial, unless they have a clinically significant increase in 
severity and/or frequency. 
 Hemoptysis is an event of special interest in this trial and should be reported as a 
separate Adverse Event every time it occurs, even if it is considered to be a 
component of a pulmonary exacerbation and/or if it is an ongoing / intermittent 
medical history condition. 
 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 48 of 72 
 
Confidential 
 
 
Serious adverse event (SAEs) 
A serious adverse event (SAE) for this trial is defined as any unfavorable medical occurrence 
that at any dose:  
1) Results in death 
 
2) Is life-threatening 
NOTE: the term “life-threatening” refers to an event in which the subject was at risk 
of death at the time of the event; it does not refer to an event, which hypothetically 
might have caused death if it were more severe. 
3) Requires inpatient hospitalization or prolongation of existing hospitalization 
NOTE: The following do not meet the definition of hospitalizations for SAE reporting 
purposes: 
• An Emergency Department visit that did not result in an admission to the 
hospital 
• Hospitalizations for social reasons 
• Planned hospitalizations for surgery or procedure planned prior to the 
subject’s entry into the trial, unless the subject experiences an additional AE 
that prolongs the pre-planned hospitalization. This pre-planned hospitalization 
must be documented in the subject’s CRF medical record page at screening 
(Visit 0). 
 
4) Results in persistent or significant disability or incapacity 
 
5) Is a congenital anomaly or birth defect 
 
6) Other important medical event 
NOTE: Appropriate medical judgment should be exercised for important medical 
events that may not be immediately life-threatening or result in death or 
hospitalization but may jeopardize the subject or may require intervention to prevent 
one of the other outcomes listed in the definitions above. These should usually be 
considered serious. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 49 of 72 
 
Confidential 
 
 
8.3.3.2 Causality assessment 
The Investigator will make a causality assessment according to his/her best judgment.  The 
following criteria can be used as a guidance to assess the causal relationship.  These are not 
definitive, but presented as examples. 
Definitely related: 
• There is evidence of exposure to the investigational medication or procedure 
• The temporal sequence of the AE onset relative to administration of the 
investigational medication or procedure is reasonable 
• The SAE is more likely explained by the investigational medication or procedure than 
by another cause 
• De-challenge (if performed) is positive 
• Re-challenge (if feasible and if performed) is positive 
• The AE shows a pattern consistent with previous knowledge of the investigational 
medication  or investigational medication   class 
Probably related: 
• There is evidence of exposure to the investigational medication or procedure 
• The temporal sequence of the AE onset relative to administration of the 
investigational medication or procedure is reasonable 
• The AE is more likely explained by the investigational medication or procedure rather 
than by another cause 
• De-challenge (if performed) is positive 
• Re-challenge (if performed) is positive or ambiguous 
Possibly related: 
• There is evidence of exposure to the investigational medication or a protocol 
procedure 
• The temporal sequence of the AE onset relative to administration of the 
investigational medication or procedure is reasonable 
• The AE could have been due to another equally likely cause 
• De-challenge (if performed) is negative or ambiguous 
• Re-challenge (if performed) is negative or ambiguous 
Probably not related: 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 50 of 72 
 
Confidential 
 
 
• There is evidence of exposure to the investigational medication or protocol procedure 
• There is another more likely cause of the AE 
• De-challenge (if performed) is negative or ambiguous 
• Re-challenge (if performed) is negative or ambiguous 
Definitely not related: 
• The subject did not receive the investigational medication or undergone any protocol 
procedure  
• Temporal sequence of the AE onset relative to administration of the investigational 
medication or procedure is not reasonable  
• There is another obvious cause of the AE 
• De-challenge (if performed) is negative 
• Re-challenge (if performed) is negative 
8.3.3.3 Severity assessment 
Mild: the subject has an awareness of a sign or symptom, but it is easily tolerated and does 
not alter normal activity 
Moderate: the sign or symptom causes discomfort and/or interference with the subject’s 
usual activity 
Severe: the sign or symptom causes significant impairment of function or incapacitation, 
and/or the subject is unable to perform usual activities 
8.3.4 Reporting procedures 
8.3.4.1 All adverse events 
The Investigator will assess all AEs and record details of seriousness (see Section 8.3.3.1), 
severity (see Section 8.3.3.3), duration, action taken with the investigational medication, and 
relationship to the investigational medication (causality, see Section 8.3.3.2). The 
Investigator will also record details of de-challenge and re-challenge with the investigational 
medication. 
All adverse events that meet any of the serious criteria defined in Section 8.3.3.1 will be 
reported as SAEs. 
All AEs, whether serious or not, will be reported from signing of the informed consent form 
until 7 days after the last trial visit. 
All SAEs, including those spontaneously reported to the Investigator by the subject, must be 
reported using the SAE Form. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 51 of 72 
 
Confidential 
 
 
If a subject experiences an SAE any time after the 30 day post final trial visit follow-up 
period and the SAE is considered to be related to the investigational medication, the 
Investigator should report this to Pharmaxis immediately. 
All AEs, regardless of seriousness, severity or presumed causality must be recorded in the 
subject’s medical records and in the CRF.  AEs that occur in subjects who have screen failed 
and are not entered into the CRF will be captured on the AE Reporting Log in the 
Investigator Site File. All SAEs that occur in subjects who have screen failed will be reported 
from informed consent.  
The Sponsor is responsible for reporting AEs to the relevant regulatory authorities according 
to international and local regulations applicable to this trial.    
The Investigator is responsible for reporting AEs to the appropriate IEC that approved the 
protocol, as required and documented by the IEC. 
Pulmonary exacerbations are expected to occur as part of the disease but will be recorded as 
adverse events. Expedited reporting of serious exacerbations to Regulators and Ethics 
Committees will only be carried out if the exacerbation is considered to be related to trial 
drug and is clinically different to that normally expected in a particular subject (e.g. more 
severe). In such cases, the difference should be noted on the AE form.  
8.3.4.2 Serious adverse events 
The Principal Investigator or designee will report all SAEs immediately and in any 
situation no later than 24 hours after any member of the investigational team becomes 
aware of the event. 
The Investigator must make an assessment of causality (see Section 8.3.3.2) and severity (see 
Section 8.3.3.3) of all SAEs.  All actions taken and outcomes must also be recorded. 
The SAE Report Form should be completed and forwarded to:  
 
 
 
SAEs will be followed up until the event has resolved and the report is assessed as complete; 
or the subject is lost to follow-up.  In addition, an Investigator may be requested by 
Pharmaxis to provide or obtain specific additional follow-up information in an expedited 
fashion for the purposes of full safety assessment. 
All follow-up information should be reported as described above.  
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 52 of 72 
 
Confidential 
 
 
8.3.4.3 Pregnancy 
Pregnancy is not usually considered an SAE or an AE.    
If an Investigator becomes aware that a subject, or the sexual partner of a male subject, 
becomes pregnant while they are participating in the trial or within the 7-day post trial 
follow-up period they will notify Pharmaxis immediately.   
A Pregnancy Report Form should be completed and be forwarded to;  
 
 
 
Female subjects who become pregnant will be withdrawn from treatment but will continue to 
be followed up for scheduled safety assessments for the duration of the trial. 
All pregnancies should be followed to term and the outcome reported to Pharmaxis.  In the 
case of a pregnancy in the sexual partner of a male subject consent will be sought from the 
partner to obtain follow-up information. 
If a subject or baby experience any adverse event during the pregnancy or after birth this will 
be reported as described throughout Section 8.3. 
9 SUBJECT COMPLETION / DISCONTINUATION 
9.1 Completion 
A subject will be considered to have completed the trial if he or she has completed 
assessments up to visit 4. Subjects who prematurely discontinue investigational drug 
treatment during the trial and fail to present for the scheduled trial visits for any reason will 
not be considered to have completed the trial.  Subjects who discontinue from the IMP but 
continue to participate in the trial to the final assessment will be considered to have 
completed the trial. 
9.2 Trial treatment discontinuation 
All subjects who discontinue IMP treatment and remain in the trial will be requested to attend 
an IMP discontinuation visit within 2 weeks of the last dose.  A complete evaluation should 
be made at this visit. 
All efforts should be made to ensure that subjects who discontinue IMP treatment remain 
in the trial, and continue all other scheduled visits as per protocol. 
A subject will be discontinued from treatment if she becomes pregnant. 
9.3 Trial withdrawal 
A subject will be withdrawn from the trial for any of the following reasons: 
• Loss to follow-up; 
• Withdrawal of consent; 
• The subject’s attending physician requests that the subject be withdrawn from the 
trial; or 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 53 of 72 
 
Confidential 
 
 
• The Investigator or the Sponsor, for any reason, stops the trial or stops the subject 
participating in the trial. 
Protocol deviations will not lead to automatic withdrawal unless they indicate a significant 
risk to the subject’s safety.  All protocol deviations must be discussed promptly with the 
Sponsor. 
All subjects who are withdrawing from the trial will attend their next scheduled visit.  This 
should be within two weeks of administration of the last dose of IMP.  A complete final 
evaluation at the time of the subject’s withdrawal should be made and an explanation be 
given as to why the subject is withdrawing or being withdrawn from the trial.  The reason and 
date of withdrawal must be noted on the CRF.  If the reason for withdrawal is an AE or a 
clinically significant laboratory test result, monitoring will continue until resolution or until 
an appropriate medical judgment concerning the cause or importance has been made.  The 
specific event or test result(s) must be recorded on the CRF.  
10 STATISTICAL METHODS 
10.1 General considerations 
A full description of the statistical methods planned for this trial can be found in the DPM-
CF-303 Statistical Analysis Plan (SAP).  
Efficacy analyses will be conducted using the intention to treat (ITT) analysis set (refer 
Section 10.1.2.1) as well as the per protocol (PP) analysis set (refer Section 10.1.2.2). Safety 
analyses will be conducted on the safety analysis set (refer Section 10.1.2.3). 
Significance tests will be performed assuming a two-sided 0.05 significance level; two-sided 
95% confidence intervals will also be computed.  
 
10.1.1 Sample size justification 
Enrolment will continue until at least 350 subjects have been randomized to treatment in a 
1:1 ratio. 
Assuming that the change from baseline in FEV1 on control is 0 mL and the change from 
baseline in FEV1 on mannitol is 80 mL, then a sample size of 350 (175 Mannitol : 175 
Control) subjects will yield 90 % power at the 0.05 significance level to detect this difference 
between the treatment groups assuming a pooled standard deviation of 230 mL. The sample 
size calculation is based on a t-test of the treatment contrast at week 26. While this approach 
is not completely concordant with the primary analysis which computes the mean change in 
FEV1 over all three post-baseline visits it can be considered a suitable method for estimating 
sample sizes for longitudinal analyses and is likely to be conservative. 
The estimated pooled standard deviation of 230 mL is based on the observed pooled standard 
deviation in the pooled adult DPM-CF-301 and DPM-CF-302 data from subjects who 
completed the studies. 
This minimum sample size is based upon the observed pooled standard deviation from both 
DPM-CF-301 and DPM-CF-302 studies in subjects with baseline FEV1 of more than 40% but 
less than 90%. However the observed standard deviations were different in these two 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 54 of 72 
 
Confidential 
 
 
previous studies, and were highly influenced by a few outlying values.  In addition, the 
present trial (DPM-CF-303) will be conducted at different sites and in different countries to 
the previous studies.  Thus there is some uncertainty as to what the observed standard 
deviation is likely to be in this trial (DPM-CF-303). For these reasons a sample size re-
estimation is planned to be completed after at least 300 subjects have been recruited and will 
be based on all available 26-week data. This blinded sample size re-estimation will be based 
on the method of Kieser and Friede [15] which preserves the overall type 1 error rate. 
Therefore no adjustments to the overall significance level for the trial is required.  See 
Section 10.1.5 for more information. 
  
10.1.2 Analysis sets 
10.1.2.1 Intention to treat (ITT) analysis set 
The ITT analysis set (also known as the Full Analysis Set) will include all subjects who were 
randomized to treatment. Subjects will be analyzed according to the treatment group to which 
they were randomized. 
10.1.2.2 Per protocol (PP) analysis set 
The per protocol analysis set consists of all randomized subjects, who have: 
• Strictly met all the inclusion and exclusion criteria (i.e. will exclude those subjects 
who have been granted an exception to be included in the trial); 
• No major protocol deviations which would affect efficacy evaluations; 
• Taken trial drug for at least 60% of the 26-week treatment period; 
• A valid baseline FEV1 measure; and 
• At least two valid assessments of FEV1 following the baseline visit (Visit 0). 
The decision to include subjects in the per protocol dataset will be made prior to unblinding 
of the randomization schedule. For the per protocol analysis any non-valid assessments of 
FEV1 will be excluded from the analysis.  The validity of the FEV1 measurements will be 
assessed prior to unblinding. The subject must meet the requirement for a valid baseline and 
two valid post-baseline FEV1 assessments. 
10.1.2.3 Safety analysis set 
The safety analysis set will include all subjects who received at least one dose (or part 
thereof) of randomized trial treatment. Subjects will be analyzed in the treatment group based 
on the treatment they received. 
10.1.2.4 Mannitol Tolerance Test (MTT) analysis set 
The MTT set will include all subjects participating in the mannitol tolerance test prior to 
randomisation regardless of their subsequent randomisation status. It includes subjects who 
fail the MTT (MTT positive) or who have an incomplete procedure, along with those who 
pass the MTT (MTT negative).   
10.1.3 Missing data 
Where a subject has missing baseline data, where possible, the screening (Visit 0) value will 
be used.  




 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 56 of 72 
 
Confidential 
 
 
10.1.8 Baseline demographic and clinical characteristics 
Baseline characteristics will be described using the safety population.  If required, these may 
also be produced for the intent to treat analysis set (ITT). Demographics, medical history and 
other baseline variables will be summarized as appropriate to the type of data. 
10.2 Efficacy analysis 
10.2.1 Primary objective 
To determine whether inhaled mannitol (400mg b.i.d.) is superior to control for improving 
lung function as measured by mean change from baseline FEV1 (mL) over the 26-week 
treatment period in adult subjects (18 years or older) with CF. 
10.2.2 Primary endpoint 
The primary endpoint is the mean change from baseline FEV1 (mL) measured at weeks 6, 14 
and 26. 
10.2.3 Primary analysis 
The mean absolute change from baseline FEV1 (mL) over weeks 6, 14 and 26 will be 
compared between the two treatment groups with a REML based repeated measures 
approach.  
Analyses will include the fixed, categorical effects of treatment, rhDNase use, country, visit, 
and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline 
percent predicted FEV1. An unstructured (co)variance structure will be used to model the 
within-subject errors. 
The planned primary efficacy model will take the form: 
 
Significance tests will be based on least-squares means using a two-sided 0.05 significance 
level.  Two-sided 95% confidence intervals will be computed. 
 
 
Change in % predicted FEV1, relative change in FEV1 (% change) and relative change in % 
predicted FEV1 will also be analyzed using the primary model. 
10.2.4 Primary analysis – missing data 
Subjects who discontinue drug treatment will remain in the trial and continue to provide all 
scheduled FEV1 measurements. While all efforts will be made to ensure subjects remain in 
the trial, the following planned imputation strategy will allow for an appropriate primary 
analysis in the presence of missing FEV1 data. 
Missing baseline (Visit 1) measurements for the primary efficacy variable (FEV1) will be 
imputed using screening (Visit 0) values, if available. 
Missing post-baseline measurements for the primary efficacy variable (FEV1) will be 
imputed utilizing an Imputation Using Dropout Reason (IUDR) methodology.  For subjects 
who discontinue due to safety, tolerability, lack of efficacy or were lost to follow-up, missing 
post-baseline FEV1 measures will be imputed using the baseline (Visit 1) FEV1 measurement 
(baseline observation carried forward [BOCF] procedure).  Missing FEV1 measurements as a 
Change from baseline FEV
1 = Baseline % predicted FEV
1 + Treatment + rhDNase + Visit + Country +
Treatment × Visit
(
)


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 57 of 72 
 
Confidential 
 
 
result of other causes of trial discontinuation (e.g. relocation, pregnancy) will not be 
explicitly imputed. 
Imputation of missing FEV1 measurements by means of BOCF is a reasonable assumption in 
the studies of adult subjects with cystic fibrosis, as these subjects who discontinue will no 
longer receive treatment and are thus likely to promptly return to their baseline lung function. 
Imputation by BOCF specifically inhibits any possible prolongation of an observed early 
treatment benefit implicitly conferred by a mixed model. 
A framework of imputation by BOCF in combination with the IUDR strategy seeks to 
specifically address the primary regulatory question of interest, that is to provide a reliable 
estimation of the treatment effect over 26 weeks as observed in all randomized subjects. 
10.2.5  Primary sensitivity analyses 
The following planned sensitivity analyses are intended to gain insights into how different 
analytical assumptions influence the results of the planned primary analysis.  Depending on 
the extent and pattern of withdrawals and “missingness” further sensitivity analyses in 
additional to those given below may be performed. If necessary, further details will be 
provided in the SAP. 
10.2.5.1 Primary sensitivity analysis #1:  
To elicit insights into the effect of imputation via the planned BOCF + IUDR framework the 
primary analyses will be repeated with no explicit imputation of missing post-baseline FEV1. 
10.2.5.2 Primary sensitivity analysis #2: 
To elicit insights into the effects of including data from subjects after cessation of trial 
treatment (by including these data, the effects of subsequent therapy are attributed to trial 
treatment), the primary analyses will be repeated excluding these data both with imputation 
of missing (and excluded) post-baseline FEV1 assessments and without explicit imputation. 
Data from IMP discontinuation visit or early withdrawal from the study that has been 
collected will be examined here also. 
10.2.5.3 Primary sensitivity analysis #3: 
Sensitivity of the primary result to choice of “across weeks 6 to 26” versus “at week 26” 
estimates of the treatment effect will be gauged by computing the least square mean 
difference at week 26 for the purposes of comparison. 
10.2.5.4 Primary sensitivity analysis #4:  
A potential disadvantage of employing a single imputation method such as BOCF is the risk 
of artificially attenuating the natural variability in the longitudinal data. To gauge the possible 
impact of this effect, a two-sample t-test at week 26 will be undertaken computing point 
estimates from the data with BOCF but computing variation only from subjects who 
completed the trial. Furthermore a non-parametric equivalent (e.g. Wilcoxon rank sum test) 
will be undertaken on the data with BOCF imputation. These results will be compared to the 
week 26 contrast computed by the primary efficacy model (Primary sensitivity analysis #2). 
10.2.5.5 Primary sensitivity analysis #5:  
The primary analysis will be repeated using the mean FEV1 measurement from screening 
(Visit 0) and baseline (instead of the baseline FEV1 measurement) in order to determine if the 
primary results are sensitive to any observed changes between screening and baseline in 
FEV1. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 58 of 72 
 
Confidential 
 
 
10.2.5.6 Primary sensitivity analysis #6 
Two responder analyses will be undertaken: 
1. A responder will be defined as those who have an increase from baseline FEV1 of 
greater than 100 mL (subjects who discontinued from the trial will be classified as 
non-responders). 
2. A non-responder will be defined as those who have a reduction from baseline FEV1 of 
more than 100 mL (subjects who discontinued from the trial will be classified as non-
responders). 
Proportions in each treatment group will be assessed for each definition and compared 
between treatment groups using logistic regression. 
10.2.5.7 Primary sensitivity analysis #7 
In addition to the responder analysis described above, a responder analysis will be undertaken 
where the cut-off for classification as a responder will be change from baseline FEV1 greater 
than: -300, -250, -200, -150, -100, -50, 0, 50, 100, 150, 200, 250 & 300mL respectively. 
These results will be plotted in a graphical summary for both treatment groups. These results 
can be scrutinized to ensure a consistent trend of treatment effect that is insensitive to any 
particular definition of response. 
10.2.5.8 Primary sensitivity analysis #8 
To explore the impact of patterns of “missingness” in the data, multiple imputation (MI) with 
penalties will be used. Missing data across the treatment period, namely week 6 to week 26, 
will be first imputed by MI (i.e. multiple times). Then the impact of various penalties will be 
explored including linking penalties to reason for “missingness” and increasing penalties for 
subjects with multiple missing data (as these subjects could be less likely benefit from the 
treatment). The imputed longitudinal data will be analyzed by mixed-effect model repeated 
measures (MMRM) model as above. 
10.2.5.9 Primary sensitivity analysis #9 
To explore the effect of different imputation methods, the primary analysis will be repeated 
using a worst observation carried forward (WOCF) + IUDR method rather than the BOCF + 
IUDR framework. 
10.2.6 Primary per protocol analysis 
The primary analysis is planned to estimate the treatment effect of being randomized to 
mannitol. In order to estimate the treatment effect of taking mannitol a per protocol analysis 
is planned. This entails re-fitting the primary efficacy model to the per-protocol analysis set. 
The results of this per protocol analysis will provide an extra robustness check on the main 
results from the ITT population. 
10.2.7 Secondary analyses  
Three key secondary objectives are ordered as follows and will be subjected to a hierarchical 
testing procedure outlined in Section 10.2.8 
10.2.7.1 Hierarchical secondary objectives 
Objective #1: To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control 
for improving lung function as measured by mean change from baseline FVC (mL) over the 
26-week treatment period in adult subjects with CF. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 59 of 72 
 
Confidential 
 
 
Analysis: The absolute change in FVC will be analyzed as per the primary analysis (i.e. 
REML based repeated measures approach using a model including the fixed, categorical 
effects of treatment, rhDNase use, country, visit, and treatment-by-visit interaction, as well 
as, the continuous, fixed covariate of baseline percent predicted FEV1). 
Objective #2: To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control in 
increasing the time to first pulmonary exacerbation over the 26-week treatment period in 
adult subjects with CF. 
Analysis: The time (in days) from the date of first treatment to the date of the first pulmonary 
exacerbation (any grade) will be analyzed using the Cox’s Proportional Hazards model with 
time to first exacerbation as the outcome, and treatment, country, rhDNase use and historical 
exacerbation rate as factors.  The hazard ratio will be presented with 95% confidence limits.  
When a subject does not have an exacerbation during the trial period the subject will be 
censored at the date of their last participation in the trial. 
Objective #3: To determine whether in adult subjects with CF, inhaled mannitol (400 mg 
b.i.d.) is superior to control for reducing the number of days on antibiotics (oral, inhaled or 
IV) due to pulmonary exacerbation. 
Analysis: The number of days on antibiotics will be compared between treatment groups 
using a negative binomial model with the number of days on antibiotics recorded by each 
subject over the trial period as the outcome variable, and treatment group, country, rhDNase 
use and historical exacerbation rate as predictors.  An offset variable of the natural log of 
number of days in the trial will be used in the model to adjust for different lengths of follow-
up.  The rate ratio will be presented with 95% confidence limits. 
Objective #4: To determine whether in adult subjects with CF, inhaled mannitol (400 mg 
b.i.d.) is superior to control for decreasing the number of days in hospital due to pulmonary 
exacerbation. 
Analysis: The number of days in hospital (admissions only) due to pulmonary exacerbation 
will be compared between treatment groups using a negative binomial model with the 
number of days in hospital due to pulmonary exacerbation experienced by each subject over 
the trial period as the outcome variable, and treatment group, country, rhDNase use and 
historical exacerbation rate as predictors.  An offset variable of the natural log of number of 
days in the trial will be used in the model to adjust for different lengths of follow-up.  The 
rate ratio will be presented with 95% confidence limits. 
Objective #5: To determine whether inhaled mannitol (400 mg b.i.d.) decreases the rate of 
pulmonary exacerbations over the 26-week treatment period compared to control in adult 
subjects with CF. 
Analysis: The rate of pulmonary exacerbations will be compared between treatment groups 
using a negative binomial model with the number of pulmonary exacerbations experienced by 
each individual over the trial period as the outcome variable, and treatment group, country 
and rhDNase use as predictors.  Historical exacerbation rate will be used as a covariate.  An 
offset variable of the natural log of number of days in the trial will be used in the model to 
adjust for different lengths of follow-up.  The rate ratio will be presented with 95% 
confidence limits. 
10.2.7.2 Non-hierarchical secondary objectives 
Objective #1:  To determine whether in adult subjects with CF, inhaled mannitol (400 mg 
b.i.d.) is superior to control for decreasing incidence of pulmonary exacerbations. 
Logistic regression will be used to estimate the treatment effect (odds ratio) on the proportion 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 60 of 72 
 
Confidential 
 
 
of subjects with one or more exacerbations. Covariates of country, rhDNase use and 
historical exacerbation rate will be included in the logistic regression model. 
Objective #2: To determine whether in adult subjects with CF, inhaled mannitol (400 mg 
b.i.d.) is superior to control for improving ease of expectoration. 
Analysis: The change in VAS score from baseline will be analyzed in a similar manner to the 
primary endpoint.  The mean absolute change from baseline VAS score over weeks 6, 14 and 
26 will be compared between the two treatment groups with a REML based repeated 
measures approach. Analyses will include the fixed, categorical effects of treatment, rhDNase 
use, country, visit, and treatment-by-visit interaction, as well as the continuous, fixed 
covariates of baseline VAS score and baseline % predicted FEV1. An unstructured 
(co)variance structure will be used to model the within-subject errors. 
Objective #3: To determine whether in adult subjects with CF, inhaled mannitol (400 mg 
b.i.d.) is superior to control for improving respiratory symptoms measured by CFQ-R 
respiratory domain. 
Analysis: Component questions in the questionnaire will be appropriately transformed 
according to the scoring manual, so that the best response will be uniformly the highest score 
and the worst response will be uniformly the lowest score.  The mean absolute change from 
baseline in the CFQ-R respiratory domain score over weeks 6, 14 and 26 will be compared 
between the two treatment groups with a REML based repeated measures approach. Analyses 
will include the fixed, categorical effects of treatment, rhDNase use, country, visit, and 
treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline CFQ-R 
respiratory domain score and baseline % predicted FEV1. An unstructured (co)variance 
structure will be used to model the within-subject errors. 
The CFQ-R respiratory domain includes the question “Have you had to cough up mucus?” 
The scoring algorithm scores an affirmative answer to this question as a negative outcome for 
the subject, however, due to the mechanism of action of mannitol (i.e. inducing coughing up 
mucus) an affirmative answer here may not be a negative outcome and hence this question is 
inappropriate here. Therefore, the above analyses will be repeated on the CFQ-R respiratory 
domain score omitting this question.  
10.2.8 Hierarchical testing of key secondary objectives 
The hypotheses for the primary efficacy endpoint and the three key secondary efficacy 
endpoints will be formally tested utilizing a hierarchical testing approach to preserve the 
type-I error rate. Objectives will be tested in the order in which they are ranked in Section 2. 
10.2.9  Secondary analyses – missing data 
Change from baseline FVC:  
Missing post-baseline measurements will be handled as per the primary efficacy endpoint 
(FEV1). 
Time to first pulmonary exacerbation: 
Subjects who withdraw from the trial prior to experiencing an exacerbation will be censored 
at the date of the last participation in the trial.  
Pulmonary exacerbation rate:  
In the event a subject discontinues from the trial before week 14 with no observed instances 
of a pulmonary exacerbations the number of pulmonary exacerbations will be imputed using 
half the subject’s historical (previous 12 months) pulmonary exacerbation count (rounded 
upwards) and their treatment exposure time will be imputed as 26 weeks.  


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 61 of 72 
 
Confidential 
 
 
In the event a subject discontinues from the trial after week 14 with no observed instances of 
a pulmonary exacerbations the number of pulmonary exacerbations will be imputed using one 
quarter the subject’s historical (previous 12 months) pulmonary exacerbation count (rounded 
upwards) and their treatment exposure time will be imputed as 26 weeks. 
Number of days in hospital and number of days on antibiotics: 
Primary negative binominal analysis allows for different lengths of follow-up via offset 
variable. No further allowance for missing data will be made in these analyses. 
Pulmonary exacerbation incidence: 
No allowance for missing data will be made in this analysis.  
Ease of expectoration: 
Missing post-baseline measurements will be handled as per the primary efficacy endpoint 
(FEV1). 
CFQ-R respiratory domain score: 
Missing post-baseline measurements will be handled as per the primary efficacy endpoint 
(FEV1).  
10.2.10 Key secondary sensitivity analyses 
Change in absolute FVC from baseline:  
* Analysis will be repeated without imputation of missing data. 
Pulmonary exacerbation rate:  
* Analysis will be repeated without imputation of missing data. 
* A zero inflated negative binomial model will be fitted and compared to the specified 
negative binomial model. 
10.2.11 Subgroup analyses 
Limited subgroup analyses of relevant primary and secondary will be performed to assess 
consistency of response between those: 
• with and without rhDNase use; 
• with and without Pseudomonas aeruginosa infection; 
• with differing baseline percentage of predicted FEV1. 
11 ETHICAL ASPECTS 
The trial will be conducted in accordance with the International Conference on 
Harmonization (ICH) and Good Clinical Practice (GCP) guidelines.  In addition, the trial will 
be conducted in compliance with all applicable laws and regulatory/health authority(ies) 
requirements relevant to the use of new therapeutic agents in each participating country.  
11.1 Informed consent 
This trial will be conducted in compliance with the US federal FDA 21 CFR Part 50-
Protection of Human Subjects requirements.  Written informed consent will be obtained from 
each subject before any trial related procedures or assessments are performed and after the 
aims, methods, anticipated benefits, and potential hazards are explained.  Explanation will 
also be provided to the subjects that they are free to refuse participation in the trial and free to 
withdraw from the trial at any time without prejudice to future treatment. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 62 of 72 
 
Confidential 
 
 
The subject’s willingness to participate in the trial will be documented in writing on an 
informed consent form, which will be signed by the subject and the person obtaining the 
consent with the date and time of that signature indicated.  The Investigator(s) will keep the 
original informed consent forms and copies will be given to the subjects. In addition, the 
person conducting the informed consent discussion will document the process of obtaining 
consent in the subject’s medical record. 
Written and/or oral information about the trial in a language understandable by the subject 
will be given to all subjects.  The information provided must include a statement that this is a 
clinical research study/trial, the duration and an adequate explanation of the aims, methods, 
anticipated benefits, potential hazards, and insurance arrangements in force. 
11.2 Heath authorities, independent ethics committees / institutional review 
boards 
The Investigator(s) will ensure that the conduct of the trial conforms to ICH/GCP Guidelines 
and with national laws and regulations for clinical research.  
Before starting this trial, the protocol will be submitted to the national/local health authorities 
and to the IEC/IRB for evaluation.  As required, the trial will not start before the IEC/IRB 
and health authorities give approval or a favorable opinion. 
11.3 Confidentiality regarding trial subjects 
The Investigator(s) must assure that the privacy of the subjects, including their personal 
identity and all personal medical information, will be maintained at all times.  In CRFs and 
other documents submitted to the Sponsor, subjects will not be identified by their names, but 
by an identification code (e.g., subject or screen number).  
The Monitor, properly authorized persons on behalf of the Sponsor’s quality assurance unit, 
or competent authorities may scrutinize personal medical information for the purpose of 
verifying data recorded on the CRF.  Personal medical information will always be treated as 
confidential, according to local privacy regulations.  
11.4 Data safety monitoring board (DSMB) 
A DSMB will be established.  The constitution and duties of the DSMB will be documented 
in a DSMB charter, but the primary function will be to provide ongoing review of safety data. 
12 TRIAL 
MANAGEMENT 
& 
ADMINISTRATIVE 
REQUIREMENTS 
12.1 Protocol amendments 
 
12.2 Direct access to source data / documents 
The Monitor(s), Auditor(s), and Regulatory Inspector(s) will be given direct access to source 
data and documentation (e.g., medical records, laboratory reports, diagnostic imaging) for 
source data verification, provided that subject confidentiality is maintained in accordance 
with local requirements and privacy regulations. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 63 of 72 
 
Confidential 
 
 
12.3 Monitoring and quality assurance 
12.3.1 Information to trial personnel 
The Investigator(s) is responsible for ensuring that all trial personnel are qualified and trained 
for their designated roles and responsibilities. He/she shall provide information about the trial 
to all staff members directly involved in the trial or in any element of subject management, 
both before starting the practical performance of the trial and during the course of the trial 
(e.g., when new staff become involved). 
The Monitor(s) is responsible for initiating the site, for ensuring site compliance with the 
protocol and for closing out the site at the end of the trial.  Additional information available 
during the trial should be provided to the Investigator by the Sponsor on an ongoing basis. 
The Investigator is responsible for ensuring that the site staff are fully informed and 
appropriately trained. Specific training in relation to additional information should be 
supported and documented by the Monitor as required. (The Investigator must ensure and 
document that new staff members involved in the trial are fully informed and trained prior to 
completing any trial related tasks. The Monitor is responsible for ensuring that training has 
been completed to ensure trial compliance). 
12.3.2 Trial monitoring 
For this trial, the average monitoring frequency is expected to be once every five to ten 
weeks, but is subject to recruitment rates.  The Monitor(s) or Sponsor representative is 
responsible for ensuring that the trial is conducted according to the protocol, Standard 
Operating Procedures (SOPs) and in compliance with GCP. 
The Monitor(s) is the primary link between the Sponsor and the Investigator.  The main 
responsibilities of the Monitor(s) is to visit the Investigator before, during, and after the trial 
to ensure adherence to the protocol, and to assure that all data are correctly and completely 
recorded and reported and that informed consent is obtained and recorded for all subjects 
before their participation in the trial. 
The Monitor(s) will contact and visit the Investigator at regular intervals throughout the trial.  
The Monitor(s) will be allowed access to check and verify the various records (CRFs and 
other pertinent data records) relating to the trial to verify adherence to the protocol and to 
ensure the completeness, consistency, and accuracy of the data being recorded. 
As part of the supervision of the trial progress other Sponsor personnel may, on request, 
accompany the Monitor(s) on visits to the trial center.  The Investigator and assisting staff 
must agree to cooperate with the Monitor(s) to resolve any problems, errors, or possible 
misunderstandings concerning any data discrepancies detected in the course of these 
monitoring visits. 
12.3.3 Audit and inspection 
According to ICH / GCP Guidelines, the Sponsor may audit the investigational site to 
compare raw data, source data, and associated records with the interim (if applicable) or final 
report of the trial to assure that data have been accurately reported and the trial was 
conducted in compliance with the protocol, SOPs, GCPs and applicable regulatory 
requirements.  The Sponsor’s worldwide Clinical Quality Assurance department is 
responsible for the auditing of the trial.  Auditing may be contracted to an external body. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 64 of 72 
 
Confidential 
 
 
The Investigator(s) must accept that regulatory authorities may conduct an inspection to 
verify compliance of the trial with the protocol, GCPs and applicable regulatory 
requirements. 
12.4 Protocol deviations 
The protocol must be read thoroughly and the instructions must be followed. However, 
exceptions will be made in emergency situations when the protection, safety, and well-being 
of the subject requires immediate intervention based on the judgment of the Investigator or a 
responsible, appropriately trained, and credentialed professional(s) designated by the 
Investigator as a sub-Investigator.  
In the event of a significant protocol deviation due to an emergency, accident, or error, the 
Investigator or designee must contact the Medical Monitor at the earliest possible time by 
telephone. This allows for an early joint decision to be made as to whether or not the subject 
should continue in the trial. The Investigator, the Sponsor, and the Medical Monitor will 
document this decision. 
13 DATA HANDLING AND RECORD KEEPING 
13.1 Source data 
The Investigator is required to prepare and maintain adequate and accurate case histories (i.e., 
medical records) designed to record all observations and other data pertinent to the trial for 
each trial subject.  The medical records must contain adequate information to allow for 
verification of subject identity throughout the trial.  
Any data recorded directly on the CRF, as agreed to by the Sponsor for which no other 
written or electronic record will be maintained in the subject’s medical record, will be 
considered source data (e.g., results of physical examinations, vital signs testing, or the drug 
administration procedure).  The agreement between the Investigator and the Sponsor, 
including the type of parameters allowed to be entered directly on the CRFs, must be 
documented in the subject’s source documentation. 
The CRF and the subject’s medical records pertinent to the trial will be reviewed by the 
Pharmaxis’ designated Monitor, auditors and possibly by representatives from the IRB/IEC 
and regulatory bodies such as the US Food and Drug Administration (FDA) to the extent 
permitted by regulations. 
The Investigator is required to retain a subject identification code list to allow unambiguous 
identification of each subject included in the trial. This list should contain the subject’s full 
name, date of birth, dates of participation and identification number as per country 
regulations. The Investigator must agree to supply all details to the Sponsor auditor(s) and/or 
regulatory authorities, ensuring the data are held confidentially at the Investigator’s center 
after completion of the trial. A note will be made in the hospital or clinical medical records, if 
appropriate, that the subject is participating in a clinical trial. 
13.2 Case report form (CRF) 
In this trial, the CRF will be an electronic CRF (eCRF). The Investigator or the designated 
site person must complete the CRF and supporting documentation for each subject within a 
timely manner of the visit occurring. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 65 of 72 
 
Confidential 
 
 
The Monitor(s) and Data Manager(s) will review the completed data for accuracy, 
completeness and consistency with source documentation.  The Monitor or Data Manager 
will submit requests for correction/clarification of data (e.g., queries) to the Investigator or 
designee when inconsistencies are identified during monitoring and source data verification 
or during the edit check process.  
All corrections and alterations to CRF data must be made by the Investigator or by the 
designated site personnel in a timely manner and according to the instructions provided.  
Completed CRFs should then be reviewed and signed by the Principal Investigator or 
designated site personnel.  All persons, their roles and responsibilities delegated by the 
Investigator participating in the trial must be indicated on the delegation of authority log.  
A full audit trail detailing corrections and alternations made to the CRF will be maintained. 
13.3 Archiving of trial documentation 
Trial data and other essential documents must be retained for a period of at least 15 years for 
adult trials; at least 25 years for trials involving children; or at least 2 years after the last 
approval of a marketing application, and until there are no pending or contemplated 
marketing applications in an ICH region, or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product.  It is the responsibility 
of the Sponsor to inform the Investigator(s)/institution(s) when these documents need no 
longer be retained.  The original record of the CRFs will be archived by the Sponsor for the 
lifetime of the product.  No trial document or image will be destroyed without prior written 
agreement between the Sponsor and the Investigator(s).  Should the Investigator(s) wish to 
assign the trial records to another party or move them to another location, advance written 
notice will be given to the Sponsor. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
15 REPORTING AND PUBLICATION OF RESULTS 
The Sponsor is responsible for publically registering this trial on the National Library of 
Medicine’s website (http://clinicaltrials.gov) within 21 days of initiating enrolment.  
All information, including but not limited to information regarding dry powder mannitol or 
the Sponsor’s operations supplied by the Sponsor to the Investigator and not previously 
published, along with any data generated as a result of this trial, are considered confidential 
and remain the sole property of the Sponsor.  The Investigator agrees to maintain this 
information in confidence, and will use the information only to perform the trial. 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 66 of 72 
 
Confidential 
 
 
The Sponsor is responsible for preparing a clinical trial report, in cooperation with the 
Investigator(s).  The Sponsor and the Principal/Coordinating Investigator will sign the final 
report. 
The Sponsor shall have the right to publish data and information without approval from the 
Investigator.  If an Investigator wishes to publish information from the trial, a copy of the 
manuscript must be provided to the Sponsor for review at least 60 days before submission for 
publication or presentation.  Expedited reviews will be arranged for abstracts, poster 
presentations, or other materials.  If requested by the Sponsor in writing, the Investigator will 
withhold such publication for up to an additional 60 days to allow for filing of a patent 
application.  The Sponsor will not mandate modifications to scientific content and does not 
have the right to suppress information.  The Investigator will recognize the integrity of a 
multicenter trial by not publishing data derived from the individual site until the combined 
results from the completed trial have been published in full, within 12 months after 
conclusion, abandonment, or termination of the trial at all sites, or the Sponsor confirms there 
will be no multicenter trial publication.  Authorship of publications resulting from this trial 
will be based on the guidelines on authorship, such as those described in the Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals, which state that the named 
authors must have made a significant contribution to the design of the trial or analysis and 
interpretation of the data, provided critical review of the paper, and given final approval of 
the final version. 
15.1 Authorship 
The publications should acknowledge the contribution of investigators jointly as the CF-303 
Trial Investigators and, where journal and space permit, the names of all investigators will be 
listed in the acknowledgement section. 
For the primary publication and any secondary analyses of the data set, the Principal / 
Coordinating Investigator plus the three highest recruiters who also fulfill the authorship 
criteria as outlined in the international committee of medical journal editors (ICMJE) 
guidelines will be named as authors on behalf of the CF-303 Trial Investigators.  Sponsor 
personnel who also fulfill the ICMJE’s criteria for authorship will also be offered authorship. 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 67 of 72 
 
Confidential 
 
 
16 REFERENCES 
1. 
Committee for Medicinal Products for Human Use (CHMP), Guideline on the clinical 
development of medicinal products for the treatment of cystic fibrosis. 
EMEA/CHMP/EWP/9147/2008-corr, 2009, European Medicines Agency. 
2. 
Strausbaugh, S.D. and P.B. Davis, Cystic fibrosis: a review of epidemiology and 
pathobiology. Clin Chest Med, 2007. 28(2): p. 279-88. 
3. 
Salvatore, D., et al., An overview of international literature from cystic fibrosis 
registries. Part 3. Disease incidence, genotype/phenotype correlation, microbiology, 
pregnancy, clinical complications, lung transplantation, and miscellanea. J Cyst 
Fibros, 2011. 10(2): p. 71-85. 
4. 
Daviskas, E., et al., Inhalation of dry powder mannitol increases mucociliary 
clearance. Eur Respir J, 1997. 10(11): p. 2449-2454. 
5. 
Robinson, M., et al., The effect of inhaled mannitol on bronchial mucus clearance in 
cystic fibrosis patients: a pilot study. Eur Respir J, 1999. 14(3): p. 678-85. 
6. 
King, M., Mucoactive therapy: What the future holds for patients with cystic fibrosis. 
Pediatric Pulmonology, 1997. 24(Suppl 14): p. 122-123. 
7. 
Daviskas, E. and S.D. Anderson, Hyperosmolar agents and clearance of mucus in the 
diseased airway. J Aerosol Med, 2006. 19(1): p. 100-9. 
8. 
Daviskas, E., et al., Inhaled mannitol for the treatment of mucociliary dysfunction in 
patients with bronchiectasis: effect on lung function, health status and sputum. 
Respirology, 2005. 10(1): p. 46-56. 
9. 
Feng, W., et al., Improved clearability of cystic fibrosis sputum with dextran 
treatment in vitro. Am J Respir Crit Care Med, 1998. 157(3 Pt 1): p. 710-714. 
10. 
Bilton, D., et al., Inhaled dry powder mannitol in cystic fibrosis: an efficacy and 
safety study. Eur Respir J, 2011. 38(5): p. 1071-1080. 
11. 
Aitken, M.L., et al., Long-term inhaled dry powder mannitol in cystic fibrosis: an 
international randomized study. Am J Respir Crit Care Med, 2012. 185(6): p. 645-52. 
12. 
Miller, M.R., et al., Standardisation of spirometry. Eur Respir J, 2005. 26(2): p. 319-
38. 
13. 
Fuchs, H.J., et al., Effect of aerosolized recombinant human DNase on exacerbations 
of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. 
The Pulmozyme Study Group. N Engl J Med, 1994. 331(10): p. 637-42. 
14. 
Dwyer, T.J., et al., Effects of exercise on respiratory flow and sputum properties in 
patients with cystic fibrosis. Chest, 2011. 139(4): p. 870-7. 
15. 
Kieser, M. and T. Friede, Simple procedures for blinded sample size adjustment that 
do not affect the type I error rate. Stat Med, 2003. 22(23): p. 3571-81. 
16. 
Hankinson, J.L., J.R. Odencrantz, and K.B. Fedan, Spirometric reference values from 
a sample of the general U.S. population. Am J Respir Crit Care Med, 1999. 159(1): p. 
179-87. 
 
 
 
 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 68 of 72 
 
Confidential 
 
 
 
17 SIGNATURE PAGE 
Protocol 
I confirm that I have read this protocol, I understand it, and I will work according to this protocol and 
in accordance with the International Conference on Harmonization (ICH) and Good Clinical Practice 
(GCP).  I agree to report all information or data in accordance with the protocol, and in particular, I 
agree to report any serious adverse events.  I will accept the monitors’, auditors’, and regulatory 
inspectors’ oversight of the trial.  I will abide by the publication plan set forth in the Investigator 
Agreement with Pharmaxis.  I will promptly submit the protocol to the applicable ethical review 
board. 
Clinical Site:  
Site Number: 
Site Principal Investigator: 
_____________________________  _______________________________ 
Print Name  
 
 
 
Title 
_____________________________  _______________________________ 
Signature 
 
 
 
 
Date 
 
Accepted for the Sponsor – Pharmaxis Ltd 
_____________________________  _______________________________ 
Print Name  
 
 
 
Title 
_____________________________  _______________________________ 
Signature 
 
 
 
 
Date 
 
Accepted for the Sponsor’s Representative (if applicable________________) 
 
 
 
 
 
 
 
 
(Organization name) 
_____________________________  _______________________________ 
Print Name  
 
 
 
Title 
_____________________________  _______________________________ 
Signature 
 
 
 
 
Date 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 69 of 72 
 
Confidential 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
h 2014; 
 
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 70 of 72 
 
Confidential 
 
 
 
 
 
  
 
 


 
DPM-CF-303 Protocol v2.0 13th October 2014 
Page 71 of 72 
 
Confidential 
 
 
  
 
 
 
 
 
 
.   
 
 
 



SAP_001.pdf: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DPM-CF-303 Long Term Administration of Inhaled Mannitol in Cystic Fibrosis -  A Safety 
and Efficacy in Adult Cystic Fibrosis Subjects 
 
Statistical Analysis Plan: v1.0 23May 2017 
NCT02134353 
 


Statistical Analysis Plan 
 
 
 
Page 1 of 108 
Document 
Type: 
Template 
Document ID: 
 
Issue Date:          03 SEP 2013 
Effective Date:    01 OCT 2013 
 
Sponsor Name: 
Pharmaxis Ltd 
Protocol Number and Title: 
 
DPM-CF-303 
Long Term Administration of Inhaled Mannitol 
in Cystic Fibrosis – A Safety and Efficacy Trial 
in Adult Cystic Fibrosis Subjects 
 
Protocol Version and Date: 
FINAL v1.8 
27MAR2014 
 
<Protocol Amendment 
numbers and dates> 
V2.0 13OCT2014 
 
 
INC Research Project Code: 
 
Author(s): 
 
n 
SAP Version: 
1.0 
SAP Version Date:  
23MAY2017 
 
Notice of Confidential and Proprietary Information: 
The information contained in this document is confidential belonging to Pharmaxis Ltd. 
Acceptance of this document constitutes agreement by the recipient that no information 
contained herein will be published or disclosed without prior written authorization from an 
official of Pharmaxis Ltd. However, this document may be disclosed to appropriate Institutional 
Review Board and Ethics Committees or duly authorized representatives of a national regulatory 
authority under the condition that they are requested to keep it confidential. In the event of an 
actual or suspected breach of this obligation, 
 should be notified promptly. 
 
 






Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 4 of 108 
TABLE OF CONTENTS 
1. 
GLOSSARY OF ABBREVIATIONS ................................................................ 8 
2. 
PURPOSE ..................................................................................................... 10 
2.1. 
Responsibilities ................................................................................................................. 10 
2.2. 
Timings of Analyses .......................................................................................................... 10 
3. 
TRIAL OBJECTIVES ..................................................................................... 11 
3.1. 
Primary Objective .............................................................................................................. 11 
3.2. 
Secondary Objective(s) ..................................................................................................... 11 
3.2.1. 
Hierarchical Secondary Objectives ................................................................................. 11 
3.2.2. 
Non-hierarchical Secondary Objectives .......................................................................... 11 
3.3. 
Brief Description of Trial Design ...................................................................................... 12 
3.4. 
Subject Selection ............................................................................................................... 12 
3.4.1. 
Inclusion Criteria .............................................................................................................. 12 
3.4.2. 
Exclusion Criteria ............................................................................................................. 13 
3.5. 
Determination of Sample Size .......................................................................................... 13 
3.6. 
Treatment Assignment & Blinding ................................................................................... 14 
3.7. 
Administration of Trial Medication ................................................................................... 15 
3.8. 
Trial Procedures and Flowchart ....................................................................................... 15 
4. 
ENDPOINTS .................................................................................................. 19 
4.1. 
Primary Efficacy Endpoint ................................................................................................ 19 
4.2. 
Secondary Efficacy Endpoints ......................................................................................... 21 
4.2.1. 
Hierarchical Secondary Endpoints .................................................................................. 21 
4.2.2. 
Non-hierarchical Secondary Endpoints ........................................................................... 24 
4.3. 
Safety Endpoints ................................................................................................................ 25 




Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 6 of 108 
7.4. 
Hemoptysis History ........................................................................................................... 39 
7.5. 
Medical History and Concomitant Diseases ................................................................... 39 
7.6. 
Response to Screening Mannitol Tolerance Test .......................................................... 40 
7.7. 
Medication .......................................................................................................................... 40 
7.7.1. 
Prior Medication ............................................................................................................... 40 
7.7.2. 
Screening Medication ...................................................................................................... 41 
7.7.3. 
Concomitant Medication .................................................................................................. 41 
7.7.4. 
Antibiotic Use ................................................................................................................... 42 
8. 
EFFICACY ..................................................................................................... 43 
8.1. 
Primary Efficacy Endpoint and Analysis ......................................................................... 43 
8.1.1. 
Primary Analysis of the Primary Endpoint ....................................................................... 44 
8.1.2. 
Sensitivity Analyses of the Primary Endpoint .................................................................. 46 
8.1.3. 
Supportive Analyses of the Primary Endpoint ................................................................. 50 
8.2. 
Hierachical Secondary Efficacy Endpoint(s) and Analyses .......................................... 52 
8.2.1. 
Forced Vital Capacity and Other Spirometry Parameters ............................................... 52 
8.2.2. 
Time to First Protocol Defined Pulmonary Exacerbation ................................................ 53 
8.2.3. 
Number of Days on Antibiotics Due to Protocol Defined Pulmonary Exacerbation ........ 54 
8.2.4. 
Number of Days in Hospital Due to Protocol Defined Pulmonary Exacerbation ............. 57 
8.2.5. 
Rate of Protocol Defined Pulmonary Exacerbation ......................................................... 58 
8.3. 
Non-hierachical Secondary Efficacy Endpoint(s) and Analyses .................................. 60 
8.3.1. 
Incidence of Protocol-Defined Pulmonary Exacerbations ............................................... 60 
8.3.2. 
Ease of Expectoration Visual Analogue Scale ................................................................ 61 
8.3.3. 
CFQ-R Respiratory Domain ............................................................................................ 61 
8.4. 
Summary of Analyses ....................................................................................................... 62 
9. 
SAFETY ......................................................................................................... 70 
9.1. 
Extent of Exposure ............................................................................................................ 70 
9.2. 
Trial Medication Compliance ............................................................................................ 70 
9.3. 
Adverse Events .................................................................................................................. 71 
9.4. 
Vital Signs ........................................................................................................................... 73 
9.5. 
Physical Examination ........................................................................................................ 73 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 7 of 108 
10. SAMPLE SIZE RE-ESTIMATION .................................................................. 74 
11. CHANGE FROM ANALYSIS PLANNED IN PROTOCOL ............................. 75 
12. REFERENCE LIST ........................................................................................ 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 8 of 108 
1. 
GLOSSARY OF ABBREVIATIONS 
Abbreviation 
Description 
AE 
Adverse Event 
ANCOVA 
Analysis of Covariance 
ATC 
Anatomical Therapeutic Chemical 
ATS/ERS 
American Thoracic Society/European Respiratory Society 
BDRM 
Blind Data Review Meeting 
b.i.d. 
Twice daily 
BOCF 
Baseline Observation Carried Forward 
CF 
Cystic Fibrosis 
CFTR 
Cystic Fibrosis Transmembrane Conductance Regulator 
CI 
Confidence Interval 
CRF 
Case Report Form 
DBP 
Diastolic Blood Pressure 
DMC 
Data Monitoring Committee 
FEF25-75 
Forced Expiratory Fraction from 25% to 75% of Vital Capacity 
FEV1 
Forced Expiratory Volume in 1 second 
FVC 
Forced Vital Capacity 
IMP 
Investigational Medicinal Product 
ITT 
Intent-to-Treat 
IUDR 
Imputation Using Dropout Reason 
IV 
Intravenous 
LS Means 
Least Square Means 
MDI 
Metered Dose Inhaler 
MAR 
Missing at Random 
MEAE 
Mannitol Tolerance Test-emergent Adverse Event 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
Multiple Imputation 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 9 of 108 
Abbreviation 
Description 
MMRM 
Mixed Model Repeated Measures 
MTT 
Mannitol Tolerance Test 
PDPE 
Protocol Defined Pulmonary Exacerbation 
PE 
Pulmonary Exacerbation 
PEF 
Peak Expiratory Flow 
PI 
Principal Investigator 
PP 
Per Protocol  
PT 
Preferred Term 
REML 
Restricted Maximum Likelihood 
rhDNase 
Recombinant human deoxyribonuclease 
 
SAP 
Statistical Analysis Plan 
SBP 
Systolic Blood Pressure 
SD 
Standard Deviation 
SE 
Standard Error 
SOC 
System Organ Class 
SOP 
Standard Operating Procedure 
SpO2 
Oxygen Saturation 
SAF 
Safety Set 
TEAE 
Treatment-emergent Adverse Event 
TLF 
Table, Listing, and Figure 
VAS 
Visual Analogue Scale 
 


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 10 of 108 
2. 
PURPOSE 
The purpose of this statistical analysis plan (SAP) is to ensure that the summary tables, 
data listings, and figures (TLFs) which will be produced, and the statistical 
methodologies that will be used, are complete and appropriate to allow valid 
conclusions regarding the trial objectives. 
2.1. 
RESPONSIBILITIES 
INC Research will perform the statistical analyses and are responsible for the production 
and quality control of all TLFs outlined in this document. 
2.2. 
TIMINGS OF ANALYSES 
For this trial, only a full analysis of safety and efficacy is planned after all subjects 
complete the final trial visit or withdraw early from the trial (no interim analyses will 
be performed). This SAP covers this analysis and has been finalized (on 23May2017) prior 
to the unblinding of the trial. 
An independent data monitoring committee (DMC) reviewed descriptive summaries of 
subject disposition and accumulating safety data (including summaries of forced 
expiratory volume in 1 second [FEV1] and forced vital capacity [FVC]) at a frequency 
recommended by the DMC. The final DMC charter Version 1.0, dated 29Jul2014, defined 
the timing and purpose of the DMC meetings and presented an outline of the reports to 
be provided for review at each meeting. Version 2.0, dated 15Dec2014, contained 
updates on meeting minute preparation and distribution, distribution of all safety data 
to the DMC, safety review meetings, and further updates on safety and 
pharmacovigilance. Version 3.0, dated 04Mar2015, contained updates on the Pharmaxis 
project manager and Version 2.0 of the protocol. Version 4.0, dated 23Jun2015, 
contained updates on the Pharmaxis project manager, the addition of summaries of 
FEV1 and FVC to be included in open and closed reports, and other administrative 
changes. None of the updates to the DMC charter affected blinding procedures. The 
DMC is referred to in the Protocol as the data safety monitoring board. All analyses 
required for the DMC meetings are documented in a separate DMC SAP (final 
Version 3.0, dated 02Jul2015). The data reviewed by the DMC were fully unblinded and 
reported under the actual treatment groups. Therefore a separate unblinded team from 
INC Research biostatistics performed the analyses as described in the DMC SAP to 
maintain the blinding of the trial. 
A fully blinded sample size re-estimation was planned after at least 300 subjects had 
been recruited and at least 100 subjects had Visit 4 (Week 26) spirometry data 
available. Further details are provided in Section 10 and in a separate sample size 
re-estimation plan (final Version 1.0, dated 07Dec2015). 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
*Updated in this SAP to be reported in L rather than mL to match the units used in data collection (see Section 11). 
**Clarified in this SAP that pulmonary exacerbations classified as protocol defined pulmonary exacerbations (PDPEs) will 
be used in the main analyses for these endpoints (see Section 11). 
 
Page 11 of 108 
3. 
TRIAL OBJECTIVES 
3.1. 
PRIMARY OBJECTIVE 
To determine whether inhaled mannitol (400 mg twice daily [b.i.d.]) is superior to 
control (50 mg inhaled mannitol b.i.d.) for improving lung function as measured by 
mean change from baseline FEV1 (mL)* over the 26-week treatment period in adult 
subjects with cystic fibrosis (CF). 
3.2. 
SECONDARY OBJECTIVE(S) 
There are hierarchical and non-hierarchical secondary objectives. Analysis of 
hierarchical secondary objectives will continue until a non-significant p-value 
(i.e. p>0.05) is returned.  
3.2.1. 
Hierarchical Secondary Objectives  
1. To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control 
(50 mg inhaled mannitol b.i.d.) for improving lung function as measured by mean 
change from baseline FVC (mL)* over the 26-week treatment period in adult 
subjects with CF;  
2. To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control 
(50 mg inhaled mannitol b.i.d.) in increasing the time to first pulmonary 
exacerbation** over the 26-week treatment period in adult subjects with CF; 
3. To determine whether in adult subjects with CF, inhaled mannitol (400 mg 
b.i.d.) is superior to control (50 mg inhaled mannitol b.i.d.) for reducing the 
number of days on antibiotics (oral, inhaled, or intravenous [IV]) due to 
pulmonary exacerbation**; 
4. To determine whether in adult subjects with CF, inhaled mannitol (400 mg 
b.i.d.) is superior to control (50 mg inhaled mannitol b.i.d.) for decreasing the 
number of days in hospital due to pulmonary exacerbation**; and  
5. To determine whether inhaled mannitol (400 mg b.i.d.) decreases the rate of 
pulmonary exacerbations** over the 26-week treatment period compared to 
control (50 mg inhaled mannitol b.i.d.) in adult subjects with CF.  
 
3.2.2. 
 
Non-hierarchical Secondary Objectives  
To determine whether in adult subjects with CF, inhaled mannitol (400 mg b.i.d.) is 
superior to control (50 mg inhaled mannitol b.i.d.)  


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
*Updated in this SAP to be reported in L rather than mL to match the units used in data collection (see Section 11). 
**Clarified in this SAP that pulmonary exacerbations classified as protocol defined pulmonary exacerbations (PDPEs) will 
be used in the main analyses for these endpoints (see Section 11). 
 
Page 12 of 108 
1. For decreasing the incidence of exacerbations** (i.e. the proportion of subjects 
with one or more exacerbation);  
2. For improving ease of expectoration; and  
3. For improving subject reported respiratory symptoms as measured by CFQ-R 
respiratory domain.  
3.3. 
BRIEF DESCRIPTION OF TRIAL DESIGN 
This is a phase III double-blind, randomized, parallel group, controlled, multicenter, 
and interventional clinical trial. Potential subjects will sign the informed consent form 
(ICF) and be assessed for eligibility. After satisfying all inclusion & exclusion criteria, 
subjects will be given a mannitol tolerance test (MTT). Those subjects that pass the 
MTT will be randomized in a 1:1 ratio to receive inhaled mannitol (400 mg b.i.d.) or 
control (50 mg inhaled mannitol b.i.d.) for a period of 26 weeks. Randomization will be 
stratified by Recombinant human deoxyribonuclease (
 rhDNase) use and 
country. 
3.4. 
SUBJECT SELECTION 
3.4.1. 
Inclusion Criteria 
The subject must meet all of the following criteria:  
1. Have given written informed consent to participate in this trial in accordance 
with local regulations;  
2. Have a confirmed diagnosis of CF (positive sweat chloride value ≥60 mEq/L) 
and/or genotype with two identifiable mutations consistent with CF, 
accompanied by one or more clinical features consistent with the CF 
phenotype); 
3. Be aged at least 18 years old;  
4. Have FEV1 >40% and <90% predicted (using NHanes III[1]);  
5. Be able to perform all the techniques necessary to measure lung function;  
6. Be adherent with maintenance therapies (antibiotics and/or rhDNase), if used, 
for at least 80% of the time in the two weeks prior to Visit 1; and  
7. If rhDNase and/or maintenance antibiotic are being used treatment must have 
been established at least 1 month prior to screening (Visit 0). The subject should 
remain on the rhDNase and/or maintenance antibiotics for the duration of the 
trial. The subject should not commence treatment with rhDNase or maintenance 
antibiotics during the trial.  


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 13 of 108 
3.4.2. 
Exclusion Criteria 
The subject must NOT meet any of the following criteria:  
1. Be investigators, site personnel directly affiliated with this trial, or their 
immediate families. Immediate family is defined as a spouse, parent, child, or 
sibling, whether biologically or legally adopted;  
2. Be considered “terminally ill” or eligible for lung transplantation;  
3. Have had a lung transplant;  
4. Be using maintenance nebulized hypertonic saline including in the 2 weeks prior 
to Visit 1;  
5. Have had a significant episode of hemoptysis (>60 mL) in the three months prior 
to Visit 0;  
6. Have had a myocardial infarction in the three months prior to Visit 0;  
7. Have had a cerebral vascular accident in the three months prior to Visit 0;  
8. Have had major ocular surgery in the three months prior to Visit 0;  
9. Have had major abdominal, chest, or brain surgery in the three months prior to 
Visit 0;  
10. Have a known cerebral, aortic, or abdominal aneurysm;  
11. Be breast feeding or pregnant, or plan to become pregnant while in the trial;  
12. Be using an unreliable form of contraception (female subjects at risk of 
pregnancy only);  
13. Be participating in another investigative drug trial, parallel to, or within 4 weeks 
of Visit 0;  
14. Have a known allergy to mannitol;  
15. Be using non-selective oral beta blockers;  
16. Have uncontrolled hypertension i.e. systolic blood pressure (SBP) >190 and/or 
diastolic blood pressure (DBP) >100;  
17. Have a condition or be in a situation which in the Investigator‟s opinion may put 
the subject at significant risk, may confound results, or may interfere 
significantly with the subject‟s participation in the trial;  
18. Have a failed or incomplete MTT. 
3.5. 
DETERMINATION OF SAMPLE SIZE 
Enrolment will continue until at least 350 subjects have been randomized to trial 
medication in a 1:1 ratio. Assuming that the change from baseline in FEV1 on control 
(50 mg inhaled mannitol b.i.d.) is 0 mL and the change from baseline in FEV1 on inhaled 
mannitol (400 mg b.i.d.) is 80 mL, then a sample size of 350 (175 Mannitol: 175 Control) 
subjects will yield 90% power at the 0.05 significance level to detect this difference 
between the treatment groups assuming a pooled standard deviation (SD) of 230 mL. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 14 of 108 
The sample size calculation was based on a t-test of the treatment contrast at Week 26. 
While this approach is not completely concordant with the primary analysis which 
computes the mean change in FEV1 over all three post-baseline visits it can be 
considered a suitable method for estimating sample sizes for longitudinal analyses and is 
likely to be conservative.  
The estimated pooled SD of 230 mL is based on the observed pooled SD in the pooled 
adult DPM-CF-301 and DPM-CF-302 data from subjects who completed the studies.  
This minimum sample size is based upon the observed pooled SD from both DPM-CF-301 
and DPM-CF-302 studies in subjects with baseline FEV1 of more than 40% but less than 
90%. However the observed SDs were different in these two previous studies, and were 
highly influenced by a few outlying values. In addition, this trial will be conducted at 
different sites and in different countries to the previous studies. Thus there is some 
uncertainty as to what the observed SD is likely to be in this trial. For these reasons a 
sample size re-estimation was planned to be completed after at least 300 subjects have 
been recruited and at least 100 subjects had Visit 4 (Week 26) spirometry data 
available. This blinded sample size re-estimation was based on the method of Kieser 
and Friede[2] which preserves the overall Type 1 error rate. Therefore no adjustments to 
the overall significance level for the trial are required. See Section 10 for more details. 
 
3.6. 
TREATMENT ASSIGNMENT & BLINDING 
Subjects are randomized in a 1:1 ratio to receive either inhaled mannitol (400 mg 
b.i.d.) or control (50 mg inhaled mannitol b.i.d.) using centralized randomization. 
Randomization will be stratified by rhDNase use and country. Note that in cases of 
misstratification, i.e. where the incorrect rhDNase use is entered in the randomization 
system, the correct rhDNase use recorded in the case report form (CRF) will be used in 
summaries and analyses. 
During the trial, the subject, the investigative staff, and the Sponsor (or designee) will 
be blinded to the treatment allocation. Unblinding a subject should only be done in a 
medical emergency and, where possible, should be discussed with the sponsor prior to 
unblinding. 
To ensure subject safety throughout the trial, an independent DMC will be established 
at the beginning of the trial to review all accumulating safety data. Unblinded data will 
be prepared by an INC statistician who is independent from the study team. All 
unblinded analyses will be stored in a restricted area. DMC charter Version 4.0 dated 
23Jun2015 details the procedures to ensure maintenance of overall trial blinding. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 15 of 108 
3.7. 
ADMINISTRATION OF TRIAL MEDICATION 
The inhalation technique for inhaled mannitol (400 mg b.i.d.) and control (50 mg 
inhaled mannitol b.i.d.) is identical. 
The trial medication is to be administered in a standardized manner. The Investigator is 
responsible for instructing the subject on the correct trial medication inhalation 
technique, and on use of the bronchodilator (albuterol/salbutamol metered dose inhaler 
(MDI) or similar) 5 to 15 minutes prior to the trial medication administration.  
The Investigator will prescribe the subject with a bronchodilator (albuterol/ 
salbutamol-MDI or similar) to be used as premedication prior to inhalation of the trial 
medication. This bronchodilator may also be used in the event of post-treatment chest 
tightness.  
Subjects will take trial medication twice a day, once in the morning and once in the 
evening. The evening dose should be administered approximately 2 hours before sleep.  
 
Each kit dispensed contains additional supply to account for the protocol allowed visit 
windows. 
3.8. 
TRIAL PROCEDURES AND FLOWCHART 
This trial consists of 5 visits over a period of 28-weeks.  
 
Table 1 below provides the complete schedule of assessments for the trial.


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 16 of 108 
Table 1: Time and Events Schedule 
Event 
Screeni
ng Visit 
0 
 
Visit 
1 
 
 
Visit 2 
 
 
Visit 3 
 
 
 
Visit 4 
 
 
IMP 
discontinuatio
n visita 
Week 
-5 to- 2  
-1 
0b 
2 
4 
6 
8 
12 
14 
16 
20 
24 
26 
27 
 
 
Visit window 
 
 1 
day 
 
 3 
days 
 3 
days 
 7 
days 
 3 
days 
 3 
days 
 7 
days 
 3 
days 
 3 
days 
 3 
day 
- 7 days 
to  
+ 28 
days 
 1 
day 
 
Within 2 
weeks of IMP 
discontinuatio
n 
Informed consent  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history / 
demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
Physical examination/ vital 
signs 
X 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
X 
Pulmonary function tests 
X 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
X 
Urine pregnancy test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary exacerbations 
review 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
X 
MTT procedure 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomize subject 
 
 
Xc 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dispense trial medication & 
bronchodilator 
 
 
X 
 
 
X 
 
 
X 
 
 
 
 
 
 
 
                                                 
a The IMP discontinuation visit is used for all subjects that discontinue IMP early, but are remaining in the study. 
b Subjects should be stable and clear of pulmonary exacerbations for at least two weeks prior visit 1. If a subject has an exacerbation after Visit 0 (screening), visit 1 should occur 2 to 5 weeks from the end of the treatment of the 
exacerbation or the end of the adverse event, whichever is later. 
c Randomize eligible subjects if compliance with maintenance therapies (antibiotic & rhDNase) is at least 80% in the two weeks prior to visit 1. 


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 17 of 108 
Event 
Screeni
ng Visit 
0 
 
Visit 
1 
 
 
Visit 2 
 
 
Visit 3 
 
 
 
Visit 4 
 
 
IMP 
discontinuatio
n visita 
Week 
-5 to- 2  
-1 
0b 
2 
4 
6 
8 
12 
14 
16 
20 
24 
26 
27 
 
 
Visit window 
 
 1 
day 
 
 3 
days 
 3 
days 
 7 
days 
 3 
days 
 3 
days 
 7 
days 
 3 
days 
 3 
days 
 3 
day 
- 7 days 
to  
+ 28 
days 
 1 
day 
 
Within 2 
weeks of IMP 
discontinuatio
n 
Administer treatment dose in 
clinic 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
Sputum qualitative 
microbiology 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening blood sample 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Issue subject diary 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review subject diary 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
X 
Collect subject diary 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Adverse event assessment 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
Ease of expectoration VAS 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
X 
CFQ-R respiratory domain 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
X 
IMP compliance and 
accountabilityd 
 
 
 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
Discuss adherence to 
treatment (if subject has 
discontinued IMP, schedule 
IMP discontinuation visit 
within 2 weeks of last IMP) 
 
 
 
X 
X 
 
X 
X 
 
X 
X 
X 
 
 
 
 
                                                 
d IMP accountability and collection must occur at the next scheduled visit for any subjects that withdraw from the study or discontinue from IMP early 


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 18 of 108 
Event 
Screeni
ng Visit 
0 
 
Visit 
1 
 
 
Visit 2 
 
 
Visit 3 
 
 
 
Visit 4 
 
 
IMP 
discontinuatio
n visita 
Week 
-5 to- 2  
-1 
0b 
2 
4 
6 
8 
12 
14 
16 
20 
24 
26 
27 
 
 
Visit window 
 
 1 
day 
 
 3 
days 
 3 
days 
 7 
days 
 3 
days 
 3 
days 
 7 
days 
 3 
days 
 3 
days 
 3 
day 
- 7 days 
to  
+ 28 
days 
 1 
day 
 
Within 2 
weeks of IMP 
discontinuatio
n 
Remind subject of next visit 
or phone call, withholding 
periods, to complete subject 
diary, and to return trial drug 
(if applicable)e 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
Discharge subject from trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
                                                 
e The subject diary should be collected for all subjects, including those who withdraw early from the study 




Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
*Updated in this SAP to be reported in L rather than mL to match the units used in data collection (see Section 11). 
**Clarified in this SAP that pulmonary exacerbations classified as protocol defined pulmonary exacerbations (PDPEs) will 
be used in the main analyses for these endpoints (see Section 11). 
 
Page 20 of 108 
and accuracy. 
In addition to the primary endpoint, the following variables will be analyzed: 
 
Mean absolute change from baseline percent predicted FEV1 (%) over 26 weeks. 
 
Mean relative change from baseline FEV1 (L) over 26 weeks. 
 
Mean relative change from baseline percent predicted FEV1 (%) over 26 weeks. 
Percent predicted is a clinically accepted measure which adjusts for the subject age, 
height, gender, and race. The formula is: 
Percent predicted FEV1 = 100×(FEV1/Predicted FEV1) 
Predicted FEV1 is derived using the formulae by Hankinson et al[1]: 
Predicted FEV1 = α+β1×age+β2×age2+β3×height2 
where height is taken as the screening value and measured in cm and age is calculated 
at the date of the spirometry measurement. The coefficients are as follows: 
Table 2: Predicted FEV1 Coefficients 
Age 
Race  
Gender α 
β1 
β2 
β3 
18-19 
Caucasian Male 
-0.7453 -0.04106 
0.004477 
0.00014098 
18-19 
African 
descenta 
Male 
-0.7048 -0.05711 
0.004316 
0.00013194 
≥20 
Caucasian Male 
0.5536 
-0.01303 
-0.000172 
0.00014098 
≥20 
African 
descenta 
Male 
0.3411 
-0.02309 
- 
0.00013194 
≥18 
Caucasian Female 
0.4333 
-0.00361 
-0.000194 
0.00011496 
≥18 
African 
descenta 
Female 
0.3433 
-0.01283 
-0.000097 
0.00010846 
a Referred to as African-American in Hankinson et al[1]. 




Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
*Updated in this SAP to be reported in L rather than mL to match the units used in data collection (see Section 11). 
**Clarified in this SAP that pulmonary exacerbations classified as protocol defined pulmonary exacerbations (PDPEs) will 
be used in the main analyses for these endpoints (see Section 11). 
 
Page 22 of 108 
 
Change in sputum production (volume, color, consistency). 
 
Increased dyspnea. 
 
New or increased hemoptysis. 
 
Malaise, fatigue, or lethargy. 
 
Fever (>38 oC). 
 
Anorexia or weight loss. 
 
Sinus pain or tenderness. 
 
Change in sinus discharge. 
 
FVC or FEV1 decreased by >10% from previous recorded value. 
 
Radiographic signs indicative of pulmonary infection. 
 
Increased cough. 
 
Changes in physical examination of the chest. 
PDPEs will be identified from the pulmonary exacerbation (PE) Review CRF page, 
where IV antibiotics were recorded as being given for a PE and, in addition, 4 or 
more of the above signs or symptoms were ticked.  
Time to first PE will also be calculated, in a similar manner, and explored under this 
endpoint, however the hierarchical testing will be based on time to first PDPE. A PE 
is defined as any event recorded on the PE Review CRF page that has associated 
antibiotic use (oral, inhaled, or IV), whether or not it meets the above conditions. 
3) Number of days on antibiotics (oral, inhaled, or IV) due to PDPE** over the 26-week 
treatment period. Medication use for a PE will be identified on the concomitant 
medication page by a yes/no box; a further check will be made to ensure 
medications are for a PDPE (i.e. that the PE event to which the medication is linked 
satisfies the above criteria for a PDPE). It will also be checked that both the PDPE 
and the medication use started on or after Trial Day 1 (defined in Section 6.2.2). 
Antibiotics are identified by their Anatomical Therapeutic Chemical (ATC) Level 2 
code J01 (antibacterials for systemic use). 
Number of days on one antibiotic = stop date–start date+1 
The number of days for all occurrences will be summed. If multiple antibiotics are 
received for the same event, the durations will be computed separately and added 
together. If an antibiotic is ongoing at the end of the subject‟s participation in the 
trial, the subject‟s date of last participation in the trial will be used in the 
calculation instead of the stop date. 
Date of last participation in the trial is defined in Section 6.2.5. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
*Updated in this SAP to be reported in L rather than mL to match the units used in data collection (see Section 11). 
**Clarified in this SAP that pulmonary exacerbations classified as protocol defined pulmonary exacerbations (PDPEs) will 
be used in the main analyses for these endpoints (see Section 11). 
 
Page 23 of 108 
As a supportive analysis, the following endpoints will be calculated: 
- 
Number of distinct days on antibiotics due to PDPE over the 26-week treatment 
period: if multiple antibiotics are received for the same event and overlap 
(i.e. stop date of one antibiotic≥start date of next antibiotic), days with more 
than one antibiotic will be counted only once. 
Number of distinct days on antibiotics = sum(days with at least one antibiotic 
intake for an event). 
If an antibiotic is ongoing at the end of the subject‟s participation in the trial, 
days will be counted up until the subject‟s date of last participation in the trial. 
- 
Number of days on antibiotics (oral, inhaled, or IV) due to PE over the 26-week 
treatment period. 
- 
Number of distinct days on antibiotics due to PE over the 26-week treatment 
period. 
As supportive information, the following variables will be calculated: 
- 
Number of distinct episodes of use of antibiotics due to PDPE, defined as any 
recorded use of antibiotics due to PDPE with a different start date from any 
other recorded use of antibiotics due to PDPE. 
- 
Number of courses of antibiotics due to PDPE, defined as any recorded use of 
antibiotics due to PDPE with a start date 14 or more days after the stop date of 
all previous antibiotics for any PDPE. 
All subjects experiencing a PDPE would have received IV antibiotics. 
These supportive endpoints/variables will not be part of the hierarchical testing. 
4) Number of days in hospital (admissions only) due to PDPE** over the 26-week 
treatment period. For each hospital admission, the number of days in hospital will 
be calculated as (end date)-(start date)+1. Each hospitalization with a reason of PE 
will be cross-referenced with a PE from the PE Review CRF page to determine if the 
hospitalization was due to a PDPE. If the start date of the hospitalization is included 
within the dates of any PDPE for that subject, then that hospitalization will be 
designated as due to PDPE. If the hospitalization is ongoing at the end of the 
subject‟s participation in the trial, the subject‟s date of last participation in the 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
*Updated in this SAP to be reported in L rather than mL to match the units used in data collection (see Section 11). 
**Clarified in this SAP that pulmonary exacerbations classified as protocol defined pulmonary exacerbations (PDPEs) will 
be used in the main analyses for these endpoints (see Section 11). 
 
Page 24 of 108 
trial will be used in the calculation instead of the end date. 
As a supportive analysis, the following endpoint will be calculated: 
- 
Number of days in hospital (admissions only) due to PE. 
The hierarchical testing will be based on days in hospital due to PDPE. 
5) Rate of PDPE** (per person year) over the 26-week treatment period. 
The overall rate of PDPE (per person year) over the 26-week treatment period will 
be calculated for each treatment group as: 
Overall Rate = total number of PDPE/total follow-up duration 
where total follow-up duration (years) = ([last participation date]–[date of Trial 
Day 1]+1)/365.25 summed over all subjects in the treatment group. 
Trial Day 1 is defined in Section 6.2.2. 
Date of last dose of trial medication is defined in Section 6.2.1. 
In the above calculations, rate will be rounded to two decimal places for displaying 
purposes. 
The overall rate of PE (per person year) over the 26-week treatment period will also 
be calculated, in a similar manner, and explored under this endpoint, however the 
hierarchical testing will be based on the rate of PDPE. 
4.2.2. 
Non-hierarchical Secondary Endpoints 
1) Incidence of PDPEs** (yes or no, binary outcome) over the 26-week treatment 
period. 
Incidence of PEs (yes or no, binary outcome) over the 26-week treatment period will 
also be explored under this endpoint, however the main focus will be on the 
incidence of PDPEs. 
2) Ease of expectoration measured at Weeks 6, 14 and 26 using the absolute change 
from baseline visual analogue scale (VAS) score. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
*Updated in this SAP to be reported in L rather than mL to match the units used in data collection (see Section 11). 
**Clarified in this SAP that pulmonary exacerbations classified as protocol defined pulmonary exacerbations (PDPEs) will 
be used in the main analyses for these endpoints (see Section 11). 
 
Page 25 of 108 
3) Mean absolute change from baseline CFQ-R respiratory domain score measured at 
Weeks 6, 14 and 26. This will be appropriately transformed according to the scoring 
manual[5], so that the best response will be uniformly the highest score and the 
worst response will be uniformly the lowest score. More details are provided in 
 
The CFQ-R respiratory domain includes the Question 42 (CRF Question 3), “Have you 
had to cough up mucus?” The scoring algorithm scores an affirmative answer to this 
question as a negative outcome for the subject, however, due to the mechanism of 
action of mannitol (i.e. inducing coughing up mucus) an affirmative answer here 
may not be a negative outcome and hence this question is inappropriate here. 
Therefore, the endpoint will also be derived omitting this question. 
4.3. 
SAFETY ENDPOINTS  
Safety endpoints include adverse events (AEs; including deaths), extent of trial 
medication exposure and trial medication compliance, vital signs, and physical 
examination data. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 26 of 108 
5. 
ANALYSIS SETS 
5.1. 
SAFETY SET  
The Safety (SAF) set will include all subjects who were administered at least one dose 
(or part thereof) of randomized trial medication. Subjects will be analyzed according to 
trial medication received. The SAF set will be used for all analyses of safety endpoints. 
 
5.2. 
INTENT-TO-TREAT SET  
The Intent-to-Treat (ITT) set will include all randomized subjects. Subjects will be 
analyzed according to randomized trial medication. The ITT set will be used for all 
analyses of efficacy endpoints. 
 
5.3. 
PER PROTOCOL SET  
The Per Protocol (PP) set consists of all randomized subjects, excluding those who had 
deviations from the protocol that may affect the assessment of response to trial 
medication. The criteria for exclusion from the PP are defined in Section 5.5.  
 
5.4. 
MANNITOL TOLERANCE TEST SET 
The MTT set will include all subjects participating in the MTT prior to randomization 
regardless of their subsequent randomization status. It will include subjects who fail the 
MTT (MTT positive) or who have an incomplete procedure, along with those who pass 
the MTT (MTT negative).  If subject is re-screened, only the re-screen subject number 
will be included in the MTT set, the original subject number will be excluded. 
5.5. 
PROTOCOL DEVIATIONS 
Protocol deviations identified by the clinical research associates during their monitoring 
visits were captured in 
using broad category groupings. 
All recorded protocol deviations were reviewed during the course of the trial. In 
addition, protocol deviations were identified through programmatic checks in order to 
assist in the assignment of subjects to the PP set. At the BDRM, held prior to the 
unblinding of the trial deviations were grouped into subcategories under each broad 
category grouping and decisions were made on whether to exclude each subject from 
the PP set by categorizing each recorded and programmed protocol deviation as major 
or minor, where major identifies a reason for exclusion from the PP set.  


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 27 of 108 
All major protocol deviations, from 
 and programmed, will be listed and 
summarized for the ITT set based on the 
category and assigned subcategory. 
Important minor protocol deviations, including those related to trial inclusion or 
exclusion criteria, conduct of the trial, subject management or subject assessments, 
were identified at the BDRM and will be listed by 
 category and assigned 
subcategory.  
Criteria to determine if a subject will be included in the PP set were detailed in a BDRM 
preparation plan together with details of the programmatic listings to be prepared. The 
adjusted criteria confirmed during the BDRM to determine if a subject will be excluded 
from the PP set were: 
 
Did not meet all the inclusion and exclusion criteria. 
 
Was randomized but did not take at least one dose of trial medication. 
 
Compliance to trial medication while taking trial medication <60%. 
 
No valid baseline FEV1 measure, where a baseline measure was considered non 
valid if precluded medications were not withheld as detailed in the protocol. 
 
Started treatment with maintenance hypertonic saline where it was considered 
that there was a potential for efficacy assessments to be impacted. 
 
Started or stopped treatment with rhDNase or maintenance antibiotics where it 
was considered that there was a potential for efficacy assessments to be 
impacted. 
Further details of the rules applied to determine inclusion in the PP set will be 
documented in the BDRM Highlights and will be agreed and finalized prior to database 
lock. 
Only FEV1 measurements taken in the absence of precluded medications will be 
considered valid. Precluded medications and required withholding periods are detailed 
in Table 3 (as detailed in the protocol and CRF). 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 28 of 108 
Table 3: Medication-withholding periods 
Medication 
Time interval from 
last dose until 
spirometry 
Short-acting β2 agonists (isoproterenol, isoetharine, metaproterenol, 
salbutamol, albuterol, levalbuterol, terbutaline) 
Short-acting anticholinergics including combination therapies (e.g. 
ipratropium) 
At least 6 hours 
Long acting β2 agonists (e.g. salmeterol or eformoterol) 
Long acting anticholinergics (e.g. tiotropium) 
At least 12 hours 
Oral bronchodilators (e.g. theophylline and β-agonist tablets) 
At least 12 hours 
Any precluded medications taken not in accordance with the above withholding periods 
were reviewed at the BDRM, and an assessment was made on the validity of the 
associated spirometry measurements. 
At the BDRM, a local major deviation was defined for the visit if the spirometry 
assessment was determined to be non valid, leading to the exclusion of all the specific 
assessment‟s data collected at the visit from the PP analysis. Of note, local major 
deviations will not lead to the exclusion of the subject from the PP set; any derived 
variables based on these excluded measurements will be treated as missing data and 
will not be imputed for the PP analysis. Local major deviations will be flagged in the 
data listing of major protocol deviations, but not included in the corresponding 
summary table. 
The finalization of protocol deviations and exclusions of subjects from the PP set and of 
individual visit data from the PP analysis will be made 
 
 
 
 
 
The number and percentage of subjects included in and excluded from the SAF and 
PP sets will be presented for the ITT set, including a breakdown of all categorized 
reasons for exclusion from the PP set. All reasons for each subject will be included, but 
each subject will only be counted once within each reason category. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 29 of 108 
6. 
GENERAL ASPECTS FOR STATISTICAL ANALYSIS 
6.1. 
GENERAL METHODS 
Unless otherwise specified, all demographic and baseline data will be presented by 
treatment group and overall. Efficacy and safety data will be presented by treatment 
group. All subjects entered into the database will be included in subject data listings. 
Continuous variables will be summarized using the number of observations (n), n missing 
(n miss), mean, SD, median, minimum, and maximum. Categorical variables will be 
summarized using the number (n) and percentage (%) of subjects with non-missing data 
per category. Where relevant, the number of missing values will be included as a 
“Missing” category. Unless otherwise specified, the denominator for each percentage 
will be the number of non-missing observations within the analysis set and treatment 
group. 
All tests of hypotheses will be 2-sided and conducted at the 5% significance level, and 
all confidence intervals (CIs) will be 2-sided at the 95% level.  
 
 
. 
6.2. 
KEY DEFINITIONS 
6.2.1. 
Dates of First and Last Trial Medication Intake 
In this document, trial medication refers to the randomized trial medication (inhaled 
mannitol [400 mg b.i.d.] and control [50 mg inhaled mannitol b.i.d.]) and does not 
include the MTT. 
The date of first trial medication is taken as the date of first administration of trial 
medication after randomization. 
The date of last trial medication is taken as the date of last administration of trial 
medication.  
If date of last administration of trial medication is missing, the date will be imputed 
using the last available known start or end date of trial medication. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 30 of 108 
6.2.2. 
Trial Day 
Trial day is defined as the number of days from the date of randomization to the event 
date and will be calculated as follows: 
 
If the event date≥date of randomization, trial day = event date–date of 
randomization+1. Trial Day 1 is therefore defined as the day of randomization. 
 
If the event date<date of randomization, trial day = event date-date of 
randomization. 
6.2.3. 
Treatment Day 
Treatment day is defined as the number of days from the date of first dose to the event 
date and will be calculated as follows: 
 
If the event date≥date of first dose, treatment day = event date–date of first 
dose+1. Treatment Day 1 is therefore defined as the day of first dose. 
 
If the event date<date of first dose, treatment day = event date-date of first 
dose. 
6.2.4. 
Baseline 
The baseline value for all efficacy endpoints will be taken as Visit 1. It will be assumed 
that assessments performed on this visit were prior to first trial medication 
administration, with the exception of post-dose spirometry. Therefore, efficacy 
baseline will be the Visit 1 measurement unless the Visit 1 measurement is missing, 
where the Visit 0 measurement will be used as baseline. 
The baseline value for safety endpoints (vital signs and physical examination) will be 
taken as the latest available measurement prior to or on Treatment Day 1 (i.e. day of 
first trial medication dose). It will be assumed that safety assessments performed on 
Treatment Day 1 were prior to trial medication administration. Baseline will be the 
Visit 1 measurement. 
6.2.5. 
Date of Last Participation in the Trial 
A subject‟s date of last participation in the trial is the last date of contact that the 
subject has with the trial and is recorded as the date of completion or date of 
withdrawal on the completion page of the CRF. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 31 of 108 
6.2.6. 
Follow-up Phase 
The follow-up phase covers the whole time that a subject is in the trial between Trial 
Day 1 and their date of last participation in the trial. 
follow-up duration = (last participation date)–(date of Trial Day 1)+1 
6.2.7. 
On-treatment and Off-treatment Period 
Subjects discontinuing the trial medication were encouraged to continue in the trial to 
provide all scheduled measurements.  This will result in some subjects having 
information recorded both while taking trial medication and after trial 
medication has been discontinued. 
The following definition of “on-treatment” and “off-treatment” periods are applied: 
For Safety data: 
- 
On-treatment period: period of time while the subject is on trial medication; it 
starts with the first intake of trial medication after randomization and ends 28 days 
after the last trial medication intake. 
All safety analyses will be conducted considering the measurements and AEs observed 
during the on-treatment period (excluding MTT-emergent AEs [MEAEs]). 
For Efficacy data: 
- 
On-treatment period: period of time while the subject is on trial medication; it 
starts with the first intake of trial medication after randomization and ends 7 days 
after the last trial medication intake.  
- 
Off-treatment period: period of time while the subject is not on trial medication; it 
starts the eighth day after the last trial medication intake and ends on the date of 
last participation in the trial. 
All efficacy analyses will be conducted considering all measurements collected 
(i.e. including both on-treatment and off-treatment period data). 
In addition, for the primary endpoint, supportive analyses will be conducted considering 
only measurements collected during the on-treatment period. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 32 of 108 
6.3. 
MISSING DATA 
Missing or partial dates will be resolved in the most conservative manner. Additional 
details regarding partial or missing dates for the different safety data are given in 
Sections 6.2.1, 7 and 9 where applicable. 
Details of imputation of missing values for efficacy endpoints are given in Section 8. 
Subjects who discontinue trial medication should remain in the trial and continue to 
provide all scheduled measurements. While all efforts will be made to ensure subjects 
remain in the trial, the following planned imputation strategy will allow for appropriate 
analyses of FEV1, FVC, ease of expectoration VAS score, and CFQ-R respiratory domain 
in the presence of missing data. 
To calculate baseline values, missing Visit 1 measurements will be replaced by Visit 0 
(screening) measurements, if available. 
Missing post-baseline measurements as a result of withdrawal from the trial will be 
imputed in both ITT and PP analyses using an imputation using dropout reason (IUDR) 
methodology. For subjects who withdraw from the trial due to AE, death, physician 
decision, or lack of efficacy, missing post-baseline measures as a result of withdrawal 
from the trial will be imputed using the baseline measurement (baseline observation 
carried forward [BOCF] procedure). Missing measurements as a result of other causes of 
withdrawal from the trial (i.e. lost to follow-up, relocation, pregnancy, major protocol 
deviation, sponsor decision, withdrawal of consent, or other) will not be imputed. 
Missing data at intermediate visits (i.e. where data is available at a later visit) will not 
be imputed. Any measurements excluded from the PP analysis at the BDRM, and any 
derived variables based on these excluded measurements, will be treated as missing 
data but will not be included in the imputation process. 
Imputation of missing FEV1 measurements by means of BOCF is a reasonable assumption 
in studies of adult subjects with CF, as those subjects who withdraw from the trial will 
no longer receive trial medication and are thus likely to promptly return to their 
baseline lung function. Imputation by BOCF specifically inhibits any assumed 
prolongation of an observed early trial medication benefit implicitly conferred by a 
mixed model. 
A framework of imputation by BOCF in combination with the IUDR strategy seeks to 
specifically address the primary question of interest, that is to provide a reliable 
estimation of the treatment group effect over 26 weeks as observed in all randomized 
subjects.  
For time to first PDPE, subjects who do not have a PDPE during the trial will be 
censored at the date of last participation in the trial. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 33 of 108 
For rate of PDPE, if a subject withdraws from the trial before Week 14 with no observed 
instances of a PDPE the number of PDPEs will be imputed using half the subject‟s 
historical (previous 12 months) PE count (rounded upwards) and their follow-up duration 
will be imputed as 26 weeks. If a subject withdraws from the trial after Week 14 with 
no observed instances of a PDPE the number of PDPEs will be imputed using one quarter 
the subject‟s historical (previous 12 months) PE count (rounded upwards) and their 
follow-up duration will be imputed as 26 weeks. 
For the secondary efficacy analyses of number of days on antibiotics due to PDPE, 
number of days in hospital due to PDPE, and incidence of PDPEs, no imputation of 
missing data will be performed. 
Imputed data will not be displayed in data listings unless otherwise specified. 
6.4. 
VISIT WINDOWS 
All ITT analyses will be performed using the visit as recorded on the CRF. In the case 
where a subject performed the IMP discontinuation visit, the following visit windows 
will be used to assign this visit to the most appropriate visit number for the purposes of 
analysis: 
 
Table 4: Visit windows for assigning IMP discontinuation visits to visit numbers 
Visit 
Target Trial Day 
Window 
Visit 1 (Baseline) 
1 
≤Treatment Day 1 
Visit 2 (Week 6) 
43 
Day 14 – Day 70 
Visit 3 (Week 14) 
99 
Day 71 – Day 140 
Visit 4 (Week 26) 
183 
Day 141 – Day 211 
If this re-assignment of the IMP discontinuation visit to a visit number results in two 
spirometry assessments being available for the same visit then the following rules for 
selecting which assessment to use in the analysis will be used: 
 
If one assessment is recorded during the on-treatment period and the other is 
recorded during the off-treatment period, the assessment recorded during the 
on-treatment period will be used.  
 
Otherwise, if both assessments are recorded during the on-treatment period or 
both are recorded during the off-treatment period then, the one closest to the 
planned or scheduled visit date will be used. If the two observations are 
equidistant from the target day the one after the target day will be used in the 
analysis. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 34 of 108 
6.5. 
POOLING OF CENTERS 
No investigation of center effects is planned, however the stratification factor of 
country will be included in statistical analysis models as detailed in the following 
sections. Low numbers of subjects were recruited for at least one country, so countries 
will be pooled together as United States versus the rest of the world for the 
stratification factor. 
6.6. 
SUBGROUPS 
Subgroup analyses of primary and hierarchical secondary endpoints will be performed to 
assess consistency of response between subgroups of subjects: 
 
With and without rhDNase use.  
 
With differing disease severity (percent predicted FEV1 at baseline). The 
following cut point will be used: >70% and ≤70%. 
In addition subgroup analyses of the primary endpoint will be performed to assess the 
consistency of response between subgroups of subjects: 
 
With and without Pseudomonas aeruginosa infection as specified on the sputum 
qualitative microbiology collected at screening. Pseudomonas aeruginosa 
infection is assumed if there is a recording of mucoid or non-mucoid 
Pseudomonas aeruginosa infection at screening regardless of organism presence 
or clinical significance. Subjects who did not have a sputum sample analyzed at 
screening will be excluded from these subgroup summaries and analyses. 
All subgroup analyses will be carried out by subsetting the overall population according 
to the above subgrouping factors and repeating the analysis for each level of the factor. 
Where applicable (i.e. for rhDNase use and disease severity) the related variable in the 
analysis model will be dropped. 


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 35 of 108 
7. 
DEMOGRAPHIC, OTHER BASELINE CHARACTERISTICS, AND 
MEDICATION 
7.1. 
SUBJECT DISPOSITION AND WITHDRAWALS 
7.1.1. 
Subject Disposition 
The number of screened subjects who participated in the MTT and MTT status (negative 
[passed], positive [failed], or incomplete) will be presented for the MTT set. 
Percentages will be based on the number of subjects participating in the MTT. 
The number and percentage of subjects randomized, not randomized, and treated in 
the trial will be presented, together with the number and percentage of subjects 
randomized in each center within each country, and the number and percentage of 
subjects included in each of the analysis sets. Percentages will be based on the number 
of subjects randomized. 
7.1.2. 
Withdrawal from the Trial 
The number and percentage of randomized subjects who completed the trial and who 
withdrew from the trial early, including a breakdown of the corresponding reasons for 
withdrawal, will be presented for the ITT set. All reasons for withdrawal listed in the 
CRF will be included in the summary, whether or not any subjects withdrew for each 
reason. 
Time to withdrawal from the trial in days will be calculated as: 
Time = (date of withdrawal from the trial)–(date of Trial Day 1)+1 
A Kaplan-Meier plot of time to withdrawal from the trial for the ITT set will be 
presented. Subjects who do not withdraw will be censored at the date of last 
participation in the trial. The number of subjects who withdraw and who are censored 
will be summarized. Kaplan-Meier product limit estimators of the survivor function 
(probability of staying in the trial) will be summarized for 25th percentile, median, and 
75th percentile, and their 95% CIs. 
For the study periods [0-6) weeks, [6-14) weeks, [14-26) weeks, [26-31) weeks, and 
[31-∞) weeks, the number of subjects in the trial at the beginning of the period, the 
cumulative number of withdrawn subjects at the end of the period, and the probability 
of withdrawal at the end of the period with the associated 95% CIs will be presented for 
the ITT set. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 36 of 108 
The number and percentage of subjects in categories of time to withdrawal 
{[0-2) weeks, [2-4) weeks, [4-8) weeks, etc. in 4 weekly intervals} and the number and 
percentage of subjects withdrawing between each visit will also be presented for the 
ITT set. 
In addition, the follow-up duration will be summarized for the ITT set using summary 
statistics for continuous variables and also for categorical variables using monthly 
categories (i.e. 0-1, >1-2, etc.). This will be calculated as: 
Follow-up duration (months) = ([last participation date]–[date of Trial Day 1]+1) 
x12/365.25 
Follow-up duration in months will be rounded to one decimal place for displaying 
purposes. 
The number of subjects who attended Visits 2, 3, and 4 will be summarized for the ITT 
set using summary statistics for categorical variables. 
7.1.3. 
Discontinuation from Trial Medication 
The number and percentage of subjects who completed the trial on trial medication will 
be presented for the ITT set. 
The number and percentage of subjects who discontinued from trial medication 
(whether or not they continued in the trial), including a breakdown of the 
corresponding reasons for discontinuation will be presented for the ITT set. If reason for 
discontinuation is missing for subjects who withdrew from the trial at the same time as 
trial medication discontinuation, the reason for withdrawal will be used. In addition, 
the number and percentage of subjects who discontinued trial medication without off-
trial medication efficacy data and the number and percentage of subjects who 
discontinued trial medication with off-trial medication efficacy data, including a 
breakdown of the corresponding reasons for discontinuation will be presented for the 
ITT set. In each case, all reasons for discontinuation listed in the CRF will be included in 
the summary, whether or not any subjects discontinued for each reason.  
For those subjects with off-trial medication efficacy data, the number and percentage 
of subjects who went on to complete the trial while off trial medication and the number 
and percentage of subjects who subsequently withdrew early from the trial while off 
trial medication will be presented for the ITT set. 
If applicable, a similar breakdown for subjects who never started trial medication will 
be presented for the ITT set. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 37 of 108 
Time to discontinuation from trial medication in days will be calculated for subjects 
receiving at least one dose of trial medication as: 
Time = (date of discontinuation from trial medication)–(date of Treatment Day 1)+1 
Subjects not starting trial medication will have a time to discontinuation of 0 (not censored). 
Subjects who do not discontinue will be censored at the date of last dose in the trial. 
A Kaplan-Meier plot of time to discontinuation from trial medication for the ITT set will 
be presented. The number of subjects with an event and censored will be summarized. 
Kaplan-Meier product limit estimators of the survivor function (probability of staying 
event free) will be summarized for 25th percentile, median, and 75th percentile, and 
their 95% CIs. 
For the study periods [0-6) weeks, [6-14) weeks, [14-26) weeks, [26-31) weeks, and 
[31-∞) weeks, the number of subjects in the trial at the beginning of the period, the 
cumulative number of discontinued subjects at the end of the period, and the 
probability of discontinuation at the end of the period with the associated 95% CIs will 
be presented for the ITT set. 
The number and percentage of subjects in categories of time to discontinuation 
{[0-2) weeks, [2-4) weeks, [4-8) weeks, etc. in 4 weekly intervals} and the number and 
percentage of subjects discontinuing between each visit will also be presented for the 
ITT set. 
7.2. 
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS 
Demography (gender, race, ethnicity, country, age [years] at screening, weight [kg] at 
screening and height [cm] at screening), percent predicted FEV1 at screening, percent 
predicted FEV1 at screening cut points (>90%, >80% to ≤90%, >70% to ≤80%, >40% to 
≤70%, and ≤40%), disease severity (percent predicted FEV1 at baseline), and disease 
severity (percent predicted FEV1 at baseline) cut points (>90%, >80% to ≤90%, >70% to 
≤80%, >40% to ≤70%, and ≤40%) will be summarized for the ITT, PP, and SAF sets, and 
also for the subset of the MTT set who did not go on to be randomized (with the 
exception of the disease severity at baseline variables). Age, weight, and height will be 
summarized using summary statistics for continuous variables. Gender, race, ethnicity, 
and country will be summarized using summary statistics for categorical variables. 
 
Age at screening = (date of MTT-date of birth+1)/365.25 truncated to complete years. 
 
Note that due to patient confidentiality regulations in Hungary, it is only possible to 
collect the year of birth for each subject in that country. In the trial database, the day 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 38 of 108 
and month of birth will be recorded as 31st December for all Hungarian subjects, 
therefore age values will be an underestimation. 
 
Screening medications will be summarized for the ITT set, and for the subset of the MTT 
set who did not go on to be randomized, by anatomical main group, therapeutic 
subgroup and preferred drug name terms using summary statistics for categorical 
variables. Screening medications are defined in Section 7.7.2. A subject who took more 
than one screening medication will be counted only once if these medications belong to 
the same anatomical main group, therapeutic subgroup or preferred drug name. Tables 
will be sorted alphabetically by anatomical main group, therapeutic subgroup and 
preferred drug name. 
 
Screening sputum qualitative microbiology data will be summarized for the ITT set using 
summary statistics for categorical variables. Clinically significant screening laboratory 
tests, screening sputum qualitative microbiology, and screening urine pregnancy test 
data will be listed. 
7.3. 
PRIMARY DIAGNOSIS 
The primary diagnosis information collected at screening will be summarized for the ITT 
and SAF sets, and also for the subset of the MTT set who did not go on to be 
randomized. This will include time since diagnosis (years), age at diagnosis (years), 
cystic fibrosis transmembrane conductance regulator (CFTR) mutation (both deltaF508, 
one deltaF508, at least one other known mutation, and both unknown), use of rhDNase, 
previous diagnosis of bronchiectasis, number of hospitalizations in last 12 months due to 
PE, number of PEs treated with IV antibiotics in last 12 months, previous hypertonic 
saline use, and hypertonic saline use at screening.  
Time since diagnosis (years) and age at diagnosis (years), will be summarized using 
summary statistics for continuous variables. All other endpoints will be summarized 
using summary statistics for categorical variables. Appropriate categories will be 
defined based on available data for number of hospitalizations in last 12 months due to 
PE and number of PEs treated with IV antibiotics in last 12 months. 
Time since diagnosis will be calculated as: 
Time since diagnosis = (age at screening-age at diagnosis) 
where age at diagnosis = (date of first diagnosis-date of birth+1)/365.25 truncated to 
complete years. 
If date of first diagnosis is partially missing, the most conservative case will be 
considered when calculating time since diagnosis: if a partial date is missing a start day, 




Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 40 of 108 
7.6. 
RESPONSE TO SCREENING MANNITOL TOLERANCE TEST 
The MTT parameters FEV1 and oxygen saturation (SpO2) will be summarized by timepoint 
and by MTT result (negative [passed], positive [failed], and incomplete) for the MTT 
set. In addition the maximum percentage fall in FEV1 and greatest absolute drop in 
SpO2, from the 40 mg, 120 mg, 240 mg and 400 mg doses attempted, will be summarized 
by MTT result (negative, positive, and incomplete) for the MTT set. 
Percentage fall in FEV1 will be calculated as: 
Percentage fall in FEV1 = 100×((Baseline FEV1–post Baseline FEV1)/Baseline FEV1) 
Percentage fall in FEV1 will be rounded to two decimal places for displaying purposes. 
Absolute drop in SpO2 will be calculated as: 
Absolute drop in SpO2 = Baseline SpO2–post Baseline SpO2 
7.7. 
MEDICATION 
Prior and concomitant medications will be coded using WHO Drug Dictionary version 
DD B2March 2010. Medication will be presented by anatomical main group (ATC 
Level 1), therapeutic subgroup (ATC Level 2) and preferred drug name. If anatomical 
main group, therapeutic subgroup or preferred drug name is unavailable, “uncoded” 
will be used. A subject who took more than one medication will be counted only once if 
these medications belong to the same anatomical main group, therapeutic subgroup or 
preferred drug name. Tables will be sorted alphabetically by anatomical main group, 
therapeutic subgroup and preferred drug name. 
If either the start or stop date of medication is missing, the most conservative case will 
be considered when assigning medications to categories: for a missing start date (where 
stop date is after date of Trial Day 1) the date will be imputed as the date of Trial 
Day 1; for a missing stop date the date will be imputed as the date of last participation 
in the trial. If a partial date is recorded, the following convention will be used to assign 
the medication: 
 
If a partial date is missing a start day, „01‟ will be used for the day; if a start 
date is missing a month, „January‟ will be used for the start month. 
 
If a partial date is missing a stop day, last day of the given month will be used 
for the stop day; if a stop date is missing a month „December‟ will be used for 
the stop month. 
7.7.1. 
Prior Medication 
Prior medications will be defined as medications that stop before Trial Day 1. Prior 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 41 of 108 
medications will be flagged on the concomitant medication listing. 
The number and percentage of subjects with prior medications will be summarized for 
the ITT set by anatomical main group, therapeutic subgroup and preferred drug name. 
7.7.2. 
Screening Medication 
Screening medications will be defined as any medications that were started prior to the 
screening visit and were ongoing at the time of screening, or any that were started on 
the day of the screening visit, or stopped on the day of the screening visit. Screening 
medications will be flagged on the concomitant medication listing.  
The number and percentage of subjects with screening medications will be summarized 
by anatomical main group, therapeutic subgroup and preferred drug name for the 
ITT set and for the subset of the MTT set who did not go on to be randomized. 
7.7.3. 
Concomitant Medication 
Concomitant medications taken during the follow-up phase will be defined as any 
medications that were taken on or after Trial Day 1. All concomitant therapies will be 
listed. 
The number and percentage of subjects with concomitant medications during the 
follow-up phase will be summarized for the ITT and SAF sets by anatomical main group, 
therapeutic subgroup and preferred drug name. In addition, separate summaries will be 
presented for the ITT set for the number and percentage of subjects with the following 
categories of concomitant medications by anatomical main group, therapeutic subgroup 
and preferred drug name: 
 
Maintained medications - defined as concomitant medications started before 
Trial Day 1. 
 
New medications during trial medication - defined as concomitant medications 
started on or after Treatment Day 1 and before or on date of last trial 
medication. 
 
New medications whilst off trial medication - defined as concomitant 
medications started after last date of trial medication or started on or after 
Trial Day 1 and before first dose of trial medication. 
All concomitant medications recorded should fall into one of the above categories. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 42 of 108 
7.7.4. 
Antibiotic Use 
Concomitant antibiotic use due to PDPE and PE will be summarized for the ITT set by 
preferred drug name. These medications will be identified as detailed in Section 4.2.1. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 43 of 108 
8. 
EFFICACY 
The hypotheses for the primary efficacy endpoint and the key secondary efficacy 
endpoints will be formally tested using a hierarchical testing approach to preserve the 
Type 1 error rate. Objectives will be tested in the order in which they are ranked in 
Section 4. Analysis of hierarchical secondary objectives will continue until a 
non-significant p-value (i.e. p>0.05) is returned. 
All efficacy analyses will be performed on the ITT set unless otherwise specified. 
8.1. 
PRIMARY EFFICACY ENDPOINT AND ANALYSIS 
The primary endpoint is the absolute change from baseline FEV1 (L) over the 26-week 
treatment period (measured at Weeks 6, 14 and 26). The primary analysis will include 
assessments as specified up until the time of last participation for each subject, 
including those performed off trial medication. For subjects who have an IMP 
discontinuation visit, the spirometry assessment done at this visit can be used instead of 
the assessment performed at the scheduled visit in line with the rules defined in 
Section 6.4. 
In order to assess the potential impact of missing data on the results, sensitivity 
analyses will be performed (see Section 8.1.2 for more details): 
 
Pattern Mixture Model. 
 
Tipping Point Analysis. 
 
Mixed model repeated measures (MMRM) without imputation. 
 
Responder Analysis. 
The following supportive analyses will also be performed: 
 
Using the PP set. 
 
Absolute change from baseline FEV1 (L) at 26 weeks and at 6 and 14 weeks. 
 
Absolute change from baseline percent predicted FEV1 (%) over 26 weeks. 
 
Relative change from baseline FEV1 (L) over 26 weeks. 
 
Relative change from baseline percent predicted FEV1 (%) over 26 weeks. 
In addition, the following supportive analyses on the absolute change from baseline 
FEV1 (L) over the 26 week treatment period will be conducted based on on-treatment 
period data only: 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 44 of 108 
 
MMRM with BOCF+IUDR imputation. 
 
Pattern mixture model. 
 
MMRM without BOCF. 
The primary analysis of absolute change in FEV1 over the 26 week treatment period and 
the supportive analysis of relative change in FEV1 over the 26 week treatment period 
will be repeated by the subgroups specified in Section 6.6 on the ITT set only. 
The results from the primary analysis, the sensitivity analyses, the supportive analyses, 
and the subgroup analyses for the primary endpoint will be presented in forest plots to 
graphically explore the consistency of the estimated treatment effect.  
8.1.1. 
Primary Analysis of the Primary Endpoint 
Descriptive Summaries: 
FEV1 (L) absolute change from baseline and relative change from baseline (% change) 
and percent predicted FEV1 (%) absolute change from baseline and relative change from 
baseline (% change) will be summarized by visit using summary statistics for continuous 
variables. Two summaries will be produced based on actual data and imputed missing 
data as described below. All these summaries will be performed on the ITT and PP sets. 
In addition, FEV1 (L) absolute change from baseline and relative change from baseline 
(% change) will be summarized for on trial medication data only (i.e. excluding data 
>7 days after trial medication stop date), by visit, using summary statistics for 
continuous variables, based both on actual data and imputed missing data, for the 
ITT set. 
Primary Analysis Method: 
The mean absolute change from baseline FEV1 (L) over 26 weeks (including assessments 
at Weeks 6, 14 and 26) will be compared between the two treatment groups with a 
restricted maximum likelihood (REML) based MMRM approach. 
The model will include the fixed, categorical effects of treatment group, rhDNase use, 
pooled country, visit, and treatment group-by-visit interaction, as well as the 
continuous, fixed covariate of baseline FEV1 and also disease severity (percent 
predicted FEV1 at baseline). Subject will be included in the model as a random effect. 
An unstructured (co)variance structure will be used to model the within-subject errors. 
The Kenward-Roger approximation will be used to estimate denominator degrees of 
freedom. 
 
 
. 
: 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 45 of 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Least squares means (LS means) and mean treatment group difference, standard 
error (SE), 95% CIs, and p-value for the treatment group effect averaged across the 
trial, with the same weight applied to each visit, will be presented.  
Plots of the LS means (95% CI) for the primary endpoint against visit will be presented 
for the ITT and PP sets, highlighting significant differences between the treatment 
groups at any timepoint. 
Missing Data:  
The analysis will use spirometry data which are consistent with the visit assignment as 
described in Section 6.4. Subjects who discontinue trial medication should remain in the 
trial and continue to provide all scheduled FEV1 measurements. The primary analysis 
will include all available on-treatment and off-treatment period data, regardless of 
adherence to or discontinuation of trial medication. While all efforts will be made to 
ensure subjects remain in the trial, the following planned imputation strategy will allow 
for an appropriate primary analysis in the presence of missing FEV1 data.  
To calculate baseline values, missing Visit 1 measurements for the primary efficacy 
variable (FEV1) will be imputed using Visit 0 (screening) measurements, if available. 
Missing post-baseline measurements as a result of withdrawal from the trial for the 
primary efficacy variable (FEV1) will be imputed using an IUDR methodology. For 
subjects who withdraw from the trial due to AE, death, physician decision, or lack of 
efficacy, missing post-baseline FEV1 measures as a result of withdrawal from the trial 
will be imputed using the baseline FEV1 measurement (BOCF procedure). Missing FEV1 
measurements as a result of withdrawal from the trial, where the withdrawal was as a 
result of other causes (i.e. lost to follow-up, relocation, pregnancy, major protocol 
deviation, sponsor decision, withdrawal of consent, or other) will not be imputed. 
Missing data at intermediate visits (i.e. where data is available at a later visit) will not 
be imputed. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 46 of 108 
Imputation of missing FEV1 measurements by means of BOCF is a reasonable assumption 
in studies of adult subjects with cystic fibrosis, as those subjects who discontinue will 
no longer receive treatment and are thus likely to promptly return to their baseline lung 
function. Imputation by BOCF specifically inhibits any possible prolongation of an 
observed early treatment benefit implicitly conferred by a mixed model. Considering 
the higher drop-out rate observed with the experimental treatment compared to 
control in previous studies (DPM-CF-301 and DPM-CF-302), BOCF is not likely to favour 
the mannitol arm.  
The primary analysis will target the de facto estimand assessing the effect of a 
treatment policy (Estimand 1 in Mallinckrodt [6]) by: 
 
Including all available on-treatment and off-treatment period data. 
 
Handling missing data based on a clinically reasonable assumption not biased in 
favor of the mannitol arm.  
8.1.2. 
Sensitivity Analyses of the Primary Endpoint  
To elicit insights into the effect of imputation via the planned BOCF+IUDR framework, 
the following sensitivity analyses of the primary endpoint will be conducted: 
 
Sensitivity Analysis 1: Pattern Mixture Model. 
 
Sensitivity Analysis 2: Tipping Point Analysis. 
 
Sensitivity Analysis 3: MMRM without imputation. 
 
Sensitivity Analysis 4: Responder Analysis. 
As for the primary analysis, these sensitivity analyses target the de facto estimand 
assessing the effect of a treatment policy. These analyses will include all available on-
treatment and off-treatment period data, regardless of adherence to or discontinuation 
of trial medication.  
Planned approaches for handling missing data in Sensitivity analyses 1, 2, and 4 are not 
likely to favor the experimental arm (for more details see specific sections below.)  
In the first 3 analyses, the mean absolute change from baseline FEV1 (L) over 26 weeks 
(including assessments at Weeks 6, 14 and 26) and at each post-baseline visit will be 
compared between the two treatment groups. For the responder analysis, the 
comparison between treatment groups will be performed at Week 26 (however subjects 
who withdraw from the trial earlier are assumed to be non-responders). 
Sensitivity Analysis 1: Pattern Mixture Model 
A potential disadvantage of employing a single imputation method such as BOCF is the 
risk of underestimating the variability. To assess the possible impact of this effect, 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 47 of 108 
missing FEV1 values at post-baseline visits will be imputed using multiple imputation 
(MI) from the distribution of baseline values, using the method of Ratitch et al[7] for 
pattern imputation based on reasons for dropout. 
This approach is in line with the one defined for the primary endpoint analysis, where 
subjects withdrawing from the trial for AE, death, physician decision or lack of efficacy 
are considered to stop benefiting from the trial medication and return to their baseline 
status (i.e. BOCF approach; see GRP2 imputation model below), while for subjects 
withdrawing from the trial for other reasons, it is assumed that they would have 
continued to benefit from the trial medication in line with  subjects completing the 
trial (see GRP4 and GRP6 imputation models below). 
In a preliminary step, imputation based on the missing at random (MAR) assumption will 
be performed using the joint modeling approach in order to obtain monotone missing 
data patterns. The imputation model will include the following variables: treatment 
group, rhDNase use, pooled country, FEV1 (L) from Visit 0 to Visit 4. 
Then, a regression-based imputation will be performed for the remaining missing FEV1 
values. The strategy for imputation will be based on the definition of the following 
groups of observed data and patterns of missingness: 
(GRP1) Subjects from both treatment groups with non-missing baseline FEV1 values 
(GRP2) Subjects from both treatment groups who withdraw from the trial due to AE, 
death, physician decision, or lack of efficacy 
(GRP3) Subjects in the control group who completed the trial 
(GRP4) Subjects in the control group who withdraw from the trial because of other 
reasons 
(GRP5) Subjects in the mannitol group who completed the trial 
(GRP6) Subjects in the mannitol group who withdraw from the trial because of other 
reasons 
Imputation will be performed: 
 
In pattern (GRP2) using a model for baseline FEV1 including rhDNase use, pooled 
country and FEV1 (L) at Visit 0, estimated on the (GRP1) group. 
 
In pattern (GRP4) using a model including rhDNase use, pooled country, FEV1 (L) 
from Visit 0 to Visit 4, estimated on the (GRP3) group. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 48 of 108 
 
In pattern (GRP6) using the same model described in the previous bullet point, 
estimated on the (GRP5) group. 
One thousand imputations will be performed and for each imputed dataset the analysis 
of the change from baseline FEV1 (L) over 26 weeks (the mean of values at Weeks 6, 14 
and 26) will be based on an ANCOVA model including the following variables: treatment 
group, rhDNase use, pooled country, baseline FEV1 and disease severity (percent 
predicted FEV1 at baseline). Also the changes at each post-baseline visit will be 
analyzed using the same ANCOVA model. Estimates from the models will be then 
combined using Rubin‟s rule. 
 
Sensitivity Analysis 2: Tipping Point Analysis 
If a significant difference between treatments is found in the primary analysis, a tipping 
point analysis will be performed. 
The hypothesis behind this approach is that subjects withdrawing from the trial will 
have a worse outcome (FEV1) compared to subjects completing the trial by a certain 
amount of mL, with penalties applied to the missing information varying between the 
two treatment arms. This analysis will explore the influence of missingness, providing 
evidence of the „tipping‟ point where there is no longer evidence of a treatment effect 
on improvement from baseline of FEV1. 
In a preliminary step, imputation based on the missing at random (MAR) assumption will 
be performed in order to obtain monotone missing data patterns as above described for 
Sensitivity Analysis 1. 
Then, a regression-based imputation will be performed for the remaining missing FEV1 
values (regardless of the reason for withdrawal from the trial). The imputation model 
will include the following variables: treatment group, rhDNase use, pooled country, 
FEV1 (L) from Visit 0 to Visit 4. Subjects who withdraw from the trial will then have 
their unobserved post-baseline FEV1 values worsened by an amount δ compared to the 
observed FEV1 of subjects who continue. The analysis will find a tipping point in the 
spectrum of assumptions on the magnitude of δ in the mannitol group at which 
conclusions change from being favorable to mannitol to being inconclusive 
(non-statistically significant mean difference between treatments over 26 weeks). The 
tipping point will be determined in the scenarios described in Table 5: 


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 49 of 108 
Table 5: δ-adjustments to Identify the Tipping Point 
δ-adjustment in the control group 
δ-adjustment in the mannitol group 
(in order to identify the tipping point) 
0 
-0.020, -0.040, -0.060, … L 
-0.020 L 
-0.020, -0.040, -0.060, -0.080, … L 
-0.040 L 
-0.040, -0.060, -0.080, -0.100, … L 
-0.060 L 
-0.060, -0.080, -0.100, -0.120, … L 
-0.080 L 
-0.080, -0.100, -0.120, -0.140, … L 
-0.100 L 
-0.100, -0.120, -0.140, -0.160, … L 
 
where the δ-adjustments for the mannitol group will decrease by 20 mL up to reaching 
the non-statistical significance of the treatment comparison. 
In each scenario one thousand imputations will be performed and the analysis of the 
change from baseline FEV1 (L) over 26 weeks will be conducted using an ANCOVA model 
in line with the specification made for Sensitivity Analysis 1. 
 
Sensitivity Analysis 3: MMRM Without BOCF Imputation 
The same MMRM as for the primary analysis will be used without performing any 
imputation of post-baseline measurements. 
This analysis is based on a MAR assumption on missing data, i.e. on the assumption that 
unobserved outcomes of subjects who withdraw from the trial do not systematically 
differ from observed outcomes of subjects who remained in the trial.  
Sensitivity Analysis 4: Responder Analysis 
A subject will be defined as: 
 
A responder if they have a change from baseline FEV1 (L)≥threshold at Week 26. 
 
A non-responder if they have a change from baseline FEV1 (L)<threshold at 
Week 26 or missing change from baseline FEV1 at Week 26. 
The hypothesis is that subjects withdrawing from the trial are not expected to benefit 
from the treatment, and so are considered as „Non-responders‟. 
Three different thresholds will be considered: 0.100, 0.075 and 0.050 L.  


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 50 of 108 
Considering the higher drop-out rate observed with the experimental treatment 
compared to control in previous studies (DPM-CF-301 and DPM-CF-302), responder 
analysis is not likely to favor the experimental arm. 
The proportion of responders will be summarized and compared between treatment 
groups using logistic regression. The model will include the same covariates as specified 
in the primary analysis. The treatment group effect odds ratio and its 95% CI and 
p-value will be presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.1.3. 
Supportive Analyses of the Primary Endpoint  
8.1.3.1. 
Supportive Analyses of the Primary Endpoint – PP Set 
Supportive Analysis 1: MMRM with BOCF+IUDR Imputation, PP set 
Same statistical model as for the primary analysis (Section 8.1.1), but considering the 
PP set. This will provide an extra robustness check on the primary results from the ITT 
set. Any measurements excluded from the PP analysis at the BDRM will be treated as 
missing data but will not be included in the imputation process. 
8.1.3.2. 
Supportive Analyses of the Primary Endpoint – Results at Each 
Visit 
Supportive 
Analysis 
2: 
MMRM 
with 
BOCF+IUDR 
Imputation, 
at 
Week 6/Week 14/Week 26 
Using the same statistical model as for the primary analysis (Section 8.1.1), results will 
be presented also for the treatment group effect at each of the 3 post-baseline visits. 
 
 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 51 of 108 
 
 
 
 
 
 
 
8.1.3.3. 
Supportive Analyses of the Primary Endpoint – Additional FEV1 
Evaluations 
In addition to the evaluation of the mean absolute change from baseline FEV1 (L) over 
26 weeks, the following supportive analyses based on the FEV1 parameter will be 
analyzed: 
Supportive Analysis 3: Absolute Change from Baseline Percent Predicted FEV1 (%) 
Over 26 Weeks 
 
Supportive Analysis 4: Relative Change from Baseline FEV1 (L) Over 26 Weeks 
 
Supportive Analysis 5: Relative Change from Baseline Percent Predicted FEV1 (%) 
Over 26 Weeks 
 
Supportive analyses 3, 4 and 5 will follow the same approach as for the primary analysis 
(Section 8.1.1). For the analyses of percent predicted FEV1, the FEV1 baseline 
 
will not be included in the model; the baseline measure of the outcome will be included 
as baseline percent predicted FEV1 (disease severity). 
8.1.3.4. 
Supportive Analyses of the Primary Endpoint – On-treatment 
Period Data Only 
To elicit insights into the effects of including data from subjects after cessation of trial 
medication (by including these data, the effects of subsequent therapy are attributed to 
trial medication); the analyses outlined in Section 8.1.1 and 8.1.2 will be repeated for 
on trial medication data only (i.e. excluding data >7 days after trial medication 
discontinuation). 
Supportive Analysis 6: MMRM with BOCF+IUDR Imputation, On-treatment Period Data 
Same approach as for the primary analysis (Section 8.1.1), but considering reason for 
discontinuation from trial medication. 
Supportive Analysis 7: Pattern Mixture Model, On-treatment Period Data 
Same approach as for Sensitivity Analysis 1 (Section 8.1.2), but considering reason for 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 52 of 108 
discontinuation from trial medication. 
Supportive Analysis 8: MMRM Without BOCF, On-treatment Period Data 
Same approach as for Sensitivity Analysis 3 (Section 8.1.2). 
8.2. 
HIERACHICAL SECONDARY EFFICACY ENDPOINT(S) AND 
ANALYSES 
All summaries and main analyses outlined below for the hierarchical secondary efficacy 
endpoints will be repeated by the subgroups of rhDNase use and disease severity 
(percent predicted FEV1 at baseline) as specified in Section 6.6. For each hierarchical 
secondary endpoint, the results from the main analysis, the sensitivity analyses, the 
supportive analyses (where possible i.e. where these are on the same scale as the main 
analysis results), and the subgroup analyses will be presented in a forest plot for 
comparison. 
8.2.1. 
Forced Vital Capacity and Other Spirometry Parameters 
Descriptive Summaries: 
FVC absolute change from baseline (L) and relative change from baseline (% change) will 
be summarized by visit using summary statistics for continuous variables. 
Two summaries will be produced for the ITT set based on actual data and imputed 
missing data as described for the primary endpoint in Section 8.1.1. 
PEF (L/s), FEV1/FVC ratio (%) and FEF25-75 (L/s) absolute change from baseline and 
relative change from baseline (% change) will also be summarized by visit using 
summary statistics for continuous variables without imputation of missing data. 
Analysis Method: 
The mean absolute change from baseline FVC (L) over 26 weeks (including assessments 
at Weeks 6, 14, and 26) will be compared between the two treatment groups using the 
same model as the primary analysis (with a covariate of baseline FVC, rather than 
baseline FEV1). Missing data will be handled in the same way as for the primary 
endpoint. 
The mean absolute change from baseline FVC (L) will also be presented for the 
treatment group effect at each of the 3 post-baseline visits. 
The other pulmonary function tests (PEF, FEV1/FVC ratio, and FEF25-75) will not be 
analyzed. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 53 of 108 
The criterion for moving to the next endpoint in the analysis will be based on a p-value 
less than 0.05 for the comparison between the two treatment groups; sensitivity and 
supportive analyses will not be part of the testing hierarchy. 
8.2.1.1. 
Sensitivity Analyses of FVC 
Sensitivity Analysis 1: Pattern Mixture Model 
To assess the possible impact of employing a single imputation method, a pattern 
mixture model analysis will be conducted, following the same approach as for 
Sensitivity Analysis 1 (Section 8.1.2) for the primary endpoint (and with a covariate of 
baseline FVC, rather than baseline FEV1). 
Sensitivity Analysis 2: MMRM Without BOCF 
To elicit insights into the effect of imputation via the planned BOCF+IUDR framework, 
the main FVC analysis outlined above will be repeated with no imputation of missing 
post-baseline FVC. This analysis will be performed as described for Sensitivity Analysis 3 
of the primary endpoint in Section 8.1.2 (with a covariate of baseline FVC, rather than 
baseline FEV1). 
8.2.1.2. 
Supportive Analysis of FVC 
8.2.1.2.1. Supportive Analysis – Results at Each Visit  
Supportive 
Analysis: 
MMRM 
with 
BOCF+IUDR 
Imputation, 
at 
Week 6/Week 14/Week 26 
Least squares means (LS means) and mean treatment group difference, SE, 95% CIs, and 
p-value will be presented not only for the treatment groups averaged across the trial, 
but also for the treatment group effect at each of the 3 post-baseline visits. These 
results will be obtained by adding specific contrasts to the main model, in line with the 
approach followed for the primary analysis (Sections 8.1.1 and 8.1.3.2). 
8.2.2. 
Time to First Protocol Defined Pulmonary Exacerbation 
Descriptive Summaries: 
Subjects who do not have a PDPE during the trial will be censored at the date of last 
participation in the trial. The number of subjects with an event and censored will be 
summarized. Kaplan-Meier product limit estimators of the survivor function (probability 
of staying event free) will be summarized for 25th percentile, median, and 
75th percentile, and their 95% CIs. The plot of Kaplan-Meier estimates for the two 
treatment groups will also be presented. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 54 of 108 
As supportive information the above summaries will be repeated for time to first PE 
(i.e. all PEs recorded on the CRF with associated antibiotic use, whether or not they 
met the criteria for a PDPE). 
Analysis Method: 
The time (in days) to first PDPE will be analyzed using the Cox‟s Proportional Hazards 
model. The model will include the terms treatment group, pooled country, rhDNase 
use, and number of IV antibiotic treated PEs in year prior to screening (continuous) as 
factors. The treatment group hazard ratio will be presented with 95% CI and p-value for 
the treatment group effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The criterion for moving to the next endpoint in the analysis will be based on a p-value 
less than 0.05 for the comparison between the two treatment groups; supportive will 
not be part of the testing hierarchy. 
8.2.2.1. 
Supportive Analysis of Time to First Protocol Defined Pulmonary 
Exacerbation 
8.2.2.1.1. Supportive Analysis – All Pulmonary Exacerbations 
Supportive Analysis: Time to First Pulmonary Exacerbation 
As supportive information the above analysis will be repeated for time to first PE. 
8.2.3. 
Number of Days on Antibiotics Due to Protocol Defined Pulmonary 
Exacerbation 
Descriptive Summaries: 
The number of days on antibiotics due to PDPE will be summarized using summary 
statistics for continuous variables (for all subjects in the ITT set and repeated only for 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 55 of 108 
those with at least one distinct episode of antibiotic usage to treat PDPE) and also for 
categorical variables using weekly categories (0, 1-7 days, 8-14 days, etc.). 
The number of distinct episodes of use of antibiotics due to PDPE will be summarized 
using summary statistics for categorical variables (e.g. 0, 1-5, etc. or as appropriate to 
data). 
The number of courses of antibiotics due to PDPE will be summarized using summary 
statistics for categorical variables (no antibiotic use, 1, 2, 3, >3). 
As supportive information the above summaries will be repeated for the number of 
distinct days on antibiotics due to PDPE (excluding overlaps), the number of days on 
antibiotics due to PE (i.e. all PEs recorded on the CRF with associated antibiotic use, 
whether or not they met the criteria for a PDPE), and the number of distinct days on 
antibiotics due to PE (excluding overlaps). 
Analysis Method: 
The number of days on antibiotics due to PDPE will be compared between treatment 
groups using a negative binomial model. 
 
 The model will include the 
categorical effects treatment group, pooled country, rhDNase use, and the continuous 
covariate number of IV antibiotic treated PEs in year prior to screening. An offset 
variable of the natural log of follow-up duration (years) will be used in the model to 
adjust for different lengths of follow-up. The rate ratio will be presented with 95% CI 
and p-value for the treatment group effect. 
There will be no imputation of missing data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 57 of 108 
8.2.4. 
Number of Days in Hospital Due to Protocol Defined Pulmonary 
Exacerbation 
Descriptive Summaries: 
The number of days in hospital due to PDPE will be summarized using summary statistics 
for continuous variables (for all subjects in the ITT set and repeated only for those with 
at least one hospitalization due to PDPE) and also for categorical variables using weekly 
categories (0, 1-7 days, 8-14 days, etc.). The number of hospitalizations per subject will 
also be summarized using categories 0, 1, 2, 3, and >3. 
As supportive information the above summaries will be repeated for hospitalizations due 
to PE (i.e. all PEs recorded on the CRF with associated antibiotic use, whether or not 
they met the criteria for a PDPE). 
Analysis Method: 
The number of days in hospital (admissions only) due to PDPE will be compared between 
treatment groups using a negative binomial model. The model will include the 
categorical effects treatment group, pooled country, rhDNase use, and the continuous 
covariate number of IV antibiotic treated PEs in year prior to screening. An offset 
variable of the natural log of follow-up duration (years) will be used in the model to 
adjust for different lengths of follow-up. The rate ratio will be presented with 95% CI 
and p-value for the treatment group effect. 
 
 
There will be no imputation of missing data. 
The criterion for moving to the next endpoint in the analysis will be based on a p-value 
less than 0.05 for the comparison between the two treatment groups; supportive 
analyses will not be part of the testing hierarchy. 
8.2.4.1. 
Supportive Analysis of Number of Days in Hospital due to Protocol 
Defined Pulmonary Exacerbation 
8.2.4.1.1. Supportive Analysis – All Pulmonary Exacerbations 
Supportive Analysis: Number of Days in Hospital Due to Pulmonary Exacerbation  
As supportive information the analysis outlined in Section 8.2.4 „Analysis Method‟ will 
be repeated for hospitalizations due to PE (i.e. all PEs recorded on the CRF with 
associated antibiotic use, whether or not they met the criteria for a PDPE). 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 58 of 108 
8.2.5. 
Rate of Protocol Defined Pulmonary Exacerbation 
Descriptive Summaries: 
Number of PDPEs (0, 1, etc.) and incidence of PDPEs (yes or no) will be summarized 
using summary statistics for categorical variables. 
The number of subjects with PDPEs, the total number of PDPEs, the total follow-up 
duration (in years), and the overall rate of PDPEs (per person year) will be presented. 
As supportive information the above summaries will be repeated for overall rate of PEs 
(i.e. all PEs recorded on the CRF with associated antibiotic use, whether or not they 
met the criteria for a PDPE). 
Analysis Method: 
The rate of PDPEs will be compared between treatment groups using a negative 
binomial model. The model will include the categorical effects treatment group, pooled 
country, rhDNase use, and the continuous covariate number of IV antibiotic treated PEs 
in year prior to screening. An offset variable of the natural log of follow-up duration 
(years) will be used in the model to adjust for different lengths of follow-up. The rate 
ratio will be presented with 95% CI and p-value for the treatment group effect. 
 
 
The criterion for moving to the next endpoint in the analysis will be based on a p-value 
less than 0.05 for the comparison between the two treatment groups; supportive and 
sensitivity analyses will not be part of the testing hierarchy. 
Missing Data: 
In the event a subject withdraws from the trial before Week 14 with no observed 
instances of a PDPE the number of PDPEs will be imputed using half the subject‟s 
historical (previous 12 months) PE count (rounded upwards) and their follow-up duration 
will be imputed as 26 weeks.  
In the event a subject withdraws from the trial after Week 14 with no observed 
instances of a PDPE the number of PDPEs will be imputed using one quarter the 
subject‟s historical (previous 12 months) PE count (rounded upwards) and their 
follow-up duration will be imputed as 26 weeks. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 59 of 108 
8.2.5.1. 
Sensitivity Analyses of Rate of Protocol Defined Pulmonary 
Exacerbations 
Sensitivity Analysis 1: No Imputation 
To elicit insights into the effect of the imputation method described above, the analysis 
will be repeated with no imputation of missing data. 
 
Sensitivity Analysis 2: Zero Inflated Negative Binomial Model 
To account for the possibility of an excess reporting of zero rates, the main analysis 
outlined above will be repeated using a zero inflated negative binomial model. This 
models the data as a mixture of two separate distributions; as a negative binomial 
distribution that can generate both zero and nonzero counts, and as a constant 
distribution that generates only zero counts. First an investigation of the data will be 
carried out to assess whether the probability of observing zero counts is conditional on 
any of the covariates in the model, by plotting the marginal and conditional 
distributions of the response variable. 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity Analysis 3: Multiple Imputation 
To assess the possible impact of employing a single imputation method (i.e. risk of 
variability underestimation), an analysis based on MI will be performed. 
For all subjects who withdrew from the trial with a follow-up duration shorter than 
183 days (i.e. 26 weeks+1 day), the number of PDPEs from withdrawal up to day 183 will 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 60 of 108 
be imputed.  
The imputation will be performed using a model for the number of IV antibiotic treated 
PEs in the year prior to screening including rhDNase use and pooled country. Therefore, 
the imputation will be based on the distribution of historical PE count. 
One thousand imputations will be performed and the analysis of the total number of 
PDPEs (observed+imputed events) will be based on the same negative binomial model 
described in the „Analysis Method‟ paragraph above. Estimates from the models will 
then be combined using Rubin‟s rule.  
 
8.2.5.2. 
Supportive Analysis of Rate of Protocol Defined Pulmonary 
Exacerbations 
8.2.5.2.1. Supportive Analysis – Rate of Pulmonary Exacerbations 
Supportive Analysis: Single imputation, Pulmonary Exacerbations 
Same approach as for the analysis described in „Analysis Method‟ (Section 8.2.5), 
considering PEs (i.e. all PEs recorded on the CRF with associated antibiotic use, whether 
or not they met the criteria for a PDPE). 
8.3. 
NON-HIERACHICAL SECONDARY EFFICACY ENDPOINT(S) AND 
ANALYSES 
8.3.1. 
Incidence of Protocol-Defined Pulmonary Exacerbations 
Descriptive Summaries: 
Incidence of PDPEs (yes or no) will be summarized as described in Section 8.2.5. 
Analysis Method: 
Proportions will be compared between treatment groups using logistic regression. The 
model will include the categorical effects pooled country, rhDNase use, and the 
continuous covariate number of IV antibiotic treated PEs in year prior to screening. The 
treatment group effect odds ratio, 95% CI, and p-value will be presented. 
No imputation of missing data will be performed. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 61 of 108 
8.3.1.1. 
Supportive Analysis of Incidence of Protocol Defined Pulmonary 
Exacerbations 
Supportive Analysis: Incidence of Pulmonary Exacerbations 
The summary and analysis defined in Section 8.3.1 will be repeated for incidence of PEs 
(i.e. all PEs recorded on the CRF with associated antibiotic use, whether or not they 
met the criteria for a PDPE). 
8.3.2. 
Ease of Expectoration Visual Analogue Scale 
Descriptive Summaries: 
The ease of expectoration VAS score and absolute change from baseline will be 
summarized by visit using summary statistics for continuous variables, based both on 
actual data and imputed missing data. 
Analysis Method: 
The mean absolute change from baseline VAS score over Weeks 6, 14 and 26 will be 
compared between the two treatment groups with a REML based MMRM approach. The 
analysis will be the same as described for the primary endpoint in Section 8.1.1. The 
model will include the fixed, categorical effects of treatment group, rhDNase use, 
pooled country, visit, and treatment group-by-visit interaction, as well as the 
continuous, fixed covariates of baseline VAS score and disease severity (percent 
predicted FEV1 at baseline). Missing data will be handled in the same way as for the 
primary analysis of the primary endpoint. 
8.3.2.1. 
Sensitivity Analysis of Ease of Expectoration Visual Analogue 
Scale 
Sensitivity Analysis: MMRM Without BOCF 
To elicit insights into the effect of imputation via the planned BOCF+IUDR framework, 
the main analysis outlined in Section 8.3.2 „Analysis Method‟ will be repeated with no 
imputation of missing data. 
8.3.3. 
CFQ-R Respiratory Domain 
Descriptive Summaries: 
The CFQ-R respiratory domain scaled score and absolute change from baseline will be 
summarized by visit using summary statistics for continuous variables, based both on 
actual data and imputed missing data. 
Analysis Method: 
The mean absolute change from baseline in the CFQ-R respiratory domain score over 
Weeks 6, 14 and 26 will be compared between the two treatment groups with a REML 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 62 of 108 
based MMRM approach. The analysis will be the same as described for the primary 
endpoint in Section 8.1.1. The model will include the fixed, categorical effects of 
treatment group, rhDNase use, pooled country, visit, and treatment group-by-visit 
interaction, as well as the continuous, fixed covariates of baseline CFQ-R respiratory 
domain score and disease severity (percent predicted FEV1 at baseline). Missing data 
will be handled in the same way as for the primary analysis of the primary endpoint. 
8.3.3.1. 
Sensitivity Analysis of CFQ-R Respiratory Domain 
Sensitivity Analysis: MMRM Without BOCF 
To elicit insights into the effect of imputation via the planned BOCF+IUDR framework, 
the main analysis outlined above will be repeated with no imputation of missing data. 
8.3.3.2. 
Supportive Analysis of CFQ-R Domain 
Supportive Analysis: MMRM with BOCF+IUDR Imputation, Question 42 Excluded 
 
The above summary and analysis will be repeated for the CFQ-R respiratory domain 
score omitting Question 42 (CRF Question 3: “Have you had to cough up mucus?”), 
where the baseline covariate will be baseline CFQ-R respiratory domain score omitting 
Question 42. 
8.4. 
SUMMARY OF ANALYSES 
Table 6: Summary of Analyses 
Analysis 
Designation 
Endpoint 
Model 
Imputation 
Process Used 
Off-trial 
Medicat-
ion Data 
Included 
Anal-
ysis 
Set 
Primary 
Primary 
FEV1 Absolute 
Change from 
Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Primary – 
Sensitivity 1 
FEV1 Absolute 
Change from 
Baseline 
ANCOVA 
Pattern 
Mixture: MI 
Based on 
Reasons for 
Trial 
Withdrawal  
Yes 
ITT 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 63 of 108 
Analysis 
Designation 
Endpoint 
Model 
Imputation 
Process Used 
Off-trial 
Medicat-
ion Data 
Included 
Anal-
ysis 
Set 
Primary – 
Sensitivity 2 
FEV1 Absolute 
Change from 
Baseline 
ANCOVA 
Tipping point 
Yes 
ITT 
Primary – 
Sensitivity 3 
FEV1 Absolute 
Change from 
Baseline 
MMRM 
None 
Yes 
ITT 
Primary – 
Sensitivity 4 
FEV1 Responders Logistic 
Regression 
Missing = 
non-response 
Yes 
ITT 
Primary – 
Supportive 1 
FEV1 Absolute 
Change from 
Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
PP 
Primary – 
Supportive 2 
FEV1 Absolute 
Change from 
Baseline – At 
Week 6/Week 
14/Week 26 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Primary – 
Supportive 3 
Percent 
Predicted FEV1 
Absolute 
Change from 
Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Primary – 
Supportive 4 
FEV1 Relative 
Change from 
Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Primary – 
Supportive 5 
Percent 
Predicted FEV1 
Relative Change 
from Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Primary – 
Supportive 6 
FEV1 Absolute 
Change from 
Baseline 
MMRM 
IUDR (trial 
medication 
discontinuati
on reason)/ 
BOCF 
No 
ITT 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 64 of 108 
Analysis 
Designation 
Endpoint 
Model 
Imputation 
Process Used 
Off-trial 
Medicat-
ion Data 
Included 
Anal-
ysis 
Set 
Primary – 
Supportive 7 
FEV1 Absolute 
Change from 
Baseline 
ANCOVA 
Pattern 
Mixture: MI 
Based on 
Reasons for 
Trial 
Medication 
Discontinuati
on  
No 
ITT 
Primary – 
Supportive 8 
FEV1 Absolute 
Change from 
Baseline 
MMRM 
None 
No 
ITT 
Primary – by 
Subgroups 
FEV1 Absolute 
Change from 
Baseline 
MMRM by 
Subgroups (see 
Section 6.6) 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Primary – by 
Subgroups 
FEV1 Relative 
Change from 
Baseline 
MMRM by 
Subgroups (see 
Section 6.6) 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Secondary Hierarchical 
Secondary 1 
Hierarchical 
FVC Absolute 
Change from 
Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Secondary 1 - 
Sensitivity 1 
FVC Absolute 
Change from 
Baseline 
ANCOVA 
Pattern 
Mixture: MI 
Based on 
Reasons for 
Trial 
Withdrawal 
Yes 
ITT 
Secondary 1 - 
Sensitivity 2 
FVC Absolute 
Change from 
Baseline 
MMRM 
None 
Yes 
ITT 
Secondary 1 - 
Supportive 
FVC Absolute 
Change from 
Baseline -  At 
Week 6/Week 
14/Week 26 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 65 of 108 
Analysis 
Designation 
Endpoint 
Model 
Imputation 
Process Used 
Off-trial 
Medicat-
ion Data 
Included 
Anal-
ysis 
Set 
Secondary 1 – 
by Subgroups 
 
FVC Absolute 
Change from 
Baseline 
MMRM by 
Subgroups (see 
Section 6.6) 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Secondary 2 
Hierarchical 
Time to First 
PDPE 
Cox‟s 
Proportional 
Hazards  
censoring at 
date of last 
participation 
Yes 
ITT 
Secondary 2 – 
Supportive 
Time to First PE 
Cox‟s 
Proportional 
Hazards  
censoring at 
date of last 
participation 
Yes 
ITT 
Secondary 2 – 
by Subgroups 
Time to First 
PDPE 
Cox‟s 
Proportional 
Hazards by 
Subgroups (see 
Section 6.6) 
censoring at 
date of last 
participation 
Yes 
ITT 
Secondary 3 
Hierarchical 
Number of Days 
of Antibiotic 
Use Due to 
PDPE 
Negative 
Binomial Model 
None 
Yes 
ITT 
Secondary 3 – 
Supportive 1 
Number of Days 
of Antibiotic 
Use Due to 
PDPE Excluding 
Overlaps 
Negative 
Binomial Model 
None 
Yes 
ITT 
Secondary 3 – 
Supportive 2 
Number of Days 
of Antibiotic 
Use Due to PE 
Negative 
Binomial Model 
None 
Yes 
ITT 
Secondary 3 – 
Supportive 3 
Number of Days 
of Antibiotic 
Use Due to PE 
Excluding 
Overlaps 
Negative 
Binomial Model 
None 
Yes 
ITT 
Secondary 3 - 
by Subgroups 
 
Number of Days 
of Antibiotic 
Use Due to 
PDPE 
Negative 
Binomial Model 
by Subgroups 
(see 
Section 6.6) 
None 
Yes 
ITT 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 66 of 108 
Analysis 
Designation 
Endpoint 
Model 
Imputation 
Process Used 
Off-trial 
Medicat-
ion Data 
Included 
Anal-
ysis 
Set 
Secondary 4 
Hierarchical 
Number of Days 
in Hospital Due 
to PDPE 
Negative 
Binomial Model 
None 
Yes 
ITT 
Secondary 4 – 
Supportive 
Number of Days 
in Hospital Due 
to PE 
Negative 
Binomial Model 
None 
Yes 
ITT 
Secondary 4 – 
by Subgroups 
Number of Days 
in Hospital Due 
to PDPE 
Negative 
Binomial Model 
by Subgroups 
(see 
Section 6.6) 
None 
Yes 
ITT 
Secondary 5 
Hierarchical 
PDPE Rate  
Negative 
Binomial Model 
Half 
historical 
count over 
26 weeks for 
withdrawals 
before 
Week 14 or 
one quarter 
historical 
count over 
26 weeks for 
withdrawals 
after 
Week 14 
Yes 
ITT 
Secondary 5 – 
Sensitivity 1 
PDPE Rate  
Negative 
Binomial Model 
None 
Yes 
ITT 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 67 of 108 
Analysis 
Designation 
Endpoint 
Model 
Imputation 
Process Used 
Off-trial 
Medicat-
ion Data 
Included 
Anal-
ysis 
Set 
Secondary 5 – 
Sensitivity 2 
PDPE Rate  
Zero Inflated 
Negative 
Binomial Model 
Half 
historical 
count over 
26 weeks for 
withdrawals 
before 
Week 14 or 
one quarter 
historical 
count over 
26 weeks for 
withdrawals 
after 
Week 14 
Yes 
ITT 
Secondary 5 – 
Sensitivity 3 
PDPE Rate  
Negative 
Binomial Model 
Multiple 
imputation 
based on 
historical PE 
count 
Yes 
ITT 
Secondary 5 – 
Supportive 
PE Rate  
Negative 
Binomial Model 
Half 
historical 
count over 
26 weeks for 
withdrawals 
before 
Week 14 or 
one quarter 
historical 
count over 
26 weeks for 
withdrawals 
after 
Week 14 
Yes 
ITT 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 68 of 108 
Analysis 
Designation 
Endpoint 
Model 
Imputation 
Process Used 
Off-trial 
Medicat-
ion Data 
Included 
Anal-
ysis 
Set 
Secondary 5 – 
by Subgroups 
PDPE Rate 
Negative 
Binomial Model 
by Subgroups 
(see 
Section 6.6) 
Half 
historical 
count over 
26 weeks for 
withdrawals 
before 
Week 14 or 
one quarter 
historical 
count over 
26 weeks for 
withdrawals 
after 
Week 14 
Yes 
ITT 
Secondary Non-hierarchical 
Secondary 
Non-
hierarchical 
1 
Incidence of 
PDPEs 
Logistic 
Regression 
None 
Yes 
ITT 
Secondary 
Non-
hierarchical 
1 – 
Supportive 
Incidence of PEs Logistic 
Regression 
None 
Yes 
ITT 
Secondary 
Non-
hierarchical 
2 
Ease of 
Expectoration 
VAS Score 
Absolute 
Change from 
Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 69 of 108 
Analysis 
Designation 
Endpoint 
Model 
Imputation 
Process Used 
Off-trial 
Medicat-
ion Data 
Included 
Anal-
ysis 
Set 
Secondary 
Non-
hierarchical 
2 – 
Sensitivity 
Ease of 
Expectoration 
VAS Score 
Absolute 
Change from 
Baseline 
MMRM 
None 
Yes 
ITT 
Secondary 
Non-
hierarchical 
3 
CFQ-R 
Respiratory 
Domain Scaled 
Score Absolute 
Change from 
Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 
Secondary 
Non-
hierarchical 
3 – 
Sensitivity 
CFQ-R 
Respiratory 
Domain Scaled 
Score Absolute 
Change from 
Baseline 
MMRM 
None 
Yes 
ITT 
Secondary 
Non-
hierarchical 
3 – 
Supportive 
CFQ-R 
Respiratory 
Domain Scaled 
Score Excluding 
Question 42 
Absolute 
Change from 
Baseline 
MMRM 
IUDR (trial 
withdrawal 
reason)/ 
BOCF 
Yes 
ITT 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 70 of 108 
9. 
SAFETY 
The SAF set will be used for all safety analyses. Safety will be assessed on the basis of 
AE reports, extent of exposure and compliance, physical examinations, and vital signs. 
No inferential statistical testing is planned on the safety data. 
9.1. 
EXTENT OF EXPOSURE 
Duration of exposure (months) will be summarized and will be calculated for the SAF set 
as follows: 
Duration of exposure = (last date trial medication–first date trial 
medication+1)x12/365.25 
Duration of exposure in months will be rounded to one decimal place for displaying 
purposes. 
Duration of exposure will be summarized for the SAF set using summary statistics for 
continuous variables and also for categorical variables using monthly categories 
(e.g. 0-1, >1-2, etc.). 
If last date of trial medication is missing or partial then the algorithm specified in 
Section 6.2.1 will be applied. 
9.2. 
TRIAL MEDICATION COMPLIANCE  
Trial medication compliance (%) will be summarized for the SAF set using summary 
statistics for continuous variables. Compliance to trial medication while taking trial 
medication will be calculated based on the subject reported last date of trial 
medication as follows:   
Compliance = 100% ×
 
 Di −
3
i=1
 
 Ri 
4
i=2
2 × 10 ×  [last date of trial med∗] −[date of Trial Day 1] + 1  
* Date of last dose of trial medication is as defined in Section 6.2.1 
where: 
Di = number of capsules dispensed at Visit i.   
Ri = number of unused capsules returned at Visit i. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 71 of 108 
This calculation assumes 10 capsules were to be taken at each trial medication 
administration time; dosing was b.i.d., hence 20 capsules were to be taken each day. 
Trial medication to be taken on dates corresponding with clinic visits are administered 
at the clinic. Unreturned capsules and/or blister packs will be assumed to have been 
used by the subject. 
 
9.3. 
ADVERSE EVENTS 
AEs will be coded using MedDRA v11.1. 
AEs will be considered MTT-emergent if they started within 2 days after MTT (MTT day 
and the day after) but before Treatment Day 1. 
AEs will be considered treatment-emergent unless there is clear indication that the 
event occurred prior to Treatment Day 1 (i.e. AEs starting on Treatment Day 1 will be 
assumed to have occurred after the first dose of trial medication) or the start date is 
>28 days after permanent discontinuation of trial medication. MEAEs cannot be 
treatment-emergent AEs (TEAEs) unless they worsen on or after Treatment Day 1. AEs 
present prior to Treatment Day 1 that increased in intensity or relationship to trial 
medication while the subject was on trial medication or within 28 days of permanent 
discontinuation from trial medication will be classed as TEAE. Events with missing or 
partial dates will be handled such that in the absence of contradictory information an 
AE is treatment-emergent. So for a missing start date (where stop date is after date of 
Treatment Day 1) the date will be imputed as the date of Treatment Day 1; for a 
missing stop date the date will be imputed as the date of last participation in the trial. 
If a partial date is recorded, the following convention will be used to assign the AE: 
 
If a partial date is missing a start day and month/year is the same as the date of 
Treatment Day 1 then use the date of Treatment Day 1, else „01‟ will be used for 
the day; if a start date is missing a month and the year is the same as the date 
of Treatment Day 1 then use the date of Treatment Day 1, else January will be 
used for the start month. 
 
If a partial date is missing a stop day and month/year is same as last 
participation date then use last participation date, else last day of the given 
month will be used for the stop day; if a stop date is missing a month and year is 
the same as last participation date then use last participation date, else 
December will be used for the stop month. 
AEs will be summarized by SOC and PT. Subjects will be counted once at the SOC level 
and once at each PT within the SOC level. Where applicable, summaries will include 
number and percentage of subjects who report at least one AE, number and percentage 
of subjects reporting at least one AE in a SOC, number and percentage of subjects 
reporting at least one AE in a PT, and total number of events within a SOC and within a 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 72 of 108 
PT. Tables will be sorted by decreasing frequency (overall) of SOC, and then, within a 
SOC, descending frequency (overall) of PT. 
Trial medication related AEs are defined as those that are „possibly related‟, „probably 
related‟, or „definitely related‟. Relationship to trial medication is not expected to be 
missing after data cleaning, however, if relationship is confirmed as missing, the AE will 
be considered as related. 
An overall summary table of TEAEs will be presented detailing the number and 
percentage of subjects, and number of events for the following categories: 
 
At least one TEAE. 
 
TEAEs related to trial medication. 
 
Serious TEAEs. 
 
Related serious TEAEs. 
 
TEAEs leading to permanent discontinuation of trial medication. 
 
TEAEs leading to withdrawal from the trial. 
 
TEAEs leading to death. 
The incidence of all TEAE by SOC and PT will be presented for the following: 
 
All TEAEs. 
 
TEAEs related to trial medication. 
 
Serious TEAEs. 
 
Related serious TEAEs. 
 
TEAEs leading to permanent discontinuation of trial medication. 
 
TEAEs leading to withdrawal from the trial. 
In addition, a summary of all TEAEs by maximum intensity (mild, moderate, severe), 
SOC, and PT will be presented, where the maximum intensity per subject will be 
counted at each level of summarization. AEs leading to death (all AEs with outcome 
recorded as „Fatal‟ on the CRF), serious AEs (all AEs marked as serious on the CRF), and 
AEs Leading to withdrawal from the trial (all AEs with „Did the subject withdraw from 
the study due to this event?‟ recorded as „Yes‟ on the CRF) will be listed separately. 
MEAEs will be summarized by SOC and PT for the MTT set. 
Additional information has been collected for AEs that are considered to be hemoptysis 
events in this trial i.e. information on infection, hemoptysis volume, and whether the 
hemoptysis occurred concurrently with an exacerbation. These data will be listed and 
summarized separately. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 73 of 108 
9.4. 
VITAL SIGNS  
Vital signs assessment and absolute change from baseline in SBP (mmHg), DBP (mmHg), 
heart rate (beats/min), respiratory rate (breaths/minute), SpO2 (%), temperature (°C) 
and weight (kg) will be summarized by visit using summary statistics for continuous 
variables. 
9.5. 
PHYSICAL EXAMINATION 
Physical examination data (decrease in breath sounds/wheezing, crackles, retraction, 
and clinically significant findings) will be summarized by visit using summary statistics 
for categorical variables. 


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 74 of 108 
10. 
SAMPLE SIZE RE-ESTIMATION 
A formal sample size re-estimation was planned to be performed after at least 
300 subjects have been recruited and at least 100 subjects had Visit 4 (Week 26) 
spirometry data available. 
This blinded sample size re-estimation was based on the methods of Kieser and Friede[2] 
which preserve the overall Type 1 error rate. Thus no adjustments to the overall 
significance level for the trial are required. 
Further details are provided in a separate sample size re-estimation plan (final 
Version 1.0, dated 07Dec2015).  
The outcome of the sample size re-estimation was to increase the sample size required 
to 440 subjects. In total, 423 subjects were randomized. 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 75 of 108 
11. 
CHANGE FROM ANALYSIS PLANNED IN PROTOCOL 
1. The analysis of spirometry endpoints has been updated to report relevant 
endpoints using L, as recorded in the CRF, rather than mL, as specified in the 
protocol, to keep consistency between data collection and final reporting. 
2. The 4 hierarchical secondary endpoints and one non-hierarchical secondary 
endpoint listed below have been clarified to refer to PDPEs rather than PEs. All 
analyses will be repeated for PEs (defined as all events recorded on the 
PE Review CRF page that have associated antibiotic use) however the 
hierarchical testing will be based on the PDPE endpoints (Section 4.2): 
 
Time to first PDPE. 
 
Number of days on antibiotics (oral, inhaled, or IV) due to PDPE. 
 
Number of days in hospital (admissions only) due to PDPE. 
 
Rate of PDPE (per person year) over the 26-week treatment period. 
 
Incidence of PDPEs over the 26-week treatment period. 
3. The criteria to determine if a subject will be included in the PP set were 
adjusted during the BDRM and local major deviations were defined for the visit if 
the spirometry assessment was determined to be non valid, leading to the 
exclusion of all the specific assessment‟s data collected at the visit from the PP 
analysis. All the decisions made are documented in the 
 which 
will be finalized prior to unblinding the trial. 
4. Time to event derivations will be based on date of randomization (Trial Day 1) 
for all subjects rather than date of first treatment (Treatment Day 1), except for 
time to discontinuation from trial medication, to allow consistency of derivations 
between randomized and treated and randomized but non-treated subjects. 
5. Baseline FEV1 has been added as a continuous, fixed covariate in the REML based 
MMRM model, or the appropriate baseline value of the analysis variable 
(i.e. baseline percent predicted FEV1, baseline FVC, baseline VAS score, or 
baseline CFQ-R respiratory domain score). 
6. For IUDR, BOCF imputations will be done for AE, death, physician decision, and 
lack of efficacy, while not for lost to follow-up; the logic behind this choice is 
the fact that motivation for the latter is not related to safety. 
7. The BOCF imputation based on IUDR methodology will not be applied to all the 
missing post-baseline FEV1 measurements, but only to those which are missing as 
a result of withdrawal from the trial (i.e. missing intermediate FEV1 will not be 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 76 of 108 
imputed). It is assumed that a MAR missingness pattern is the most probable in 
this context.  
8. Protocolled primary sensitivity analyses #1 remains unchanged but has become 
primary sensitivity analysis #3. It will be performed to elicit insights into the 
effect of imputation via the planned BOCF+IUDR framework and the primary 
analyses will be repeated without imputation of missing post-baseline FEV1. 
9. Protocolled primary sensitivity analyses #2, #3, #5, #7, and #9 have been 
removed to provide a more targeted and focused set of analyses to test the 
robustness of the primary results to varying assumptions (Section 8.1).  
a. Protocolled primary sensitivity analysis #2 was to elicit insights into the 
effects of including data from subjects after cessation of trial treatment 
and the primary analyses was to be repeated excluding these data both 
with imputation of missing post-baseline FEV1 assessments and without 
imputation. These analyses will now be included as supportive analyses 
(Supportive analyses 6 and 8). 
b. Protocolled primary sensitivity analysis #3 was sensitivity of the primary 
result to choice of “across Weeks 6 to 26” versus “at Week 26” estimates 
of the treatment effect, gauged by computing the LS mean treatment 
group difference at Week 26; this result will be presented as part of the 
primary endpoint primary analysis and is now included as a supportive 
analysis (Supportive analysis 2).  
c. Protocolled primary sensitivity analysis #5 was to determine if the 
primary results are sensitive to any observed changes between screening 
and Visit 1 in FEV1, and the primary analysis was to be repeated using the 
mean FEV1 measurement from screening (Visit 0) and Visit 1.  
d. Protocolled primary sensitivity analysis #7 was a responder analysis where 
the cut-off for classification as a responder was to be change from 
baseline FEV1 greater than: -300, -250, -200, -150, -100, -50, 0, 50, 100, 
150, 200, 250, and 300 mL respectively.  
e. Protocolled primary sensitivity analysis #9 was to explore the effect of 
different imputation methods, the primary analysis was to be repeated 
using a worst observation carried forward+IUDR method rather than the 
BOCF+IUDR framework.  
10. Primary sensitivity analysis #4 has become primary sensitivity analysis #1 and has 
been changed to use the Ratitch method[7] (Section 8.1.2). The intention of this 


Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 77 of 108 
sensitivity analysis remains the same (i.e. to assess the impact of the use of a 
single imputation method in the primary analysis), only the methodology has 
been updated. Protocolled primary sensitivity analyses #4 was a two-sample 
t-test at Week 26 computing point estimates from the data with BOCF but 
computing variation only from subjects who completed the trial. Furthermore a 
non-parametric equivalent (e.g. Wilcoxon rank sum test) was to be undertaken 
on the data with BOCF imputation. These results were to be compared to the 
Week 26 contrast computed by the primary efficacy model. 
11. Primary sensitivity analysis #6 has become primary sensitivity analysis #4, with a 
different set of responder analyses (Section 8.1.2). Protocolled primary 
sensitivity analyses #6 defined two responder analyses, the first where a 
responder was defined as those who have an increase from baseline FEV1 of 
greater than 100 mL, and the second where a non-responder was defined as 
those who have a reduction from baseline FEV1 of more than 100 mL. In addition, 
the definition of responder has been revised: subjects having a change greater 
than or equal to (≥) the threshold are considered responders, instead of subjects 
having a change greater than (>) the threshold. 
12. Primary sensitivity analysis #8 has become primary sensitivity analysis #2, with a 
change in the rules of attribution of the penalties to missing observations in 
order to match a Tipping point analysis (Section 8.1.2). Protocolled primary 
sensitivity analysis #8 was to explore the impact of patterns of “missingness” 
amongst the data using MI with penalties. Missing data across Weeks 6 to 26 were 
to be imputed by MI, then the impact of various penalties was to be explored, 
including linking penalties to reason for “missingness”, and increasing penalties 
for subjects with multiple missing data who could be less likely to benefit from 
treatment. The imputed longitudinal data was to be analyzed by MMRM. In 
primary sensitivity analysis #2 all missing data as a result of withdrawal from the 
trial will be imputed regardless of reason for withdrawal, different penalties will 
be investigated for the mannitol and control arms and the analysis method will 
be ANCOVA. 
13. The continuous covariate of historical exacerbation rate, used for the analyses of 
some secondary efficacy endpoints, has been reworded to number of IV 
antibiotic treated PEs in year prior to screening. 
14. A secondary sensitivity analysis on FVC has been added.  The main FVC analysis 
will be repeated using a pattern mixture model similar to primary sensitivity 
analysis #1.  
15. A secondary sensitivity analysis on PDPE rate has been added.  An analysis based 
on MI will be performed. 


 
Pharmaxis Ltd 
DPM-CF-303 
Final v1.0 
Statistical Analysis Plan 
 
 
Page 78 of 108 
12. 
REFERENCE LIST 
1. Hankinson, J.L., J.R. Odencrantz, and K.B. Fedan, Spirometric reference values 
from a sample of the general U.S. set. Am J Respir Crit Care Med, 1999. 159(1): 
p. 179-87. 
2. Kieser, M. and T. Friede, Simple procedures for blinded sample size adjustment 
that do not affect the type I error rate. Stat Med, 2003. 22(23): p. 3571-81. 
3. Miller et al, Standardization of Spirometry. Eur Respir J, 2005. 26: p. 319-338. 
4. Fuchs, H.J., et al., Effect of aerosolized recombinant human DNase on 
exacerbations of respiratory symptoms and on pulmonary function in patients 
with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med, 1994. 331(10): 
p. 637-42. 
5. Manual Scoring for the CFQ-R: Adolescents and adults. 
6. Mallinckrodt, C.H., et al., A structured approach to choosing estimands and 
estimators in longitudinal clinical trials. Pharmaceut Statist, 2012. 11(6): p. 456-
61.  
7. Ratitch, B., M. O‟Kelly, and R. Tosiello, Missing data in clinical trials: from 
clinical assumptions to statistical analysis using pattern mixture models. 
Pharmaceut Statist, 2013. 12: p. 337–347. 




 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
  
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 






















 
 
 
 
 
 
 
 of 108